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DEVELOPMENT OF RESISTANCE TO AZT WITHIN TWO HIV-1 
INFECTED EDINBURGH HAEMOPHILIACS. 
The development of poi gene mutations associated with reduced sensitivity to 3'-
azido-2-deoxythymidine (AZT) was studied in two haemophiliacs (p74 and p87) 
infected with human immunodeficiency virus type-1 (HIV-1), undergoing AZT 
therapy. Five specific amino acid changes in the reverse transcriptase (RT) domain 
which have been implicated with this reduced sensitivity were observed in these 
patients. These are situated at amino acid positions 41, 67, 70, 215 and 219 of RT. 
The resistance conferring changes are met->leu at position 41, asp->asn at position 
67, lys->arg at position 70, thr->phe or tyr at position 215 and lys->gln at position 
219. 
The nucleotide sequence of the RT domain was obtained directly from amplified viral 
and proviral HIV-1 genomes from these patients. A total of 99 sequences were 
obtained from patient 74 and 80 from patient 87. These were obtained from ten 
samples, four plasma and six from peripheral blood mononuclear cells (PBMCs) from 
each patient spanning the 2.5 years that they were receiving AZT treatment. 
Nucleotide sequence analysis followed by phylogenetic reconstruction using 
neighbour joining and maximum likelihood methods allowed the identification of key 
events in the development of drug resistance. 
The order and timing of appearance of resistance-associated substitutions in patient 
74 was; position 70, 4.5 months, PBMCs; position 215 (T->Y), 5.5 months, plasma; 
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position 41, 13 months, PBMCs. In the case of patient 87 the order of appearance 
was: position 70, 4 months, PBMCs; positions 67, 215(T->Y), and 219, 18.5 months, 
PBMCs. Phylogenetic analysis showed different evolutionary patterns in both 
patients. A single origin was identified for the appearance of both the 41 and 215 
mutations in patient 74. In this patient all sequences containing these changes arose 
from a single ancestral genotype. Patient 87 showed a less ordered pattern of 
mutation acquisition with the presence of several distinct evolutionary lineages, each 
containing variants with resistance-associated changes. 
To investigate the possibility that drug selection within the RT domain might affect 
the evolution within the env gene, proviral nucleotide sequences of the V3 region of 
the env gene were obtained from the same PBMC samples as were used for the poi 
gene analysis. Forty-five sequences were obtained from patient 74 and forty-three 
from patient 87. Phylogenetic reconstruction showed no evidence of directional 
selection in either patient. In patient 74, where a single lineage was observed in poi, 
several distinct lineages were observed in the V3 region which persisted throughout 
the period of study. Thus the selection imposed on the pol gene by AZT had no 
detectable effect on the pattern of evolution in the V3 region of env. 
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The Human Immunodeficiency Virus (HIV), the etiological agent of Acquired 
Immunodeficiency Syndrome (AIDS), causes a progressive disease leading to severe 
and irreversible immunosuppression, which eventually leads to death (Gottlieb et al., 
1981; Masur et al., 1981; Nelson et al., 1990). AIDS patients suffer from a range of 
opportunistic infections and malignant tumours which are associated with severe 
defects of cell mediated immunity. These include persistent cytomegalovirus 
infection (CMV), persistent generalised lymphadenopathy (PGL), Kaposi's sarcoma 
and Pneumocystis carinii pneumonia (PCP). Another feature of HIV infection is the 
appearance of neoplasm in 50% of AIDS patients causing the development of 
encephalopathy resulting in memory loss, impaired speech and dementia (Price et al., 
1986; Navia et al., 1986a,b). 
The first cases of a "new acquired cellular immunodeficiency" later known as AIDS 
were reported in the United States of America in 1981, amongst a group of 
previously healthy homosexual men (Gottlieb et al., 1981). Following this initial 
report AIDS cases were identified among haemophiliacs, blood transfusion recipients, 
intravenous drug users, children born to infected mothers and sexual partners of 
infected individuals (CDC reports., 1982a,b,c,d,e). 
The causative agent of AIDS was first identified in 1983, with the isolation of a 
retrovirus from a patient suffering from chronic lymphadenopathy, (Barre Sinoussi 
et al., 1983). This virus was named Lymphadenopathy Associated Virus (LAy). The 
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following year two other groups reported the isolation of a retrovirus from patients 
suffering from AIDS, named Human T-cell Leukaemia Virus type ifi (HTLV-
llI)(Gallo et al., 1984) and AIDS Related Virus (ARV) (Levy et al., 1984). At the 
time there was uncertainty over whether they were the same virus. Publication of the 
complete nucleotide sequence of LAY, HTLV Ill and ARV (Wain-Hobson et al., 
1985; Ratner et at, 1985a; Sanchez Pescador et al., 1985) in 1985 allowed 
comparisons to be made between each (Ratner et al., 1985b). This showed that LAY 
was closely related to HTLV ifi, with a difference at nucleotide level of 1.5% with 
a 2.2% difference at amino acid level. ARV showed greater diversity to HTLV ifi, 
6.3% at the nucleotide level and 9.2% at the amino acid level. It was concluded that 
all three were variants of the same virus (Rather et at, 1985b). These viruses were 
finally brought together and HIV- 1 was adopted as the accepted nomenclature by the 
International Committee of the Taxonomy of Retroviruses (Coffin et al., 1986a,b). 
To mid 1994 the World Health Organisation (WHO) estimate that approximately 17 
million people have been infected with HIV worldwide, with 3 million deaths from 
AIDS. 
1.2 HIV-1 VIRION STRUCTURE. 
The HIV-1 virion is an icosahedral sphere approximately lOOnm in diameter 
(Gelderbiom et al., 1987). The inner core of the viral particle contains the HIV-1 
genome which comprises two positive stranded RNA molecules. Closely associated 











OF AN HIV1 VIRION 
nucleocapsid proteins (p9 and p7), which are contained within the p24 protein 
capsid. Surrounding the p24 protein capsid is the p17 protein which provides the 
matrix for viral structure and associates with the viral envelope. The envelope 
consists of a lipid bilayer derived from the host cell membrane, spanning which is 
the gp4l transmembrane glycoprotein, which is noncovalently associated to the 
gp120 surface glycoprotein (Helseth et al., 1991). A schematic representation of 
the virus is shown in figure 1.1. 
1.3 HIV-1 GENOMIC ORGANISATION. 
The HIV-1 genome is approximately 9,800 nucleotides in length with open reading 
frames encoding at least nine viral proteins (Green and Chen, 1990; Wain-Hobson 
et al., 1985). The proteins encoded by gag and poi are derived from the initial full 
genomic length mRNA. env, VPU, VIP and VPR are translated from singly spliced 
mRNA transcripts with TAT, REV and NEF being translated from multiply spliced 
mRNA's. A schematic representation of the genome is shown in figure 1.2. As 
well as the three genes encoding the three structural proteins gag, poi and env, 
common to all replicating retroviruses, HIV also contains another six genes v{f, vpu, 
vpr, tat, rev and nef. Tat is a transcriptional activator while rev controls transport of 
unspliced transcripts out of the nucleus (See sections 1.3.2.1 and 1.3.2.2). The 
function of other genes is currently under investigation (vif, vpu, vpr and nef). In the 
proviral state long terminal repeats (LTR's) flank these nine genes. These contain the 
promoter and enhancer elements involved in the regulation of viral gene expression. 
As in other retroviruses the 5' LTR alone provides active promoter and enhancer 
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sequences, while the 3' LTR provides the active termination and polyadenylation 
signals. 
1.3.1 THE STRUCTURAL GENES OF HIV-1 
1.3.1.1 RR (group specific antigens) 
The gag gene of I-HV-1 encodes the structural components of the virion. Expression 
of the gag gene products results from translation of a gag/pol full length mRNA 
transrjp,p53a• The p539' 9 protein is then cleaved by viral protease into the virion 
proteins, p24 (phosphorylated), p17 (myristylated),p9 and p7 gag proteins (Veronese 
et al., 1988). Together these form the nucléocapsid and matrix of the HIV virion. 
1.3.1.2 pol (polymerase) 
The HIV-1 pOl gene, which encodes the protease, reverse transcriptase and integrase 
viral enzymes, is also translated from a full length gag/pol transcript. Translation of 
the poi gene products requires a ribosomal frame shift, since the poi gene is in the - 
1 reading frame in relation to gag (Jacks et al., 1988), this frameshift occurring at a 
frequency of 5%. The resultant poi polyprotein is then cleaved to its individual 
products by viral protease to yield, the p22 protease, the p66 and p51 reverse 
transcriptase subunits, and the p32 integrase. The reverse transcriptase enzyme has 
in the C-terminal region of the p66 subunit, RNase H activity (Hansen et al., 1987). 
Such activity is essential in proviral DNA synthesis. 
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1.3.1.3 env (envelope) 
The env gene of FIIV-1 is transcribed as a singly spliced mRNA, which translated 
yields a 160 KDa precursor protein. This 160 KDa precursor protein is cleaved by 
cellular proteases into two components, gpl20 the external glycoprotein and gp4l the 
transmembrane glycoprotein. These mature envelope proteins are then transported 
to the cell surface (Wiley et al., 1988), where gpl20 is present as a multimeric unit, 
non-covalently linked to gp4l (Helseth et al., 1991). The non-covalent link involves 
interactions between regions close to the amino and carboxyl termini of gpl20 and 
unidentified regions of gp4l. 
1.3.2 THE REGULATORY GENES OF HP/-i 
1.3.2.1 tat (trans activator) 
Tat is translated from three multiply spliced mRNA's and is essential for viral 
replication. The tat gene is encoded by two exons, the first of which precedes the 
env gene and codes for approximately 76 amino acids, while the second is within the 
env gene and codes for approximately 12 amino acids (Arya et al., 1985). The 
most common form of tat in infected cells is an 86 amino acid long protein (Aldovini 
et al., 1986), which is localised in the nucleus (Hauber et al., 1987). Tat acts as a 
powerful transactivator of LTR gene expression. The presence of tat has been shown 
to dramatically increase transcription of all genes linked to fly-i LTR's (Arya et al., 
1985; Sodroski et al., 1984, 1985a,b). It acts by binding to a 59 nucleotide RNA 
stem loop structure TAR (transactivation response element) located between +1 and 
+60 in the viral RNA (Rosen et at, 1985). 
1.3.2.2 rev (regulator of expression of the virion) 
rev is the second regulatory gene of HIV-1 which is essential for viral replication. 
rev is translated from a multiply spliced transcript, the translation of which yields a 
19 KDa protein composed of 116 amino acids (Cullen and Greene, 1990). It is found 
in the nucleus of infected cells and predominantly in the nucleolus (Cullen et al., 
1988; Malim et al., 1989). The function of rev seems to be the promotion of nuclear 
export and cytoplasmic expression of the mRNA's which encode the viral structural 
proteins; thus it plays a crucial role in switching from "early regulatory" to "late 
structural" gene expression (Cullen, 1991). Rev function is mediated by direct 
binding to an RNA structure, the RRE (rev response element), located within the 
transcribed env gene (Malim et al., 1988, 1989, 1990; Daly et al., 1989). 
1.3.3 ACCESSORY GENES 
1.3.3.1 nef (negative effector) 
The nef gene of HIV is located as a single open reading frame at the 3' end of the 
viral genome It is a 25->27 KDa protein (Franchini et al., 1986) which is translated 
from a multiply spliced mRNA transcript resulting in a polypeptide of 200->205 
amino acids (Harris et al., 1992). Nef is a cytoplasmic protein which is myristoylated 
and is found on the cytoplasmic face of the plasma membrane (Allan et al., 1985). 
The exact function of the nef gene is unknown; however nef has been shown to 
reduce surface expression of the CD4 molecule (Garcia and Miller., 1991), to be a 
repressor of viral replication and to down regulate HIV LTR gene expression (Ahmed 
and Vankatesan, 1988). Some of these findings have yet to be supported by others. 
1.3.3.2 vpu (viral protein u) 
The vpu gene is translated from a singly spliced mRNA which encodes an 80->82 
amino acid protein. The exact function of this gene is unclear; however several 
studies have shown that the absence of vpu leads to a decrease in virion release from 
infected cells and an accumulation of virion proteins within these cells (Nelson et al., 
1988; Cao et al., 1990). The infectivity of virions which are released is not 
diminished in the absence of vpu (Nelson et al., 1988). It has also been suggested 
that the function of vpu may be to destabilise intracellular gpl60\CD4 interactions 
(Lifson et al., 1986) and recent reports suggest that vpu induces rapid degradation of 
CD4 (Wiley et al., 1994), although the mechanism is unclear. 
1.3.3.3 vif (viral infectivity factor) 
The vif gene is also translated from a singly spliced mRNA and is situated between 
the poi and env genes. It encodes a 23 -> 27 KDa protein (Kan et al., 1986). A large 
number of studies have been carried out to investigate the function of this gene; 
however this still remains unclear. It does not seem to be a virion component or play 
a role in virion assembly (Sakai et al., 1991; Fisher et al., 1987). Several authors 
suggest that it may play a role in virion infectivity (Fisher et al., 1987; Strebel et al., 
1987). 
1.3.3.4 vpr (viral protein r) 
Very little is known about the vpr gene. It is translated from a singly spliced mRNA 
as an open reading frame situated between the vif and env genes, encoding for a 78 
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to 96 amino acid protein. Western blotting of subcellular fractions has shown vpr to 
be a membrane associated virion component (Sato et al., 1990). The vpr gene has 
also been shown not to be necessary for formation and release of virions (Dedera et 
al., 1989). Recently it has been shown to be required for infection of macrophages 
(Heinzinger et al., 1994). 
1.4 HIV-1 VIRAL LIFE CYCLE 
HIV viral infection begins with the attachment of the virion surface glycoprotein 
gpl2O to the CD4  cellular receptor molecule on the surface of CD,' T-cells 
(Klatzmann et al., 1984; Lasky et al., 1987). The virus is then internalised into the 
cell by either receptor mediated endocytosis (Maddon et at, 1986) or virus mediated 
fusion (Stein et al., 1987). It has also been suggested that CD4 independent entry is 
possible (Harouse et al., 1991), due to the fact that a large number of CD4 cells, 
including human skin fibroblasts, muscle and bone derived fibroblastoid cell lines and 
follicular dendritic cells, have been shown to be susceptible to HIV infection (Tateno 
et al., 1989). 
Once internalised into the host cell the outer lipid envelope of the virus is removed 
as the virus particle undergoes fusion with the cytoplasmic vacuoles (Varmus, 
1988a,b). In the remaining core particle, replication begins as for all retroviruses 
with the production of a single stranded complementary DNA copy (-strand) of the 
viral RNA primed by the tRNA annealling to the primary binding site, by virus 
encoded reverse transcriptase. Following the classical strand switch and completion 
of synthesis of the RNA/DNA hybrid, the second, poi encoded enzyme ribonuclease 
H degrades the original RNA template, prior to reverse transcriptase synthesising a 
complementary DNA (+strand) copy of the original RNA genome. Translocation, by 
an as yet unknown mechanism, of the viral double stranded DNA to the cell nucleus 
then occurs, where linear double stranded viral DNA is inserted into the host 
chromosomal DNA by the third poi encoded gene enzyme, integrase. Circular DNA 
molecules are also formed as aberrant products of reverse transcription. 
After integration into the host cell DNA the virus may remain latent or be expressed. 
It has been suggested latency is due to the state of cell activation, and that only 10% 
of infected T-cells actively produce virus (Cullen and Greene, 1989). Others suggest 
that it is a result of low level expression of the viral tat and rev genes (Fenyo et al., 
1988; Pomerantz et al., 1990). Host transcriptional factors which bind to sites in the 
HIV-1 long terminal repeats (LTR's) can stimulate low level HIV-1 transcription. The 
initial multi-spliced viral mRNAs thus obtained encode the regulatory genes of HIV-
1, namely the "early genes" tat, rev and nef. TAT is essential for high levels of HIV 
transcription, REV regulates viral RNA transport and NEF may down regulate the 
transcriptional activity of HIV-1 LTR (Ahmed and Vankatesan, 1988). For the 
assembly of new HIV virions all the structural proteins and enzymes must be 
produced. These late gene products are encoded by unspliced and singly spliced viral 
transcripts, the unspliced gag-pol mRNA and the singly spliced env mRNA. The 
switch between early and late gene expression is dependent on the HIV-1 rev gene. 
Assembly of new infectious HIV-1 takes place in the cytoplasm under the plasma 
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membrane initially with the construction of the retroviral cores, containing the full 
length unspliced HIV-1 sense RNA, the gag proteins and the enzymes encoded by 
the poi gene. After assembly the virion buds by acquiring its outer lipid membrane 
and the env gene products (gp4l and gp120). 
1.5 RETROVIRAL THERAPY OF HIV INFECTION WITH PARTICULAR 
REFERENCE TO AZT. 
Since the identification of HIV as the causative agent of AIDS, research has been 
directed towards the development of an effective vaccine and antiviral therapy. Each 
step in the viral life cycle (see section 1.4) may potentially be targeted by 
antiretroviral agents. Success in the development of such a therapy depends largely 
on our understanding of host cell biology and our ability to prevent viral integration 
and replication. 
To date only three drugs have been licensed for the clinical treatment of HIV 
infection, namely Zidovudine (3 '-Azido-2-deoxythymidine; AZT), Didanosine 
(2'3'dideoxyinosine; ddl), and Zalcitabine (2'3'dideoxycytidine; ddC). The first of 
these to be licensed, AZT, was first synthesised in 1964 as a potential cancer 
chemotherapy agent, (Howitz et al., 1964) and was found to have antiretroviral 
activity against HIV-1 in 1985 (Mitsuya et al., 1985). It was first registered for 
clinical use in March 1987 in the United States of America as a result of the findings 
of the first large clinical trial in patients with advanced HIV disease, which showed 
significant improvement in survival in patients treated with AZT being compared to 
placebo (Fischl et al., 1987). 
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AZT belongs to a group of compounds known as dideoxynucleotides which are chain 
terminators as used in DNA sequencing. They have been shown to act against all 
polymerases and to have activity against HIV in-vitro (Mitsuya and Broder, 1986). 
Dideoxynucleosides differ from normal deoxynucleosides in that the 3' OH group on 
the sugar ring is replaced by another group which cannot form diester linkages. In 
the case of AZT the hydroxyl (OH) group is replaced by an azido (N 3) group.(Figure 
1.3) 
AZT diffuses across human cell membranes in a non-facilitated, non-concentration 
dependent manner due to the more lipophilic nature of AZT compared to thymidine 
(Zimmerman et al., 1987). Once in the cell the AZT is phosphorylated at the 5' 
position, by host cell thymidine kinase to a monophosphate (AZT-MP) form and then 
to a diphosphate (AZT-DP) form by thimidylate kinase which is then phosphorylated 
again by other cellular enzymes to the active form AZT triphosphate (AZT-T?). A 
diagrammatic representation of this is shown in figure 1.4 (Furman et al., 1986). 
The limiting step in the conversion of AZT to its active form, is the conversion of 
the monophosphate to the diphosphate form. The conversion of AZT to AZT-MP 
takes place at 60% of the rate of thymidine phosphorylation but conversion of AZT-
MP to AZT-DP takes place at only 0.3% of the equivalent thymidine rate (Albert et 
al., 1992). Therefore the intracellular concentration rendered by the active form of 
the drug is always substantially lower than that of TTP. 
11 
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FIGURE 1.4 
Zidovudine acts at the site of reverse transcription (Vrang et al., 1988). It inhibits 
viral replication in at least two ways. Firstly AZT-TP competitively inhibits the 
incorporation of thymidine into viral DNA by viral reverse transcriptase (St Clair et 
al., 1987), with AZT-TP filling 1 of every 1.5-2.4 sites available for thymidine 
incorporation. Secondly, AZT-TP acts as a chain terminator, by joining to the end 
of the growing viral DNA chain and preventing the joining of other nucleotides by 
the usual phosphodiester linkages due to the replacement of the OH group with the 
azido group (figure 1.5). However AZT does not stop virus production from infected 
cells or transmission to uninfected cells (Smith et al., 1987), as other steps in the 
virus life cycle dependent on cellular RNA polymerase are not affected by AZT. 
1.6 CLINICAL TRIALS OF AZT. 
The results of an initial dose finding phase one study (Yarchoan et al., 1986) 
suggested that AZT might be beneficial treatment for HIV-1 infection. In this study 
19 patients with AIDS or ARC were randomized, to take one of four doses of AZT 
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DNA CHAIN TERMINATION BY THE INCORPORATION OF AZT 
weeks. The results showed a decrease in opportunistic infections, night sweats and 
fever and a gradual increase in T4 lymphocyte counts and T4:T8 ratios. 
Following these initial positive results a large multicenter double blind placebo trial 
of AZT therapy was instigated, in patients with AIDS or ARC (Fischl et al., 1987). 
Patients were stratified on the basis of CD4 cell count and given either 1500mg/day 
AZT or placebo. This trial was stopped early following the recommendations of an 
independent monitoring board because there was a significant decrease in the 
mortality rate in those receiving active drug. At termination, 1 in 145 in the AZT 
group and 19 in 137 in the placebo group had died. Further benefits in this study 
included significant weight gain and CD4 increase in the AZT recipients. The 
increase in CD4 counts in the AIDS patients were only transient with the count 
falling to pretreatment levels after only 12 weeks. A reduction in detectable p24 
antigenemia was also observed. The results of this study and the need for an 
effective therapy for AIDS led to most regulatory bodies licencing AZT as an 
acceptable AIDS therapy. 
1.6.1 EARLY INTRODUCTION 
Despite the licensing of AZT for the treatment of advanced HIV disease several 
questions remained unanswered, eg timing of introduction, toxicity and long term 
effects. The first major study to investigate the use of AZT in asymptomatic patients 
with HIV infection and CD4 cell count of < 500 cells/jil was the ACTG 019 study 
(Volberding et al., 1990). This study was designed to determine the safety and 
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efficacy of AZT in prolonging survival and delaying the onset of AIDS or ARC. The 
study compared two different AZT doses (1500mg/day, n=457 ; 500mg/day, n=453) 
with a placebo group (n=428); the mean follow up was 55 weeks. Results showed 
that subjects in the AZT groups had a significant increase in CD4 cell count along 
with a significant decrease in p24 antigen levels compared to placebo. Progression 
rate to AIDS or ARC in the three groups (placebo, 500mg/day and 1500mg/day) were 
7.6, 3.6 and 4.3 /100 person years respectively. The study concluded that AZT was 
safe and effective in asymptomatic HIV infection and <500 CD4 cells/pl. Several 
other smaller studies have investigated the role of AZT in patients with asymptomatic 
HIV infection and CD4 counts between 200 and 500 x10 6 cells/I (Cooper et al., 
1993; Hamilton et al., 1992). These studies also suggest significant clinical benefit 
from early initiation of AZT therapy, in terms of significant increase in CD4 cell 
counts, reduction in p24 antigen levels, disease progression and occurrence of 
opportunistic infections. The benefits demonstrated by these shorter studies were 
recently undermined to a degree by the findings of the Anglo-French Concorde Study 
(Sellgmann et al., 1994). To date this has been the largest and longest clinical trial 
in asymptomatic HIV infected individuals (1749 patients; 5419 person/years; 3 year 
duration). Concorde compared immediate treatment with AZT (1000mg/day) on 
study entry with AZT treatment when symptoms developed. The results did not 
encourage the early use of AZT, as no statistically significant difference in death, 
clinical outcome or disease progression between the two groups was seen, in contrast 
to the findings of ACTG 019. However, as in ACTG 019, a difference was seen in 
CD4 counts over time, with a 30x 106  cell difference from baseline persisting for up 
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to 3 years in the immediate treatment group. The fact that the two studies agreed on 
this suggests that CD4 count may be less reliable as a marker for determining clinical 
outcome than previously believed. 
It is clear that higher doses of AZT, 1500mg/day causes more severe haematological 
toxicity, ie neutropenia and anaemia. A number of studies have addressed the 
question of dosage (Fischl et al., 1990; Collier et al., 1990; Volberding et al., 1990; 
Nordic Medical Research Council's HIV Therapy Group, 1992). The consensus of 
results was that a reduced daily dose of between 300 and 600mg/day of AZT is at 
least as effective as higher doses and is less toxic, with nausea being the most 
common reported toxicity. 
1.7 ISOLATION OF AZT-RESISTANT HIV. 
It was first reported in 1989, by use of a HeLa CD 1  plaque reduction assay 
(Chesebro and Wehrly, 1988) which measures the production of distinct foci 
produced by cell free virus or HIV infected cells to give an infectious centres (IC) 
number, that HIV-1, isolated from patients who had been undergoing AZT therapy 
for six months or more, showed reduced sensitivity to the drug (Larder et al., 1989). 
Comparison was made between the ID values for isolates from 18 untreated 
individuals (ID 0.01->0.05pM) and those of AZT treated patients (ID range 0.06-
>6pM after 6->18 months therapy); one-third (5115) of the treated patients showed 
a 100 fold or greater increase in ID, after a minimum of six months therapy. These 
isolates with reduced sensitivity to AZT were tested against other anti-retroviral 
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drugs, and although they were not sensitive to 3'-azido-2'3'-didioxyuridine (AZdu) 
they remained sensitive to 2 '3' -didioxycytidine (ddC), 2 '3 '-didioxy-2 ',3 '-
didehydrothymidine (D4T) and phosphonoformate (PFA). Several later studies of 
sequential I-fly isolates from patients undergoing long term AZT therapy confirmed 
the finding that AZT resistance may emerge after only 6 months of therapy and that 
although sensitivity is reduced to AZT, isolates remain sensitive to other nucleoside 
analogues (Richman et al., 1990; Land et al., 1990; Rooke et al., 1989). 
The most likely explanation for this emergence of resistant phenotypes is the 
development of mutations in the reverse transcriptase coding sequence of the 
polymerase gene. These resistant phenotypes have indeed been found to be associated 
with polymerase gene mutations (Larder and Kemp, 1989). The complete 1.7kb 
reverse transcriptase region was obtained from both sensitive and resistant isolates by 
PCR amplification of infected cell DNA. This was then inserted into the M13 based 
vector mptac 18.1 and sequenced. Comparison was made between the sequence from 
five pairs of sensitive, (ID jO 0.01) and reduced sensitivity, (ID 2->5.6) clinical 
isolates, obtained before and during AZT therapy. These showed the presence of 
three common point mutations in all five reduced sensitivity isolates and a fourth 
mutation in three of the five isolates. These mutational changes were Aspartate to 
Asparagine at position 67, Lysine to Arginine at position 70, Threonine to 
Phenylalanine or Tyrosine at position 215, and Lysine to Glutamine at position 219, 
of the reverse transcriptase domain respectively. In order to investigate these changes 
further a mutant H11/ 1 clone was constructed by inserting a 2.55kb fragment of the 
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HIV poi gene from an infectious clone, HXB2D, into the M13 vector mpl9, using 
site directed mutagenesis to insert the four implicated amino acid changes into the 
RT gene by use of synthetic oligonucleotides. A mutant isolate prepared from the 
infectious molecular clone and a wild-type isolate were then tested for AZT 
sensitivity. The results showed that the mutant isolate was 100 fold more resistant to 
AZT than the wild type, which is similar to data obtained from resistant clinical 
isolates, thus confirming that these four point mutations confer resistance to AZT. 
From a clinical point of view it was obviously important to investigate the resistance 
conferred by these mutations individually and in combination. This was investigated 
in vitro by the construction of a series of HIV-1 clones containing various 
combinations of the resistance conferring changes, (Larder et al., 1991b) and testing 
their sensitivity to AZT. Table 1.1 below shows the IC values obtained by plaque 
reduction assay for each of the constructed clones. 
The results in Table 1.1 show that in all cases in which reduced sensitivity is seen 
the amino acid change at position 70 or 215 either individually or in combination are 
present. The changes at positions 67 and 219 confer no resistance on their own but 
in general confer greater resistance in combination with others. These findings 
confirmed that viral resistance to AZT increases with the accumulation of these four 
specific reverse transcriptase mutations. Later a number of clinical isolates were 
identified which showed high level AZT resistance but contained only three of the 
four previously implicated mutations, those at positions 67, 70 and 215. A molecular 
clone previously constructed containing this genotype only gave partial resistance 
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(Larder et al., 1991b), this suggested the possibility that an additional mutation 
existed in some clinical isolates. By use of an HIV marker rescue system this was 
identified as a change at position 41 of Methionine to Leucine (Kellam et al., 1992). 
Again an Fllh/l molecular clone was constructed containing changes at positions 41, 
67, 70, and 215. This gave highly resistant virus after transfection of T-cells, 179 
fold higher resistance than wild type, which is similar to levels seen in highly 
resistant clinical isolates. 
TABLE 1.1 
MUTATIONS FOLD INCREASE IC50 umol/I 
INSERTED IN RESISTANCE 
- - - 
- 1 0.01 
N6 7 - - 
- 1 0.01 
- R70 - 
- 8 0.08 
- - ''215 - 16 0.16 
- - 
- Q219 1 0.01 
N67 R70 - 
- 17 0.17 
- - F215 Q219 22 0.22 
N67 R70 - Q219 28 0.28 
N 67 R70 Y215 
- 35 0.35 
N 67 R70 F215 Q219 160 1.60 
(Adapted from Larder, Kellam and Kemp 1991b) 
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It is now widely accepted that these five point mutations are responsible for 
development of reduced sensitivity isolates to AZT (See figure 1.6). Most have never 
been observed in untreated patients although there is some evidence to suggest that 
the change at position 70 may in fact be a pre-existing polymorphism. Zhang et al 
(1991) showed the presence of this substitution in a batch of Factor VIII concentrate 
prepared before the use of AZT as an anti viral agent and it has also been found in 
the PBMC's of infected individuals who have never received AZT (Mohri et al., 
1993). More recently an indepth sequence study of treated and untreated patients 
showed the presence of the resistance conferring change at position 70 in 7/25 
patients never treated with AZT (Najera et al., 1995). 
Other mutations have been implicated as conferring AZT resistance by others (Japour 
et at., 1991; Sheehy and Desselberger, 1993). Japour and colleagues measured AZT 
sensitivity using an RNA:RNA hybridisation assay, which measures the amount of 
intracellular HIV- 1 specific RNA. They then sequenced one resistant isolate and 
identified eight amino acid changes; when these were compared to published 
sequences for wild-type HIV-1 four of the changes were seen in conserved amino 
acids, those at positions 125, 142, 215 and 294, 215 previously having been identified 
as conferring AZT resistance (Larder and Kemp, 1989b). Sheehy and Desselberger 
identified ten amino acid changes (108, 135, 173, 211, 245, 281, 334, 335, 379, 464) 
in three isolates which showed reduced sensitivity but contained none of the five (41, 
67, 70, 215, 219) most strongly implicated mutations. The amino acid changes 
identified by these studies may influence resistance development , but until 
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introduced into a defined genetic background by site directed mutagenesis and the 
resulting virus measured for drug sensitivity their effect will remain unclear. 
1.8 HIV-1 REVERSE TRANSCRIPTASE STRUCTURE. 
Structural analysis of the reverse transcriptase of HIV-1 has shown that it exists as 
a heterodimer consisting of subunits of 66,000 (p66) and 51,000 (p51) daltons 
(Kohlstaedt et al., 1992; Jacob-Molina et al., 1993). Each of the polymerase subunits 
is divided into four subdomains namely the "fingers ","palm", "thumb" 
and"connection", with the p66 subunit also having RNAase H function. 
The subunits although having the same amino acid sequence take up different 
conformations, with the p66 subunit having a large cleft which is not present in the 
p51 subunit due to the different relative positions of the four subdomains. The 
polymerase active site is located in the palm of the p66 subunit and is defined by the 
three aspartic acid residues at positions 110, 185 and 186. It appears that the palm 
and thumb of p66 act as a holding mechanism which hold the template/primer 
complex in the correct position to the polymerase active site. 
The AZT resistance conferring mutations are not found at the polymerase active site, 
those at positions 41, 67 and 70 are located in the fingers subdomain with the 
changes at positions 215 and 219 found in the palm subdomain. It is thought that 
these changes effect the interaction between the protein and the template. 
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1.9 AZT RESISTANCE M1JTATION ACQUISITION. 
Prior to the discovery of the resistance associated change at position 41 (Met->Leu), 
the order of acquisition of the four initially implicated amino acid changes was 
investigated. Variants of HIV-1 with reduced sensitivity to AZT were selected for 
by passage of HIV infected cells in increasing levels of AZT in cell culture (Larder 
et al., 1991a). The HIV variants used in this study were the wild type virus HXB2 
and two partially resistant variants HIVRTMF and IIIVRTMC/F. These variants 
were constructed by site directed mutagenesis of pHXB2-D, the variant HIIVRTMF 
containing the THR->TYR mutation at position 215 and the HIVRTMC/F variant the 
mutations at positions 67 ASP->ASN, 70 LYS->ARG and 215 THR->TYR. On 
passage in cell culture the wild type sensitive virus became partially resistant by 
passage 12 (ID increased from 0.014 to 0.2pM), and the partially resistant variant, 
HTVRTMC/F became highly resistant (ID increased from 0.4 to 2.5pM). The other 
partially resistant variant HIVRTMF showed little change in sensitivity after passage 
12, although the drug concentration was increased from 0.1 to 20j.iM in the cell 
culture. Selective PCR was then used after each passage to investigate substitutions 
which may have occurred at any of the resistance conferring positions (67, 70, 215 
and 219). No additional mutations were seen in HIVRTMF. By passage 6, mutants 
were seen in HXB2RT, position 70 became fully mutant and then reverted to a 
mixture by passage 11, at which time position 215 became fully mutant. A mixed 
population at position 67 was also observed by passage 8. The HIVRTMC/F variant 
was investigated for the presence of a change at position 219, no change was seen 
until passage 11 when a weak PCR signal was detected. 
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The mutations detected by selective PCR were investigated further by amplifying 
DNA from passage 12 HXB2 and HIVRTMC/F infected cells. The amplified DNA 
was then inserted into the M13 vector mptacl8. 1 and sequenced. Sequence analysis 
showed the change at position 215 (Thr->Tyr) in HXB2, the mixed populations 
observed in HXB2 at positions 67 and 70 were not identified by sequencing of the 
RT clones. HIVRTMC/F sequence showed a change at codon 219 (Lys->Glu), 
however this is not a change previously seen in clinical isolates. 
This study was followed by an investigation of the acquisition of resistance in H11I 1 
isolates from treated individuals (Boucher et al., 1992). Serial isolates were obtained 
from 18 asymptomatic patients over 2 years of AZT therapy. Selective PCR was 
used to investigate amino acid positions 67, 70 and 219. The status of the isolates 
at position 215 had already been investigated in a previous study (Boucher et al 
1990), 16/18 isolates being mutant between 48 and 112 weeks AZT therapy. All 
pretreatment isolates were wild type at codon 70. Between weeks 16 and 32, 11/18 
isolates showed a mixed or mutant population at this codon, although of isolates 
obtained between weeks 76 and 132 only 7/18 showed a mutant genotype. Seventeen 
of the isolates obtained between weeks 76 and 132 were wild type at codons 67 and 
219, with one isolate showing a mixed population at codon 67 and wild type at codon 
219. During the study three of the patients progressed to AIDS, and these patients 
were analyzed by selective PCR at all four codons (67, 70, 215 and 219). In all three 
cases the mutation at position 70 appeared first, and then disappeared with the 
appearance of the change at position 215. In 2/3 cases the change at 70 reappeared. 
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In one patient the change at 67 appeared transiently and then reappeared with the 
appearance of the 219 mutation; following this the gene remained homogeneous with 
mutations at all four codons. Mutations at positions 67 and 219 were not detected 
in the other patients. 
More recently a detailed genotypic analysis of virus from 17 HIV-1 infected patients 
was carried out using selective PCR to look at all five codons associated with AZT 
resistance (Kellam et al., 1994). This study along with the work of the earlier studies 
enabled the authors to propose a model for the acquisition of the five implicated 
resistance mutations. The first mutation to appear is at position 70, although 
additional viral populations with single amino acid changes at positions 41 or 215 
may coexist early in therapy. Different combinations of these three changes (41, 70, 
215) may then become linked to give double mutants with varying degrees of 
resistance. Eventually the 41/215 mutant outgrows all the others and becomes fixed 
in the viral population. The appearance of the changes at positions 67, 70, and 219 
with the double mutant 41/215 occurred in only one of the two patients from this 
group studied sequentially, after 136 weeks therapy. However it has been noted that 
although the pattern of resistance development is similar between patients the speed 
of mutation acquisition may differ. Therefore the changes at positions 67, 70, and 219 
may have appeared in the other patient later. 
These findings together with the findings of earlier mutation acquisition studies 
suggest that variants with a higher level of resistance have a growth advantage in the 
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presence of drug, with each new dominant viral population having a higher 
resistance level to AZT than the previous population. 
1.10 AZT RESISTANCE MUTATION REVERSION POST-TREATMENT 
With reduction in sensitivity to the drug and the development of haematologic 
toxicity after prolonged therapy, cessation of therapy may become a necessity. 
Studies in-vivo and in-vitro have investigated the rate of reversion to wild type 
sequence following the removal of the selection pressure of the drug (Albert et al., 
1992; Boucher et al., 1993). 
The study of Boucher and coworkers was the most extensive. They investigated the 
reversion of the resistance conferring mutations to wild-type both in-vivo and in-vitro. 
Paired isolates were obtained from six homosexual men whose therapy was 
discontinued due to haematologic toxicity. For each patient a reference isolate was 
obtained before or on the day of discontinuation of AZT therapy. Five of the patients 
had partially resistant virus (IC_,,,O.OlpM->0.5OjiM) and one had a highly resistant 
virus population. Post-treatment isolates were obtained 8 -> 69 weeks after cessation. 
Three of the partially resistant isolates showed no change in sensitivity at 13, 29 and 
32 weeks post-therapy, one showed a 30 fold decrease in IC -,o after 8 weeks and one 
showed a four fold decrease in ICI resulting in sensitive isolates. Selective PCR was 
used to investigate the amino acids at the resistance conferring positions (41, 67, 70, 
215 and 219). The majority of the amino acids at these five positions showed an 
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increase in the frequency of wild-type sequence, but two instances of total reversion 
to wild-type were seen, for one patient at codon 70, and for another at codon 41. 
To investigate the reversion rate further the wild-type strain HXB2 and three 
molecular clones, two partially resistant (HIVRTMJ (ARG position 70) and 
HTVRTMF (TYR at position 215)) and one highly resistant (HIVRTMC (ASN at 
position 67, ARG at position 70, PHE at position 215 and GLN at position 219)) 
were passaged in the absence of AZT . No significant changes were seen after 
passage 12. However when wildtype HXB2 and HIVRTMF were mixed equally and 
passaged, by passage 20 there was an increase in the proportion of sensitive virus and 
a seven fold decrease in IC. It was concluded from this work that reversion is slow 
and may be related to the length of treatment. This conclusion was also supported 
by the work of Albert et al, who directly sequenced RNA from four patients post 
treatment. Two of the individuals showed no sign of reversion to wild-type at 4 and 
9 months, one showed partial reversion at 18 months and the fourth showed almost 
complete reversion at 9 months. 
1.11 TRANSMISSION OF AZT RESISTANT STRAINS OF HIV-1 
The increased use of AZT for the treatment of HIV- 1 infection and the development 
of resistance to AZT within treated individuals, increases the possibility of 
transmission of resistant variants. Several cases of primary infection by resistant 
virus have been reported (Fitzgibbon et al., 1993; Erice et al., 1993; Conlon et al., 
1994; Wahlberg et al., 1994; Angarano et al., 1994). 
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Sexual transmission of resistant variants containing mutations at positions 70 (Conlon 
et at, 1994), 215 (Wahlberg et al., 1994; Erice et al., 1993) and both 41,215 
(Angarano et at, 1994) have been shown by either PCR or sequence analysis. 
Despite this evidence there is still debate as to whether resistant strains are selected 
against during transmission. In one study only one of four donor/recipient couples 
transmitted a resistant strain (Wahlberg et al., 1994), whereas in another seven of 
eight couples transmitted a resistant virus (Angarano et al., 1994). 
The transmission of a resistant variant of HIV-1 from one child to another in the 
home has also been reported (Fitzgibbon et al., 1993). Both children were born to 
HIV-1 infected mothers; the infected child was infected perinatally, and the other 
found to be repeatedly seronegative. Sequence analysis of both the pot and the V3 
region of the envelope genes was carried out. Analysis of the V3 region showed that 
the sequence from the recipient child was closer to that of the donor child than to that 
of its mother or four local unrelated children. poi gene analysis showed the presence 
of the resistance conferring mutation at position 215 (Thr->Tyr) in both children but 
not in the mother of the recipient child. Thus transmission of the resistant virus may 
have been caused by unrecognised exposure to the donor child's blood in the home. 
These cases of transmission of resistant genotype virus further complicate the use of 
AZT in the treatment of HIV-1 infection. 
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1.12 SEQUENCE VARIATION IN THE V3 REGION OF gp120. 
HIV-1 has been shown to have a high degree of sequence variability, particularly 
within the gpl20 region of the envelope protein (Hahn et al., 1986; Simmonds et al., 
1990a; Coffin, 1992). Five hypervariable regions (Vi -> V5) have been identified 
within gpl20, which show less than 25% conservation at the amino acid level, 
(Modrow et al., 1987). Located between these five hypervariable regions are four 
highly conserved areas (Cl -> C4) (Wiley et al., 1986; Modrow et al., 1987). 
A major feature of HIV-1 infection is the genetic variation which is seen not only 
between different viral isolates from different individuals but also between isolates 
from the same individual. During the course of infection this variation becomes more 
apparent(Fisher et al., 1988; Simmonds et al., 1990a; Simmonds et al., 1991; Balfe 
et al., 1990; Wolfs et al., 1992), although several studies have shown sequence 
homogeneity in the envelope region during acute primary infection (Wolfs et al., 
1991; Wolfs et al., 1992; Zhang et al., 1993; Hahn et al., 1986; Simmonds et al., 
1990a; Simmonds et al., 1991; Balfe et al., 1990). 
The sequence variation that occurs in gpl20 particularly within the V3 region has 
been shown to affect the biological phenotype of the virus. Specific amino acid 
changes have been shown to influence viral characteristics such as cell tropism,the 
ability to induce syncytia and the ability to replicate in-vitro (Chesebro et al., 1992; 
Ivanoff et al., 1992; Shioda et al., 1992; Tersmette et al., 1988). Virus isolated from 
patients early in infection tend to show a slow low replicating, macrophage tropic, 
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non-syncytium inducing (NSI) phenotype, whereas virus isolated later in infection 
may exhibit a rapid high replicating, T cell tropic, syncytium inducing (SI) phenotype 
(Koot et al., 1993; Tersmette et al., 1988). The transition from an NSI to SI 
phenotype has been shown to be associated with an increased rate of disease 
progression in approximately 50% of cases. (Tersmette et at., 1989a,b; Schuitemaker 
et al., 1991, 1992). This change of phenotype has been shown to be linked to the 
replacement of specific amino acids within the V3 loop region (amino acids 296 -> 
330), with more positively charged amino acids (de Jong et al., 1992b; Fouchier et 
al., 1992). de Jong et al showed by mutagenesis of single amino acids in the V3 
loop that the minimal requirement for the SI phenotype, was a change at amino acid 
306 of serine to arginine linked with a change at either position 320 of aspartic acid 
to glutamine or 324 of aspartic acid to aspargine. A single change of aspartic acid 
to arginine at position 320 also gave a complete SI phenotype, with a single change 
of serine to arginine at position 306 giving an intermediate SI phenotype. 
Single amino acid changes within the conserved GPGR motif at the tip of the V3 
loop have also been shown to influence cellular tropism and growth characteristics 
of the virus (Takeuchi et at., 1991; Cordonnier et al., 1989; Freed and Risser, 1991; 
de Jong et al., 1992b). Changes to GQRR and GQRK influence SI capacity and 
increase the rate of viral replication (de Jong et at., 1992b) with a change to GSGR 
altering the host range of isolates (Takeuchi et at., 1991); however, the effects of any 
individual substitutions are dependent on the genetic background. 
1.13 EDINBURGH HAEMOPHILIA COHORT 
In March 1984, 32 Haemophilia A patients were treated with a batch of Factor Vifi 
concentrate, prepared from locally collected donations by the Scottish National Blood 
Transfusion Service (SNBTS). Following exposure to this batch of Factor VIII, 18 
developed FIIV-1 infection, while the other 14 remained seronegative. These patients 
became known as the Edinburgh Haemophilia Cohort. Those who seroconverted 
received more units of the implicated batch than those who did not (Ludlam et al., 
1985). This batch of Factor Vifi concentrate was prepared at a time when 
seropositivity was low in the donor population, as indicated by low seropositivity in 
sera obtained from intravenous drug abusers (Robertson et al., 1986), the major risk 
group within the Edinburgh area. It is therefore likely that only a few infected donors 
contributed to the plasma pool. 
HIV-1 infection of these patients from a common source allowed variation between 
patients to be studied. Samples were obtained from eight members of the cohort 
(patients 74, 77, 79, 82, 83, 84, 87 and 91), and one non-cohort patient (patient 12), 
who was infected in the United States following use of commercial factor VIII. 
Nucleotide sequences were obtained by use of limit dilution, nested PCR and to avoid 
Taq induced errors, direct sequencing of the consensus PCR product. Three 
hypervariable regions of gpl20, namely V3, V4 and V5 were studied. Phylogenetic 
analysis of the sequences derived from these regions showed that six of the eight 
cohort patients were closely linked (77, 79, 83, 84, 87 and 91) whereas two (74 and 
82) were less closely related. The non-cohort patient (12) was unrelated. These 
studies suggested that patients 74 and 82, who have no evidence of other risk factors, 
may have been infected by either different HIV- 1 strains in the same implicated 
factor VIII batch or by other contaminated batches of factor VIII. 
One haemophiliac patient 82, for whom a sero-conversion plasma sample (1984) was 
available, was used for sequential studies of HIV sequence change (Simmonds et al., 
1991; Holmes et al., 1992). A further eight samples (both plasma and PBMC's) were 
obtained from this patient at four time points between June 1987 and August 1989. 
Another haemophiliac, patient 80, for whom a 1989 plasma sample was available was 
used for sequence comparison. Nucleotide sequence was obtained at all time points 
in the V3, V4 and V5 env variable regions. Phylogenetic analysis and sequence 
comparison in these regions showed that: 1) these regions exhibit rapid sequence 
evolution, 2) evolution of HIV in-vivo is discontinuous, ie the following predominant 
sequence may not be derived from the previous one, 3) there can be a persistence of 
seroconversion sequence in the PBMCs even five years after primary infection, 
suggesting it may remain latent in the viral population, and 4) sequence which 
initially appears in the plasma later becomes the predominant type in the PBMC's, 
suggesting sequence studies based on PBMC sequence may be misleading. Further 
phylogenetic study of the V3 region in plasma RNA from this patient (82) up to 7 
years after primary infection was carried out (Holmes et al., 1992). The main result 
of this phylogenetic study was that at three years post seroconversion (1987) two 
main lineages of V3 sequence evolution had appeared which persisted such that by 
year seven no new sequences were seen in the viral population. 
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A more recent phylogenetic study (Holmes et al., 1995) has investigated the 
molecular epidemiology of lilY-i infection in these patients and others from 
Edinburgh using both gag p17 and env V3 sequence. The phylogenies constructed 
showed that the haemophiliac patients were divided into a number of distinct groups 
and were infected by at least two batches of contaminated factor Vifi, supporting the 
earlier work of Balfe et al 1990. This study also showed a common evolutionary 
origin for HIV infecting heterosexuals and intravenous drug users (IVDU's), 
suggesting that infection in these groups may have been due to a single HIV-1 
variant. The evolutionary distance between the groupings of the haemophiliacs and 
the heterosexualsflVDU's in the reconstructed phylogemes show that it is unlikely 
that the haemophiliac community were infected by the drug using community in 
Edinburgh. 
The reconstructed phylogenies of the p17 gag and the V3, V4/V5 env regions 
presented in the studies of Balfe et al 1990 and Holmes et al 1995 show tight 
clustering of the patients within the Edinburgh Haemophilia Cohort (p28, p56, p58, 
p70, p77, p79, p84, p87, p89, p91 p110  and p180). However three patients who 
seroconverted at the same time form two distinct groups outwith the main cluster 
(p74, p80 and p82). Patients 80 and 82 group together, although patient 80 never 
received any factor VIII from the implicated batch. Patient 74 clusters closely to the 
main cohort in the p17 gag and V4/V5 phylogenies but forms a distinct group in 
analysis of the V3 region. Examination of sequences obtained at sero-conversion 
from four of the main cohort patients (p28, p77, p79  and p84) in the V3 and V4 
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regions showed monotypic sequence (Zhang et at, 1993). This is similar to the 
findings in a group of German haemophiliacs contaminated from a common source, 
where the V1/V2 sequences were homogeneous at sero-conversion (Kleim et at, 
1991). Sero-conversion sequences obtained from patients 74 and 82 were distinct 
from those obtained from the main cohort. Thus it is unsurprising that the 
reconstructed phylogenies group these patients (p82 and p74) away from the main 
cohort. 
1.14 THE WORK PRESENTED IN THIS THESIS. 
The research outlined in this thesis was designed to study the development of AZT 
resistance in HIV-1 infected haemophiliacs. Two patients from the Edinburgh 
haemophilia cohort (patients 74 and 87) were studied longitudinaly over a 2.5 year 
period of AZT treatment. The first part of the work (Chapter 3) investigates the 
nucleotide sequence changes in both viral RNA and proviral DNA obtained from 
sequential plasma and PBMC samples spanning the period of treatment. Nucleotide 
sequences were obtained from two regions of the RT domain in the poi gene. The 
first of these regions POL A includes the amino acid positions 41, 67 and 70 and the 
second region POL B contains the amino acid positions 215 and 219, mutations of 
which have been implicated in AZT resistance. The patterns of resistance 
development have thus been studied. 
In order to investigate whether the selection pressure placed on the RT domain of the 
pol gene has any effect on the concurrent viral evolution in other regions proviral 
Wj 
nucleotide sequences were also obtained of the V3 env region, from the same PBMC 
samples. 
The second part of the work (chapter 4) uses the nucleotide sequences obtained from 
both the p01 and env regions to reconstruct evolutionary phylogenies for each. This 
enabled comparison to be made between the evolutionary patterns observed both 
within and between patients. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 BLOOD SAMPLES. 
Seropositive blood samples from two HIV-1 infected haemophiliacs patients receiving 
AZT, were obtained by the Haemophilia Centre, Royal Infirmary, Edinburgh. 
Samples were collected before, during and after stopping Zidovudine (AZT) therapy. 
The plasma and peripheral blood mononuclear cells (PBMC's) were separated by 
density centrifugation (400g for 30 minutes) on sodium metrizoate/Ficoll. Plasma 
samples were stored at -70 °C and the PBMC's stored in liquid nitrogen. 
2.2 EXTRACTION OF DNA FROM PBMC's 
Buffy coat containing approximately 5x106 cells was washed in 20mls RPMI and 
centrifuged at 1500rpm for 10 minutes. The resulting cell pellet was resuspended in 
400pl of lysis buffer (50mM EDTA pH 8.0, 100mM Tris-HC1 pH7.5, 50mM NaCl; 
0.01% proteinase K; 1% N-lauroylsarcosine ), mixed and incubated at 65°C for 2 
hours. Following incubation the DNA was extracted twice with 600ji1 of phenol and 
once with 600p1 of chloroform. The aqueous phase was removed, mixed with lml 
of 100% ethanol and the DNA allowed to precipitate overnight at -20°C. To pellet 
the DNA the resulting precipitate was centrifuged at 14000Xg for 15 minutes. The 
supernatant was discarded and the DNA pellet dried under vaccum before being 
resuspended in 20 to 200j.il of DEPC treated distilled water. 
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2.3 EXTRACTION OF VIRAL RNA FROM PLASMA. 
200iil of plasma was subjected to ultracentrifugation at 45,000Xg, at 4°C for 2 hours, 
to concentrate viral particles. The resulting pellet was then resuspended in imi 
denaturing solution (2M guanidinium thiocyanate; 12.5mM sodium citrate pH7.0; 
0.25% sarcosyl; 0.05M 2-mercaptoethanol, 50%water-saturated distilled phenol and 
lug mouse carrier RNA), 200p1 of chloroform and mixed vigorously, (Chomczynski 
and Sacchi, 1987) before being incubated on ice for 15 minutes. The solution was 
then centrifuged at 14,000Xg for 15 minutes, to separate the aqueous phase 
containing the HIV-RNA from the organic phase. The aqueous phase was added to 
an equal volume of isopropanol and the RNA allowed to precipitate for at least 45 
minutes at -20°C. Following centrifugation at, 14,000Xg at 4 °C for 15 minutes, the 
RNA pellet was then washed once in lml 75% ethanol, dried at 42 °C for 10 minutes 
and resuspended in 20pl of diethylpyrocarbonate treated distilled water, and stored 
at -70°C. 
Extractions of both DNA and RNA were carried out by Fiona Davidson, Elizabeth 
Harvey and Pamela Robertson in the Centre for HIV Research. 
2.4 REVERSE TRANSCRIPTION OF VIRAL RNA. 
In order to amplify cell free HIV-RNA directly from plasma or serum by the 
polymerase chain reaction (PCR), viral RNA must first be reverse transcribed into 
cDNA. This was performed by specific viral primer initiated cDNA synthesis. cDNA 
synthesis was carried out by adding 3pl of the extracted RNA to reverse transcription 
reaction buffer (50mM Tris-Cl, pH8.0; 5mM MgCl 2; 5mM DTT; 50mM KC1; 
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0.05pg/pl bovine serum albumin(BSA); 600pM each of dATP, dGTP, dTTP, dCTP; 
20% Dimethyl Sulphoxide(DMSO); 200ng of outer antisense primer; 15 units 
RNAsin and 10 units AMV reverse transcriptase) and incubating at 42 °C for 30 
minutes. Subsequent PCR amplification was carried out as described in section 2.6. 
2.5 LIMIT DILUTION OF DNA AND eDNA PRIOR TO PCR 
AMPLIFICATION. 
Prior to PCR amplification both the DNA and cDNA were titrated to the limit 
dilution point (Simmonds et al., 1990b). This is defined as the dilution at which 
approximately 20% or less of the following PCR reaction products are positive. By 
application of the Poisson distribution this makes it very likely that only single 
molecules of target sequence were present at the outset of the PCR reaction in tubes 
which are positive after two rounds of amplification 
2.6 AMPLIFICATION BY THE POLYMERASE CHAIN REACTION (PCR). 
The polymerase chain reaction (PCR) is a powerful in-vitro method of DNA 
amplification. It involves putting the target DNA through a series of repetitive cycles 
involving template denaturation, primer annealing and the extension of the annealed 
primers by heat stable DNA polymerase. This leads to an exponential increase in the 
amount of target sequence. 
In this project a double PCR method using nested oligonucleotide primers was used. 
This was necessary as it increases the sensitivity and specificity of the reaction and 
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is the only method sensitive enough to amplify from a single copy of target sequence. 
In the first round amplification (20p1) the DNA or cDNA which had previously been 
limit diluted was added to a PCR mix containing, 50mM KC1, 10mM Tris-HC1(pH 
8.8), 1.5mM MgC12, 0.1% Triton X-100; 3.3pM each of dGTP, dATP, dTTP, dCTP; 
0.5pM of each of the outer primers, and 30units/ml of Taq polymerase. It was then 
subjected to thirty heat cycles, each consisting of 25 seconds at 94°C, 35 seconds at 
55°C and 150 seconds at 72 °C. This was followed by 7 minutes at 72 °C. One 
microlitre of the first round amplification product was then transferred to a second 
tube containing an identical buffer but with two inner primers replacing the outer 
primers. This was then subjected to 30 cycles as described above. 
Following the second amplification the products were analysed by visualisation on 
an ethidium bromide stained agarose gel. (see section 2.7) 
2.7 AGAROSE GEL ELECTOPHORESIS OF PCR PRODUCTS 
Visualisation of PCR product was carried out using an ethidium bromide stained 2% 
Agarose gel. Six grams of agarose (Flowgen) were dissolved in 30mls lOx TBE 
buffer (0.89M Tris-borate, 0.89M boric acid, 0.1M EDTA;pH 8.5) and 270m1s 
distilled water and heated to 90 °C. The gel was then allowed to cool to approximately 
50°C, ethidium bromide (0.5j.ig/ml) added and the gel was poured onto a prelevelled 
electrophoresis plate and allowed to set for about 30 minutes, at room temperature. 
The electrophoresis was carried out at 150 volts for twenty minutes. After 
electrophoresis was completed the gel was placed on a transilluminator and the 
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positive PCR products visualised by UV light; if required a photograph was taken 
using a Polaroid camera and polaroid 667 film. 
2.8 HIV: POL and ENV GENE PRIMERS 
All primers used in this work were synthesised by the Oswel DNA Service, 
Department of Chemistry, University of Edinburgh, on an Applied Biosystems 394 
Synthesiser. After synthesis all primers were purified by HPLC. 
2.8.1 HIV POL PRIMERS 
 5'- GCTGTC'VrT-FTCTGGCAGCAC -3' (-3281) Anti-sense. 
 5'- GTAGGACCTACACCTGTCAAC -3' (+2480) Sense. 
 5'- CCA'TTTATCAGGATGGAGTTC -3' (-3245) Anti-sense. 
 5'- CCCAAAAGTTAAACAATGGCC -3' (+2602) Sense. 
 5'- GTCTCATTGTTTATACTAGG -3' (-2965) Anti-Sense 
 5'- GACACCAGGGATFAGATATC -3' (+2963) Sense 
 5'- AGTAGAAATTI'GTACAGAAATGG -3 (+2653) Sense. 
2.8.2 HIV ENV PRIMERS 
 5'- TACAATGTACACATGGAATF -3' (+6957) Sense. 
 5'- ATTACAGTAGAAAAATFCCCC -3' (-7361) Anti-sense. 
 5'- TGGCAGTCTAGCAGAAGAAG -3' (+7009) Sense. 
 5'- CTGGGTCCCCTCCTGAGG 	-3' (-7314) Anti-sense. 
All coordinates listed are in relation to HJVHXB2 sequence (+:sense, -:anti-sense). 
See Figure 2.1 for primer layout. 
2.9 PURWICATION OF PCR PRODUCTS 
Prior to sequencing it is important that excess unincorporated nucleoside triphosphates 
and primers are removed from the PCR products as these interfere with the 
subsequent sequencing reactions. 
During the course of this work several methods of nucleic acid purification have been 
used, GENE CLEAN (BlO 101 Inc.) and MAGIC PCR PREPS (PROMEGA) for 
manual sequencing, and DYNABEADS (DYNAL AS) for automated sequencing. 
Each is described individually below. 
2.9.1 GENE CLEAN (BIO 101 Inc.) 
To 50il of the PCR product amplified for sequencing (See section 2.10.1), 150p1 of 
6M Nal solution was added. The resulting solution was mixed thoroughly, before 5pl 
of Glassmilk (prepared silica matrix) was added. This was again mixed vigorously 
and incubated at room temperature for five minutes to allow formation of a 
Glassmilk/DNA complex. Following incubation the GlassmilkfDNA complex was 
pelleted by centrifugation for 5 seconds at 10,000rpm. The supernatant was removed 
and discarded and the pellet washed three times with Newwash (NaCl, ethanol, 
water). After the third wash the DNA complex was dissociated in 20il lx TE buffer 
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( 10mM Tris.HC1, pH7.4; 1mM EDTA, pH8.0) by incubation at 55°C for five 
minutes. The resulting DNA solution was then ready for sequencing. 
2.9.2 MAGIC PCR PREPS DNA PURIFICATION SYSTEM (PROMEGA 
CORPORATION) 
To lOOp! of PCR product, lOOpl of direct purification buffer (50mM KC1, 10mM 
Tris-HC1 pH 8.8, 1.5mM MgC12, 0.1% Triton X-100) was added and the mixture 
vortexed vigorously. Following this, lml of "Magic" PCR prep resin was added and 
the tubes mixed vigorously three times over a period of one minute. For each 
product, one "Magic" minicolumn was attached to a 3m1 disposable Luer lock syringe 
with the plunger removed. The resin/DNA mix was pipetted into the syringe barrel, 
the plunger reinserted, and the mix pushed through the minicolumn. The syringe was 
removed from the minicolumn, the plunger removed and the barrel reattached. 2m1 
of 80% isopropanol was then added to the syringe barrel, the plunger reinserted, and 
the isopropanol forced through the minicolumn. The syringe was then removed and 
discarded. The minicolumn was then inserted into a 1.5m1 microcentrifuge tube and 
spun at 12000xg for 20sec to dry the resin. Finally the minicolumn was transfered 
to clean 1.5m1 Eppendorf tube and 30pl TE buffer added. The minicolumn was then 
allowed to stand for 1 minute, before centrifugation at 12,000xg to elute the bound 
DNA. The DNA was then ready for sequencing. 
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2.9.3 DYNABEADS BIOMAGNETIC SEPARATION SYSTEM (DYNAL AS) 
This method involved the use of streptavidin coated magnetic beads (Dynabeads), to 
prepare single stranded DNA from double stranded PCR product for solid phase DNA 
sequencing.The final PCR reaction was carried out in a total volume of lOOjil. A 
biotinylated primer was used at one end and a non biotinylated on the other. These 
were used in a ratio of lOpmol:30pmol respectively. 
For each sample purified 20j.il of streptavadin coated beads were washed once in an 
equal volume of binding and washing buffer (10mM Tris.HC1, pH7.5; 1mM EDTA; 
2.OM NaC1). After washing by magnetic separation the dynabeads were resuspended 
in twice the volume of binding and washing buffer to give a working concentration 
of 5pg/pl. To allow the immobilisation of the PCR product 40pl of PCR product was 
added to an equal volume of washed dynabeads and incubated at 48 °C for 30 
minutes. Following incubation the tubes were placed in a magnetic separator, the 
supernatant removed and discarded. The beads were then washed in 50pl of binding 
and washing buffer, before being incubated for 10 minutes in 0.1M NaOH to separate 
the strands. The tubes were then placed back in a magnetic separator and the NaOH 
supernatant containing the non-biotinylated strand was aspirated off to a clean tube. 
The dynabeads with the immobilised biotinylated strand were washed once with 50jil 
0. 1M NaOH, once with 50p1 binding and washing buffer and once with 50jil TB 
buffer, before being resuspended in 14pl dH20. The DNA was then ready for 
sequencing. 
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If the nonbiotinylated strand was also to be sequenced the NaOH supernatant was 
neutralised with 4pl 0.2M HC1 and ipi 1M Tris.HC1 pH7.5. 
2.10 DIRECT SEOUENCING OF PCR PRODUCTS 
2.10.1 MANUAL SEOUENCING 
Manual sequencing was carried out using a SEQUENASE VERSION 2, sequencing 
kit from United States Biochemicals (USB) in conjunction with a modified method 
described by Winship (Winship, 1989). The modification consists of the inclusion of 
10% tissue culture grade DMSO which was added to the annealing and termination 
reactions. This was found to enhance the intensity of the signal and reduce 
background interference .The sequencing reaction involves the addition of 
approximately lOOng of purified PCR product to annealing mix (10% DMSO, 
200mM Tris.HC1 pH 7.5, 100mM MgCl2 ,250mM NaCl, lOng oligonucleotide 
primer) which was then boiled for three minutes to denature the template. Following 
boiling the mix was placed on ice thus preventing template renaturation, and 
extension mix (0.025 DTT, diluted labelling mix, Suipher 35 dATP, 2 units of 
sequenase) added. This mixture was then divided between four prewarmed (40 °C) 
termination mixes containing: 80pM dNTP (dGTP,dATP,dTTP,dCTP); 8pM ddNTP 
(ddGTP,ddATP,ddCTP,ddTTP) ; 50mM NaC1; 10% DMSO and left to incubate for 
five minutes. The reaction was then stopped by the addition of 4p1 of stop solution 
(95% Formamide, 20mM EDTA, 0.1% Bromophenol blue, 0.1% Xylene Cyanol FF). 
Prior to loading onto a polyacrylamide gel (see section 2.11.1) the samples were 
heated to 95°C for two minutes. 
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2.10.2 AUTOMATED SEQUENCING (APPLIED BIOSYSTEMS 373A) 
Automated flourescent sequencing offers advantages over manual sequencing in that 
the data can be collected during the polyacrylamide gel electrophorises (PAGE) and 
a higher throughput of samples is possible. Two main types of flourescent chemistry 
were available, dye primer and dye terminator. In the case of dye primer chemistry 
a flourescent dye is attached to the 5'end of the primer, whereas with dye terminator 
sequencing a dye is attached to the dideoxynucleotide triphosphates. Dye terminator 
17 chemistry was used for all the automated sequence data presented in this thesis. 
Annealing reaction were carried out in a 0.5m1 Eppendorf microcentrifuge tube 
involved the mixing of 141il of single stranded template DNA, (from Dynabead clean 
up), ipi of primer (0.8pM) and 5pl of 5X ss MOPS buffer, (400mM MOPS buffer 
pH7.5, 500mM NaCl, 100mM MgCl2, 50mM MnC12, 150mM isocitrate, 25% 
glycerol). The tubes were heated to 65°C for 2 minutes to allow the primer to anneal 
and then cooled slowly over a period of approximately 30 minutes to 30°C. With the 
annealing complete 4p1 of Sequenase terminator mix (alpha-thio dNTP's) was added. 
It was important at this stage that the tubes were kept in the dark as the terminators 
were light sensitive. The tube was then heated to 37°C for at least 2 minutes, lpl (1.5 
units) of Sequenase enzyme added and incubation continued for a further 10 minutes. 
The tubes were then placed on ice and stored in the dark. When termination was 
complete the products were cleaned to remove excess terminators (ddNTP's) which 
can flouresce and interfere with the signal read by the laser. When the Dynabead 
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clean up system was used the biotinylated strand and the non biotinylated strands 
needed to be treated separately. 
Biotinylated Strand. 
The tubes were placed in the magnetic separator and the supernatant removed 
and discarded. Using the same technique the beads were then washed twice 
with lOOjil 250mM Tris pH 8.0, 0.1% Tween 20 and once with 1xTE buffer. 
Non Biotinylated Strand. 
29.5pl of 8M Ammonium Acetate was added to the terminated reaction and 
mixed prior to the addition of 15Op1 of 95% ethanol and further vigorous 
mixing. The tubes were then placed on ice in the dark for 20 minutes, before 
being centrifuged at 10,000Xg for 20 minutes. The supernatant was removed 
and discarded, and the pellet dried on a hot block. 
Prior to loading the beads/pellet were resuspended in 5pl deionised formamide / 
50mM EDTA pH 8.0, mixed in a ratio of 5:1. The samples were heated to 90°C for 
2minutes to denature and loaded immediately onto an acrylamide gel. 
2.11 POLYACRYLAMIDE GEL ELECTROPHORESIS. 
2.11.1 MANUAL SEQUENCING. 
Polyacrylamide gel electophoresis was carried out using 8% wedge gels (0.4mm at 
the top and 1.2mm at the bottom). For 150mls of 8% gel, 75g Urea, 12g acrylamide, 
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0.6g bis acrylamide, 0.15g ammonium persuiphate and 15mls of lOX TBE buffer 
were dissolved in 50mls of distilled water. Prior to pouring between glass plates 
20j.il of TEMED (N,N,N'N'-Tetramethylethylenediamine) was added. The gels were 
run for approximately 3 hours, 75 watts until the bromophenol blue reached the 
bottom of the gel. Following electrophoresis the gel was fixed by soaking for 15 
minutes in two changes of 7% methanol:7% acetic acid solution. The gel was then 
dried for 2 to 3 hours at 80°C on a vacuum drier, placed in an autoradiography 
cassette containing Kodak XAR-5 film and exposed overnight. 
2.11.2 AUTOMATED SEQUENCING. 
For automated sequencing, it is crucial that the glass plates used are cleaned 
thoroughly with alconox, a non-flourescing detergent, and warm water. Any dirt 
which is not washed off may fluoresce and alter the data being collected by the 
computer as the gel runs. 
PAGE was carried Out using a 6% acrylamide flat gel. For a 60m1 gel, 30g Urea, 
9mls 40% acrylamide stock solution, 20mls dH 20, and 0.5g mixed bed resin were 
dissolved and filtered through a 0.2pM cellulose acetate filter, before the addition of 
6mls filtered lOX TBE. The gel mixture was then poured into a 150m1 beaker, 300pl 
ammonium persulphate and 33pl TEMED added. Immediately, the gel solution was 
poured between the glass plates and the gel casting comb inserted. The gel was then 
clamped to hold the plates tightly together, placed in a horizontal position and left 
to polymerise for at least 2 hours. 
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When polymerisation was complete, the casting comb was removed and the gel 
washed with water to remove any excess gel solution. Following washing the gel was 
allowed to air dry, then placed in the sequencing machine. Prior to loading a plate, 
a check was carried out to ensure the plates were clean; if they were not, they had 
to be removed and washed again in distilled water and rechecked. When clean, the 
comb was placed in the top of the gel, 1X TBE buffer added to the upper and lower 
buffer chambers and the samples loaded. Gels were run for 12 hours at 28 watts. 
The data was collected on an Apple Macintosh computer by Applied Biosystems 
373A software, consisting of two programs Data Collection and Data Analysis. Figure 
2.2 shows an example of the collected data. 
2.12 PROCESSING OF SEQUENCE DATA. 
2.12.1 FROM MANUAL GELS 
The developed autoradiograph was placed on a light box and the sequence data typed 
directly into Wordperfect. The file was then converted from Wordperfect to DOS 
format and then transferred to a Sun Sparc station computer for further analysis, 
described in section 2.13. 
2.12.2 FROM THE ABI AUTOMATED SEQUENCING MACHINE 
Following the collection of data on the Apple Macintosh computer the sequence files 
were transferred to a Sun Sparc station computer using the Columbia Apple Talk 
Package (CAP). After transfer to the Sun, the sequence files were preliminarily edited 
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using TED (part of the Staden Computer Package) implemented using the Seqprocess 
script (written by C.M.Wade, Center For HIV Research, University of Edinburgh). 
Following preliminary editing the data were entered into the XBap data base (Staden 
Computer Package) using the Seqedit script (C.M.Wade, as above) and stored for 
further analysis, as described in section 2.13. 
2.13 SEOUENCE ANALYSIS 
The nucleotide sequences obtained for each patient were aligned and translated to 
amino acid sequences within version 2.2 of the Genetic Data Environment Package 
(GDE: Provided by the Harvard Genome Laboratory). Phylogenetic analysis of the 
nucleotide sequence data was carried out using programs taken from version 3.52c 
of the Phylogeny Inference Package (PHYLIP). Distance based phylogenies were 
reconstructed using the neighbour-joining method (program NEIGHBOR) with 
distances estimated to each pairwise nucleotide sequence comparison using the two 
parameter maximum liklihood model (program DNADIST). Phylogenies were also 





3.1 AZT THERAPY 
3.1.1 Patient p74 was on continuous AZT therapy from February 1988 until 
August 1990. The initial dose in February 1988 was 1200mg/day which continued 
until June 1990 except for a two week period in March 1989 when the dose was 
reduced to 600mg/day due to neutropenia. In June 1990 the dose was reduced to 
600mg/day and then in July to 100mg/day before treatment was finally stopped in 
August 1990. 
3.1.2 Patient p87 started AZT therapy on a dose of 1200mg/day in October 
1987. This continued until April 1989 when the daily dose was reduced to 
600mg/day. Between May and October 1989 treatment was stopped. In October 
1989 treatment was restarted at 300mg/day and increased to 400mg/day in May 
1990, before finally being stopped in June 1990. 
3.2 SAMPLES 
A total of ten samples from each patient were collected before, during and after 
stopping AZT. From patient p74, 4 plasma samples (April 1986, July 1988, 
March 1990 and October 1990) and 6 PBMC samples (October 1987, June 1988, 
March 1989, September 1989, March 1990 and October 1990) were obtained. 
From patient p87, 4 plasma (September 1987, February 1988, May 1989 and 
September 1989) and 6 PBMC samples (November 1987, February 1988, August 
1988, March 1989, September 1989 and August 1990) were obtained by Dr H G 
Watson. Viral RNA was extracted directly from the plasma by Pamela Robertson 
as described in section 2.3 and pro-viral DNA was extracted from the PBMC's as 
described in section 2.2. 
Clinical details and sample dates are summarised on page 50 for patient p74 and 
on page 51 for patient p87. 
3.3 CALCULATION OF VIRAL LOAD FROM PLASMA 
The sensitivity of the nested PCR for single molecules of target sequence 
(Simmonds et al., 1990b) permits a straightforward method of quantitation of viral 
sequences. Following extraction of viral RNA from plasma and subsequent cDNA 
synthesis (see sections 2.3 and 2.4), samples were titrated to an end point in serial 
10 fold dilution steps and the diluted products amplified using a nested PCR. The 
final concentration producing a visible signal after two rounds of amplification 
was considered to contain at least one molecule of target sequence. The Poisson 
distribution was then used to calculate the likelihood of positive samples having 
originally contained one or more molecule of target RNA. The observed 
frequency of negative reactions was converted into molecular concentrations of 
target RNA by the Poisson formula -(In fo), where f0 is the frequency of negative 
reactions (Simmonds et al., 1990b). In the final calculation, the efficiency of the 
initial reverse transcription step, which has been estimated at 5% (Zhang et al., 
1991), must also be taken into consideration. 
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* 2 WEEKS ONLY - NEUTROPAENIA 
SAMPLES OBTAINED 
DATE YEAR OF 
INFECTION 
PLASMA PBMC' s 
1984 0 + 
04/86 2 + 
10/87 3 + 
06/88 4 + 
07/88 4 + 
03/89 5 + 
09/89 5 + 
03/90 6 + + 
10/90 6 + + 
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PATIENT P87 CLINICAL DATA 
HLA Haplotype 	 A1/2 B8/48 W4/6 DR3/4 
Risk Group 	 Haemophiliac 
Seroconversion 	 1984 
AIDS diagnostic illness PCP 
Date of Death 	 09/1990 










DATE YEAR OF 
INFECTION 
PLASMA PBMC' s 
1984 0 
09/87 3 + 
11/87 3 + 
02/88 4 + + 
08/88 4 + 
03/89 5 + 
05/89 5 + 
09/89 5 + + 
08/90 6 + 
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For example :- 
200jil of plasma is used in the RNA extraction. The pellet is finally 
resuspended in 20jil of dH20. 6.5p1  of this is then used in cDNA 
synthesis and 3/4 of this used to set up 25 PCR reactions. Therefore 
each PCR tube contains the RNA from ((3/4)16.5 x 10)125 p1 of 
plasma, which is 1.95pl. If 7/25 PCRs are positive, the expected 
frequency of positives is -ln(18/25), or 0.3285, which is multiplied 
by 1000/1.95 to give an estimated concentration of 168.46/ml. 
Taking the reverse transcription efficiency as 5%, the observed load is multiplied 
by 20 to give the inferred load, in this case the inferred viral load would be 
3,369.23. 
Viral loads have been calculated for each of the RNA samples obtained from both 
patients p74 and p87. These have been plotted along with CD 4 cell count for each 
patient in figure 3.1. 
3.4 CHANGES IN VIRAL LOAD AND CD4 CELL COUNT DURING AZT 
THERAPY. 
3.4.1 PATIENT 74 
The inferred viral load prior to commencement of AZT therapy was approximately 
3,000 viral genomes/mi. After 5 months of therapy the viral load showed little 
change from the pre-treatment level. Over the next 20 months (July 1988 to 
March 1990), the inferred viral load showed a decline of 500 viral genomes /ml. 
Between March 1990 and October 1990 (treatment stopped August 1990), the viral 
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FIGURE 3.1 
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load rose to 4,600 genomes /ml. The CD4 cell count was at its peak 
(350cells/mm3) when treatment started in February 1988 after which it dropped to 
150 cells/mm 3 over the following 5 months, before recovering to 300 cells/mm 3 in 
January 1989. The CD4 cell count then dropped steadily to 20 cells/mm 3 when 
treatment was stopped in August 1990. 
3.4.2 PATIENT 87 
The inferred viral load before AZT therapy of over 3,000 viral genomes per ml, 
persisted at an almost constant level throughout. Unfortunately a plasma sample 
was unavailable after therapy was stopped. The CD4 cell count during the period 
of treatment showed a transient rise, from 160cells/mm 3 at commencement of AZT 
therapy (Oct 1987) to a peak of 260 cells/mm 3 after 3 months. After this initial 
rise the CD4 cell count declined steadily to 20 cells/mm 3, when therapy was 
stopped after 33 months in June 1990. 
3.5 SEOUENCE ANALYSIS OF THE RT REGIONS CONTAINING THE 
AZT RESISTANCE CONFERRING SUBSTITUTIONS. 
Nucleotide sequence data were obtained from patients 74 and 87 in two regions of 
the reverse transcriptase gene, POL A and POL B. POL A includes the AZT 
resistance conferring changes at amino acid positions 41, 67 and 70. POL B 
includes the changes at positions 215 and 219. 
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Sequences were obtained directly from double PCR amplified single molecules. 
Each sequence representative of a single genome was obtained by limit dilution 
prior to PCR amplification. As in all cases the POL A and POL B sequences were 
obtained from the same first round PCR product, the association between all five 
implicated mutations can be studied. 
First round PCR amplifications in most cases were carried Out using primers (1) 
and (2) to give a 780 base product, followed by a second round of amplification 
using primers (3) and (4) to yield a final product of 622 nucleotides (primer 
information can be found in section 2.8). The products were then purified (see 
section 2.9) and sequenced directly using primer (4) to give a sense sequence of 
the POL A region and primer (3) to give an antisense sequence of the POL B 
region. However in the case of patient 87, the pretreatment, 5, 16, 45, 74 and 103 
week samples were sequenced prior to the mutation at position 41 being 
implicated in the development of AZT resistance (Kellam et al., 1992). In these 
cases, first round amplification was carried out using primers (1) and (4) to give a 
658 base primary product. The secondary amplification was then carried out to 
give two products, the first using primers (5) and (7) to give a 272 base product 
spanning the POL A region containing the mutations at positions 67 and 70, and 
the second using primers (3) and (6) yielding a 263 nucleotide product containing 
the mutations at positions 215 and 219 in the POL B region. These were 
sequenced directly from both primers ((5) and (7) for POL A and (3) and (6) for 
POL B) to obtain sequence of the whole PCR fragment. 
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A total of 99 sequences were obtained from patient 74 and 80 from patient 87. 
For patient 74, viral RNA sequences were obtained at: pre-treatment (-22 months), 
22 weeks, 110 weeks and post-treatment; 8, 8, 11 and 9 sequences respectively. 
Proviral DNA sequences were obtained at pre-treatment (9 sequences), 17 weeks 
(11 sequences), 56 weeks (9 sequences), 81 weeks (12 sequences), 110 weeks (11 
sequences) and post-treatment (11 sequences). Viral RNA sequences from patient 
87 were obtained at pre-treatment, 17 weeks, 83 weeks and 103 weeks; 7, 6, 6 and 
7 sequences were obtained respectively. Sequence from pro-viral DNA was 
obtained at 5 weeks (11 sequences), 16 weeks (9 sequences), 45 weeks (7 
sequences), 74 weeks (7 sequences), 103 weeks (11 sequences) and post-treatment 
(9 sequences). For sample dates see section 3.2. 
The amino acid sequence inferred from the nucleotide sequence in both POL A 
and POL B is summarised in figures 3.2 and 3.3 for patient 74. The POL A 
region shown is from reverse transcriptase gene amino acid 35 -> 73 and the POL 
B region from amino acid 209 -> 224. Patient 87 amino acid sequence is shown 
in figures 3.4 and 3.5. The POL A region shows amino acids 35 -> 73 for 
sequences obtained at 17, 83 and 148 weeks; all other time points are shown from 
amino acid 51 -> 73 inclusive (mutation at position 41 not investigated) of the 
reverse transcriptase gene. The POL B region is shown from amino acids 209 -> 
224. The nucleotide sequence of all distinct genotypes is shown for both patients 
in Appendix 1. 
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Examination of the amino acid sequence shown shows the presence of changes 
other than those at positions 41, 67, 70, 215 and 219 which are associated with 
AZT resistance development. Changes at amino acid positions 39, 43, 44, 51, 61, 
64, 68, 210, 211 and 214 are seen in patient 74, with changes at positions 60, 211 
and 214 seen in patient 87. Of these amino acid changes only two have been 
observed in other HIV-1 type B sequences from the Los Alamos Human 
Retrovirus and AIDS Database (Myers, 1994), these being the changes at 
positions 211 and 214. The change at position 211 (Arg->Lys) is seen in 
HIVJRCSF, HIVHAN and HIVRF, with the change at position 214 (Phe->Leu) 
being seen in HIVLAI, HIVHXB2 and HIVCAM1. The changes observed at 
positions 44, 211 and 214 have been reported by others (Sheehy and Desselberger, 
1993; Kellam et al., 1994). It is therefore unsurprising that in both these patients 
the in-vivo samples were polymorphic for these forms. The other observed amino 
acid changes (positions 39, 43, 51, 61, 64, 68, and 210 do not appear in the 
published sequences. 
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Figure 3.2 Shows the codon changes observed in the area around the resistance-
conferring mutations in the POL A region of patient 74. 
Amino acid sequence is shown from RT amino acid 35 to 73. The changes which 
have been shown to be associated with resistance are located at positions 41, 67, 
and 70. 
The resistance-conferring changes are:- 
41 	M=(MET)wildtype L=(LEU)mutant 
67 D=(ASP)wildtype N=(ASN)mutant 
70 	K=(LYS)wildtype R=(ARG)mutant 
POL A AMINO ACID ALIGNMENT FOR PATIENT P74 
AMINO ACID POSITIONS 	 35 	41 	 67 70 	73 
SAMPLE DATE DNA/RNA VF.ICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRK NO.SEQ 
PRE-TREATMENT RNA 8 
PRE-TREATMENT DNA N 1 9 
17 WEEKS DNA Ii R2 R6 11 
22 WEEKS RNA R8 8 
56 WEEKS DNA L 1 R1 	N 1 	R 7 9 
81 WEEKS DNA L10 1 3 P. 2 12 
110 WEEKS DNA A4 L 11 E 1 1 5 11 
110 WEEKS RNA A5 L 11 E 3  D, 18 11 
POST-TREATMENT 
148 WEEKS  
DNA A 7 L 11 E 1 1 7 11 
POST-TREATMENT 
148 WEEKS 
RNA A5 L 9 E 4 
Qi 
16 9 
TREATMENT STOPPED AT 132 WEEKS 
FIGURE 3.2 
Figure 3.3 Shows the codon changes observed in the area around the resistance-
conferring mutations in the POL B region of patient 74. 
Amino acid sequence is shown from RT amino acid 209 to 224. The changes 
which have been shown to be associated with resistance are located at positions 
215, and 219. 
The resistance-conferring changes are: 
215 T=(THR)wildtype 	Y=(TYR)mutant 
219 K=(LYS)wildtype Q=(GLN)mutant 
POL B AMINO ACID ALIGNMENT FOR PATIENT P74 
AMINO ACID POSITIONS 	209 	 215 	219 	224 
I I 1 I 
SAMPLE DATE DNA/RNA LL R WGF T TPDKKHQKE NO.SEQ 
PRE-TREATMENT RNA  8 
PRE-TREATMENT DNA K1 9 
17 WEEKS DNA 11 
22 WEEKS RNA Y2 8 
56 WEEKS DNA Y 9 9 
81 WEEKS DNA W 1 	L 1 Y12 12 
110 WEEKS DNA W K3 	Yll 11 
110 WEEKS RNA W-, K 5 Y 11 11 
POST-TREATMENT 
148 WEEKS 
DNA W3 K3 	Y11 11 
POST-TREATMENT 
148 WEEKS 
RNA j W 8 K 8 	Y 9 9 
TREATMENT STOPPED AT 132 WEEKS 
FIGURE 3.3 
Figure 3.4 Shows the codon changes observed in the area around the resistance-
conferring mutations in the POL A region of patient 87. 
Amino acid sequence is shown from RT amino acid 35 to 73. The changes which 
have been shown to be associated with resistance are located at positions 41, 67, 
and 70. 
The resistance-conferring changes are:- 
41 	M=(MET)wildtype L=(LEU)mutant 
67 D=(ASP)wildtype N=(ASN)mutant 
70 	K=(LYS)wildtype R=(ARG)mutant 
POL A AMINO ACID ALIGNMENT FOR PATIENT P87 
AMINO ACID POSITIONS 	35 	41 	 67 70 	73 
SAMPLE DATE DNA/RNA VEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRK NO.SEQ 
PRE-TREATMENT RNA 7 
5 WEEKS DNA 11 
16 WEEKS DNA R 1 9 
17 WEEKS RNA R4 6 
45 WEEKS DNA R3 7 
74 WEEKS DNA 
- 
- Ii N R4 7 
83 WEEKS RNA R6 6 
103 WEEKS DNA 
- 
N 1 	R3 11 







N 4 	R5 9 
TREATMENT STOPPED AT 140 WEEKS 
FIGURE 3.4 
Figure 3.5 Shows the codon changes observed in the area around the resistance-
conferring mutations in the POL B region of patient 87. 
Amino acid sequence is shown from RT amino acid 209 to 224. The changes 
which have been shown to be associated with resistance are located at positions 
215, and 219. 
The resistance-conferring changes are: 
215 T=(THR)wildtype 	Y=(TYR)mutant 
219 K=(LYS)wildtype Q=(GLN)mutant 
POL B AMINO ACID ALIGNMENT FOR PATIENT P87 
AMINO ACID POSITIONS 	 209 	 215 	219 	224 
SAMPLE DATE DNA/RNA LL R WGF T TPDKKHQKE NO.SEQ 
PRE-TREATMENT RNA K5 L 1 7 
5 WEEKS DNA K7 11 
16 WEEKS DNA K 6 L 1 9 
17 WEEKS RNA K4 6 
45 WEEKS DNA K3 L3 7 
74 WEEKS DNA K4 Y1 Q2 7 
83 WEEKS RNA K 6 Y 6 6 
103 WEEKS DNA K11 Y2  Q5 11 
103 WEEKS RNA K 7 Y 2  Q3 7 
POST-TREATMENT 
148 WEEKS 
DNA K9 Y4 Q5 9 
TREATMENT STOPPED AT 140 WEEKS 
FIGURE 3.5 
3.6 ACQUISITION OF AZT RESISTANCE CONFERRING CODON 
CHANGES IN THE RT GENE. 
3.6.1 PATIENT P74 
None of the substitutions implicated in conferring resistance were seen in either 
the viral RNA or proviral DNA samples obtained before beginning AZT therapy. 
In the viral RNA at 22 weeks all sequences show the mutation at position K70R 
(see figure 3.6). In addition the substitution at position T215Y is seen in 2/8 
sequences. By 110 weeks (viral RNA) the change at position 70 has reverted to 
wild type in all sequences; however changes at position M41L and T215Y are 
present in all sequences at this time point. These changes at positions 41 and 215 
persisted in the viral RNA, 8 weeks after stopping treatment. 
In the proviral DNA the substitution at position K70R was first observed at 17 
weeks in 6/11 sequences. At 56 weeks the proviral DNA had mutations at 
positions M41L, DON, K70R and T215Y in 1/9, 1/9, 7/9 and 9/9 sequences 
respectively. The proviral DNA at 81 weeks had mutant forms at positions M41L, 
K70R and T215Y. The substitution at position T215Y was found in all sequences 
from this time point, while the substitution at position M41L became more 
frequent (10/12 mutant) and the change at position K70R showed a lower 
frequency of mutants than was seen compared to the previous time point. By 110 
weeks all sequences coded for mutants at positions M41L and T215Y and, as with 
the viral RNA, these changes persisted in the population 8 weeks post treatment. 
These changes are shown in Figure 3.7. 
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Figure 3.6 Autoradiograph of sequence obtained from a manual sequencing. 
The sequence shown shows both wildtype and mutant nucleotide sequence at RT 
codon 70 (AAA(wt)->AGA(m)), as indicated by the arrows. The sequences 
shown here were obtained from the 17 week plasma sample from patient 87. 
:I:!1:!II 
TCATCATC 
Figure 3.7 Resistance-conferring RT codon changes at each of the respective 
positions, in patient 74. Mutant amino acid changes are shown in bold. 
Position 	41 M=(MET)wildtype L=(LEU)mutant 
67 D=(ASP)wildtype N=(ASN)mutant 
70 K=(LYS)wildtype R=(ARG)mutant 
215 T=(THR)wildtype Y=(TYR)mutant 
219 K=(LYS)wildtype Q=(GLN)mutant 
Discussed in section 3.6.1. 
RESISTANCE CONFERRING RT CODON CHANGES IN PATIENT 74 
AZT RT CODON NUMBER NUMBER OF 
THERAPY DNA/RNA SEQUENCES 
41 67 70 215 219 
PRE RNA M D K T K 8 
TREATMENT 
PRE DNA M D K T K 9 
TREATMENT 
17 WEEKS DNA M D Ks/R6 T K 11 
22 WEEKS RNA M D R T,/Y, K 8 
56 WEEKS DNA M8/L1 D/N 1 1(2/R7 Y K 9 
81 WEEKS DNA M2/L10 D K10/R2 Y K 12 
110 WEEKS DNA L D K V K 11 
110 WEEKS RNA L D K V K 11 
SWEEKS DNA L D K Y K 11 
POST 
TREATMENT 
8WEEKS RNA L D K V K 9 
POST 
TREATMENT 
STOPPED THERAPY AT 132 WEEKS 
FIGURE 3.7 
No significant difference was observed in the timing of appearance of the 
substitutions between the viral RNA and proviral DNA. More frequent sampling 
would be required to establish this point. 
3.6.2 PATIENT 87 
The pre treatment plasma sample obtained from this patient contained only wild 
type sequence. By 17 weeks a mixed population was seen at position K70R in the 
RNA with 4/6 sequences containing the resistance-conferring substitution. By 83 
weeks, all RNA sequences showed the substitutions at positions K70R and T215Y, 
with the other three positions remaining wild type. At this point AZT was stopped 
for 30 weeks. The viral RNA at recommencement (103 weeks) showing 
mutations at positions K70R, T215Y and K219Q in 2/7, 2/7 and 3/7 cases 
respectively. 
The proviral DNA at 5 weeks was completely wild type, the first changes being 
seen at position K70R, (1/9 mutant) at 16 weeks. At 45 week the change at 
position K70R,(4/7) was the only change. By week 74 resistance conferring 
changes were seen at positions D67N (1/7), K70R (4/7), T215Y (1/7) and K219Q 
(2/7). In the proviral DNA sample obtained at week 103, after restarting therapy, 
those changes present before stopping treatment persisted at similar frequencies 
1/11, 3/11, 2/11 and 5/11 respectively. Eight weeks after AZT therapy was 
stopped changes were still observed at positions D67N (4/9), K70R (5/9), T215Y 
(4/9) and K219Q (5/9) in the proviral DNA (See Figure 3.8). 
Figure 3.8 Resistance-conferring RT codon changes at each of the respective 
positions, in patient 87. Mutant amino acid changes are shown in bold. 
Position 	41 M=(MET)wildtype L=(LEU)mutant 
67 D=(ASP)wildtype N=(ASN)mutant 
70 K=(LYS)wildtype R=(ARG)mutant 
215 T=(THR)wildtype Y=(TYR)mutant 
219 K=(LYS)wildtype Q=(GLN)mutant 
Discussed in section 3.6.2. 
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RNA - D K T K 7 
5WEEKS DNA - D K T K 11 
16 WEEKS DNA - D K8/R1 T K 9 
17 WEEKS RNA M D K2/R4  T K 6 
45 WEEKS DNA - D K4/R3 T K 7 
74 WEEKS DNA - D/N1 K3/R4 TdYI K5/Q2 7 
83 WEEKS RNA M D R Y K 6 
103 WEEKS DNA - D10/N 1 Ks/R3  T91Y2 KJQS 11 




DNA M D5/N4 K4/R Ts/Y4 KIQ 9 
STOPPED THERAPY AT 140 WEEKS 
FIGURE 3.8 
BETWEEN WEEKS 83 AND 103 TREATMENT WAS STOPPED DUE TO 
HAEMATOLOGIC TOXICITY. 
It can be seen from the data presented here that the pattern of mutation acquisition 
is different in these two patients. The overall picture was complicated by the 
cessation of drug therapy for 30 weeks in patient p87, although it is interesting to 
note that some mutations present at recommencement of therapy (D67N, K219Q), 
in both viral RNA and proviral DNA were not detected in the viral RNA when 
therapy was stopped. The substitution at K219Q was never seen in patient p74. 
In addition the change at M41L was never seen in the presence of the change at 
position K70R. The change at position M41L is not seen in p87 even after 2.5 
years, although it was not studied at all time points 
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3.7 NUCLEOTIDE DISTANCE ANALYSIS OF THE REVERSE 
TRANSCRIPTASE SEQUENCES WITHIN AND BETWEEN SAMPLES 
FROM PATIENTS 74 AND 87. 
Nucleotide distances were estimated for each pairwise sequence comparison using 
the program DNADIST with between and within sample distances for patients 74 
and 87 estimated using the DNAMAT program (Balfe et al., 1990). Diagrammatic 
representation of the distances obtained is given in figure 3.9 for patient 74 and 
figure 3.10 for patient 87. All mean pairwise distances were calculated by Dr A. J. 
Leigh Brown, Centre for HIV Research, University of Edinburgh. Synonymous 
and Non-Synonymous mean pairwise distances for both patients are shown in 
appendix 2. 
3.7.1 PATIENT 74 
Viral RNA mean pairwise nucleotide distances were estimated for the four RNA 
samples obtained from patient 74. The within sample variation ranged from 0.7% 
in the pre AZT treatment sample to 2.4% after 110 weeks of therapy, the within 
sample average being 1.5%. Between sample variation ranged from 2.1% between 
weeks 110 and 140 to 5.2% between weeks 22 and 110. The first AZT resistance 
conferring changes appearing in the 22 week sample, where all sequences had the 
K70R mutation and 2/8 had the mutation at position T215Y. The nucleotide 
distance between the pretreatment sample and the 22 week sample was 2.8%. A 
5.2% distance is observed between weeks 22 and 110. In terms of the resistance 
conferring mutations the sequences at 110 weeks are homogeneous with all 
sequences having the mutations at positions M41L and T215Y, although the 
3111 
Figure 3.9 Mean nucleotide pairwise distances for within and between samples 
in the RT region of patient 74. 
Each box indicates a sample, within each box is the duration of AZT therapy at 
the time the sample was taken. 
The numbers above the boxes indicate the within-sample mean nucleotide 
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0.044 
FIGURE 3.9 Mean Pairwise Distances in the RT Region of Patient 74 
within sample distance is 2.4%, indicating the presence of a number of other 
nucleotide changes. The overall nucleotide sequence distance between the pre-
treatment sample and the last RNA sample, 8 weeks post-treatment was 6.2%. 
The proviral DNA sequences show a mean intersample distance of 1.7%, with a 
mean between sample distance of 2.6%. The greatest between sample nucleotide 
distance being 3.8% between weeks 17 and 56. In the 17 week sample 5111 
sequences have the resistance conferring change at position K70R, by 56 weeks 
resistance conferring changes are seen at position 41, 67, 70 and 215. 
The overall mean frequency of synonymous substitutions per synonymous site (d) 
was 0.0592±0.0208 and the frequency of non-synonoymous substitutions per non-
synonymous site (d.j was 0.0294±0.0085. This gives a dJd ratio of 2.0. 
3.7.2 PATIENT 87 
In patient 87 mean pairwise nucleotide diversity between sequences from the same 
RNA sample range from 0.2% after 83 weeks of AZT treatment to 1.4% after 103 
weeks treatment, with a diversity of 1% between the pretreatment sequences. The 
average within sample variation was 0.8% with an average between sample 
variation of 2.1%. The mean distance between the pretreatment sample and the 
last RNA sample obtained at 103 weeks was 1.4%, although the distance between 
the pretreatment sample and the 83 week sample, the last RNA sample before 
AZT treatment was temporarily stopped, was 2.8%. This greater distance obtained 
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Figure 3.10 Mean nucleotide pairwise distances for within and between samples 
in the RT region of patient 87. 
Each box indicates a sample, within each box is the duration of AZT therapy at 
the time the sample was taken. 
The numbers above the boxes indicate the within-sample mean nucleotide 
distances with the numbers between the boxes indicating the between-sample 
nucleotide distances. 
0.014 
I 0.010 	 0.005 	 0.002 	 0.014 
RNA IPRE-TREATMENTI 0.014 I 	17 WEEKS I 0.025 	I 	83 WEEKS L0O25 I 103 WEEKS 
0.0081 	0.015/ 	I 0.020\ 	 0.029 I 	\ 	0.017 
0.017 	 0.029\ 	0.019 
DNA 	5 WEEKS 0.006 116 WEEKS 0.016 	WEEKSI 0.025 74 WEEKS_0.023 1103 WEEKS 	0.022 
0.005 	 0.009 	 0.018 	 0.023 	 0.021 
0.020 
FIGURE 3.10 Mean Pairwise Distances in the RT Region of Patient 87 
148 WEEKS 
0.019 1 
can be explained by the higher degree of homogeneity in the 83 week sample with 
sequences showing 0.2% variation within the sample. The resistance conferring 
mutations at positions K70R and T215Y were fixed in the 83 week viral 
population whereas after 30 weeks without treatment, in week 103 the majority of 
sequences found were wildtype. 
The proviral DNA within sample pairwise distances ranged from 0.5% after 5 
weeks of AZT therapy to 2.3% at 74 weeks with an average within sample 
distance of 1.6%. The between sample distances range from 0.6% between weeks 
5 and 16 and 2.5% between weeks 45 and 74 weeks. The total distance between 
weeks 5 and 148 was 2% with an average between sample distance of 1.8%. 
The overall mean frequency of synonymous substitutions per synonymous site (d) 
and nonsynonymous substitutions per nonsynonymous site were 0.0362±0.0140 
and 0.0135±0.0041 respectively, giving a dJdI  ratio of 2.68. 
3.8 SEQUENCE ANALYSIS OF THE V3 REGION. 
Having shown the effect of the strong selection pressure placed on the reverse 
transcriptase gene by AZT therapy, it is important to know whether this has any 
effect on the pressure exerted by the patients immune response. To investigate 
this we have obtained sequences of the V3 region (250bp), including the V3 loop 
and the 5' and 3' flanking regions from both patients (p74 and p87). 
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Initial PCR reactions were carried out using primers (8) and (9) to give a first 
round amplification product of 375 bases. This was followed by a second round 
of amplification using primers (10) and (11) to yield a final product of 279 bases 
(See section 2.8 for primer data). Following purification PCR products were 
sequenced directly on the ABI 373A automated sequencer. The internal PCR 
primers ((l 0) and (11)) were used for sequencing, the complete product was 
sequenced from both ends, thus any base changes found in the sense strand 
(obtained from primer (10)), were confirmed by the antisense strand (obtained 
from primer (11)). 
All sequences were obtained from proviral DNA derived from PBMC's. A total 
of 43 sequences were obtained from patient 74, and 43 from patient 87. For 
patient 74, sequences were obtained from October 1987 (year 3), June 1988 (year 
September 1989 (year 5), March 1990 (early year 6), and October 1990 (late 
year 6), 11, 6, 10, 7, and 9 sequences respectively. For patient 87 sequences 
were obtained from November 1987 (year 3), February 1988 (early year 4), 
August 1988 (late year 4), March 1989 (early year 5), September 1989 (late year 
and August 1990 (year 6), 4, 9, 9, 6, 9 and 6 sequences respectively. 
The full nucleotide sequence obtained can be seen in Appendix 1, the amino acid 
sequence inferred from this for the V3 loop (amino acid positions 296->330) can 
be seen in figure 3.11 for patient 74 and 3.12 for patient 87. In both these tables 
the sequences are compared to the B subtype V3 consensus. 
RN 
V3 SEQUENCE VARIATION IN PATIENT P74 
SAMPLE SUBTYPE B V3 CONSENSUS NUMBER OF 
DATE CTRPNNNTR KS IHIGPGR AFYT TG EIIGD IRQAHC SEQUENCES 
13/10/87 G2 I 	R5G 1 M3 S 3 S 1 	V2 	A10 	T 1 D 3 	N 10 11 






21/06/88 G 1 R1G 3 M1 W 1 S 2 	V 1 	A3 	E 1 D 2 	N 1 6 
S 1 N 1 
05/09/89 Y2 R3G 8 R3 S 4 T 1V 1 1 1A8 A3R3 D 5 10 
K 3  
27/03/90 G2 	Y 1 R4G 5 R2M2 W2 S 3 T 1V 1 	A 5 A2R2 D 3 7 
S 2 	K2  
09/10/90 G 4 	Y 4 R8G 6 R4M4 W 4 S 1 	V4 1 1A5 A4R4 K 4 9 
S 4 	D 2  
FIGURE 3.11 
V3 SEQUENCE VARIATION IN PATIENT P87 
SAMPLE SUBTYPE B V3 CONSENSUS NUMBER OF 
DATE CTRPNNNTR KS IHIGPGR AFYT TG EIIGD IRQAHC SEQUENCES 
19/11/87 S 3 R 1 	S 4 1 2A4 	K 1 Q 1V 1 R1 4 
08/02/88 12 	S 4 E 4R5 	S 9 F 1A 9 R3R4 Q 5 R 1 9 
G 5 16 	K 1K 1  
18/08/88 G 7 Y 4 E 7R8 	S 6 Y 1 1 7A 8 R7R7 Q 8 Ni  9 
S 1 Y, E l  
14/03/89 I 	S 5 Y 1 E 1R1 	S 6 	K 1 1 1A6 R1R1 Q 1 6 
27/09/89 S 5 Y 3 S 	E 4R4 L 1S 9 1 3A9 R3R4 Q 4 9 
G 4 E 1 V 1 	K 1  
27/08/90 S 2 Y 1 E 1R2 	S 3 	S 2 V 1 1 1A5 R1E 1 D 2 6 
G 1 G 2 R1  Q 2 N 1  
FIGURE 3.12 
Examination of the amino acid sequence shown in figures 3.11 and 3.12, shows a 
high level of V3 loop variation within these two patients. Of the 35 amino acids 
shown from the V3 loop only 16 in patient 74 and 15 in patient 87 are conserved 
over the period of study. The Gln-Pro-Gln sequence motif at the tip of the loop is 
conserved throughout in patient 87, with a number of variants existing in patient 
74. All of the variants seen in patient 74 involved the replacement of the central 
Proline, at position 311 with either Serine or Tryptophan. These changes at this 
position have previously been reported to influence cell tropism and possibly 
infectivity of HIV-1 (Takeuchi et al., 1991). 
3.9 NUCLEOTIDE DISTANCES OF THE V3 SEQUENCES WITHIN AND 
BETWEEN SAMPLES 
Pairwise nucleotide distances were estimated among the V3 sequences obtained 
from both patients (p74 and p87). Both within and between sample mean 
sequence diversities are shown for patient 74 (Figure 3.13) and patient 87 (Figure 
3.14). Estimates of the mean frequency of synonymous and non-synonymous 
estimates are given for both patients in Appendix 2. 
3.9.1 PATIENT 74 
The within sample variation diversity, estimated as the mean of all pairwise 
comparisons for each sample taken after seroconversion varied from 6.15% 
(range 5.35%(year 3) to 7.07% (year 6)). The mean between sample distances 
ranged from 3.95% (between the sample at year 0 (seroconversion) and year 3) to 
M 
8.46% (between year 4 and early year 6). A progressive increase in the mean 
pairwise distances between the sequences found in year 0 (0%) and those found in 
later samples reflects the progressive evolution of the V3 sequence population. 
The overall estimates of d and d for the V3 region of patient 74 were 
0.0418±0.014 and 0.0691±0.01. These give a dJd, ratio of 0.6. 
3.9.2 PATIENT 87 
A seroconversion sequence was not available for patient 87, so an external 
sequence was used from patient 84 another haemophiliac infected with very 
closely related virus sequence from the main Edinburgh Haemophilia Cohort 
(Balfe et al., 1990; Simmonds et al., 1990b; Holmes et al., 1995). This enabled 
mean nucleotide distances to be calculated from seroconversion. The mean 
intrasample nucleotide distance for patient 87 is 5.93% ranging from 3.5% in early 
year 5 to 9.2% at year 6. The between sample distances increase from 3.82% 
between seroconversion and year 3 to 13.8% between early year 4 and year 6. 
The d and d. estimates obtained for patient 87 were 0.0482±0.0155 and 
0.0783±0.0116, giving a d/d.,1 ratio of 0.62. 
Figure 3.13 Mean pairwise nucleotide distances in the V3 region of patient 74. 
YEAR 0 = 1984 
YEAR 3 = 1987 
YEAR 4 = 1988 
YEAR 5 = 1989 
YEAR 6 = 1990 
Intra-sample distances are presented in italics on the diagonal. Mean distances 
from all pairwise inter-sample comparisons are presented below the diagonal. 
FIGURE 3.13 Mean Pairwise Distances in the V3 Region of Patient 74 




YEAR 0 0.0000 
YEAR 3 0.0395 0.0535 
YEAR 4 0.0517 0.0630 0.0681 
YEAR 5 0.0538 0.0576 0.0675 0.0577 
YEAR 6 0.0545 0.0615 
(EARLY)  
0.0724 0.0612 0.0707 
YEAR 6 
(LATE) 
0.0647 0.0657 0.0846 0.0651 0.0636 0.0578 
YEAR 0=1984 YEAR 3=1987 YEAR 4=1988 YEAR 5=1989 YEAR 6=1990 
Figure 3.14 Mean pairwise nucleotide distances in the V3 region of patient 87. 
YEAR 0 = 1984 
YEAR 3 = 1987 
YEAR 4 = 1988 
YEAR 5 = 1989 
YEAR 6 = 1990 
Intra-sample distances are presented in italics on the diagonal. Mean distances 
from all pairwise inter-sample comparisons are presented below the diagonal. 
FIGURE 3.14 Mean Pairwise Distances in the V3 Region of Patient 87. 









YEAR 0 0.0000 
YEAR 3 0.0382 0.0524 
YEAR 4 0.0687 0.0567 0.0549 
(EARLY)  
YEAR 4 0.0846 0.0756 0.0647 
(MID)  
0.0566 
YEAR 5 0.0359 0.0539 0.0626 
(EARLY)  
0.0746 0.0350 
YEAR 5 0.0579 0.0647 0.0679 
(LATE)  
0.0666 0.0512 0.0652 
YEAR 6 0.0755 0.0938 0.1388 0.1109 0.0966 0.0993 0.0920 
YEAR 0=1984 YEAR 3=1987 YEAR 4=1988 YEAR 5=1989 YEAR 6=1990 
CHAPTER 4 
PHYLOGENETIC ANALYSIS 
4.1 PHYLOGENETIC ANALYSIS 
Based on the trends shown by the nucleotide sequence distances, a more detailed 
analysis of the data based on phylogenetic reconstruction was undertaken. Two 
phylogenetic methods were employed, the neighbour joining method (Saitou. and 
Nei, 1987) and the maximum likelihood method (Felsenstein, 1981). The 
neighbour joining method is a rapid method of reconstruction based on a simple 
algorithmic approach which takes into account differences in the evolutionary rate 
between different lineages. The maximum likelihood method is a statistical 
approach which chooses a phylogeny which maximises the probability of the data 
on a particular model of molecular evolution. The phylogenetic trees presented 
here were constructed by Dr A. J. Leigh Brown and Mr C. Wade (Centre for HIV 
Research, University of Edinburgh.). 
Analysis was undertaken of both the pol and env sequences obtained from patients 
74 and 87. Nucleotide sequence was obtained from PBMCs and plasma samples 
for the poi gene analysis as described in section 3.5. The env gene phylogenetic 
analysis was based only on proviral DNA nucleotide sequences from PBMCs as 
described in section 3.8. All sample dates are given in section 3.2 and details of 
AZT therapy are given in section 3.1. A total of 99 sequences from the RT 
domain of the poi gene were obtained from patient 74, 80 sequences were 
obtained from patient 87. Each sequence was approximately 200 nucleotides in 
length and consisted of the POL A and POL B regions described in section 3.5, 
truncated so that all sequences could be aligned and merged into a single 
contiguous sequence. The env phylogenies were constructed using sequences of 
approximately 250 nucleotides in length spanning the V3 region. A total of 43 
sequences were obtained from patient 74 and 43 sequences from patient 87. 
From the reconstructed phylogenies we hope to elucidate firstly, the pattern of poi 
gene evolution during AZT mutation acquisition and secondly whether the 
evolutionary pattern of the env gene during the same period showed any effect of 
the strong selective forces acting on poi. 
4.2 PHYLOGENETIC ANALYSIS OF THE POL GENE IN PATIENT 74 
The reconstructed poi gene phylogeny for patient 74 (Figure 4.1) shows a highly 
progressive overall pattern of evolution during the period of AZT therapy. A 
gradual increase in genetic distance from the pretreatment sample was seen with 
time from the pretreatment samples to the 8 week post treatment sample (see 
figure 3.9). A maximum branch length of 13% was estimated from the 
phylogeny. Prior to treatment none of the implicated AZT resistance-conferring 
mutations were observed, in either the proviral DNA or viral RNA populations. 
The first mutation to appear was that at position 70 (LYS->ARG). This was first 
observed in the 17 week DNA sample, and it represented 55% of the proviral 
sequence population. Mutation 215 (THR->TYR) was the next to appear, being 
observed within the RNA population as early as 22 weeks after the initiation of 
therapy. This mutation showed a single evolutionary origin within the phylogeny 
(identified on the tree by node Y). Sequences subsequent to the node were 
homogeneous at position 215 for the mutant form. Mutation 67 (ASP->ASN) 
appeared next although this was observed in only a single sequence from the 56 
week sample, in combination with 70R and 215Y mutations. Predominantly 
70/215 double mutants were observed in the 56 week sample, representing 78% of 
the total (figure 3.7). Mutation 67 was followed by the appearance of the 
resistance mutation at position 41 (MET->LEU). Once again this clearly showed 
a single evolutionary origin in the phylogeny (marked on the tree as node Z). The 
appearance of the 41 mutation within the DNA population at week 56 was 
concurrent with the reversion of mutation 70 to wildtype as shown in figure 3.7. 
This is explained in the phylogenetic analysis as 70R is never seen in combination 
with 41L. All 41L sequences were exclusively 41/215 double mutants. This 
suggests that the 41/215 combination has some growth advantage over the 
41L/70R/215Y combination. The mutation at position 219 was never observed 
within this patient. 
Although unique origins were identified for both the 41 and 215 mutations 
(indicated by nodes Y and Z), a unique origin was not apparent for the 70R 
mutation. This may reflect reversion to wildtype at this position but this seems 
unlikely as sequences following node X (where 70 is likely to have appeared) 
include pre-treatment sequences. This suggests that the tree is not clearly 
resolved at this point, with the accumulation of insufficient genetic distance within 
the poi sequences prior to the appearance of the mutation at position 70 to 
establish the phylogeny with confidence. 215Y arose only once in the phylogeny, 
which probably reflects the requirement for two tightly linked nucleotide 
substitutions to achieve the T->Y codon change. Why 41L should arise only once 
is less obvious, but may be explained by the simultaneous reversion of 70R to 
wild type. The phylogenetic analysis revealed that this was not simply 
coincidental in time but simultaneous. 
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FIGURE 4,1 
A phylogenetic tree obtained by the maximum likelihood reconstruction method 
of the evolutionary relationships among the RT sequences from patient 74. 
KEY. 
Node X - 	likely origin of mutation K70R. 
Node Y - single evolutionary appearance of mutation T215Y. 
Node Z - 	single evolutionary appearance of mutation M41L. 
A 	- pre-treatment sample. 
B - sample after 17 weeks of AZT therapy. 
C 	- sample after 22 weeks of AZT therapy. 
D - sample after 56 weeks of AZT therapy. 
E 	- sample after 81 weeks of AZT therapy. 
F - sample after 110 weeks of AZT therapy. 
G 	- post-treatment sample obtained 8 weeks after cessation of therapy (140 weeks). 
* 	- 	viral RNA sequences obtained from plasma, unmarked sequences of proviral DNA 
41 	- 	presence of mutation (M41L). 
67 - presence of mutation (D67N). 
70 	- 	presence of mutation (K7OR). 
215 - presence of mutation (7215Y). 
e.g. C, , 70, 215. indicates a sequence obtained from plasma after 22 weeks of AZT therapy 
containing mutations at amino acid positions K70R and T215Y. 
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4.3 PHYLO GENETIC ANALYSIS OF THE POL GENE IN PATIENT 87. 
In contrast to patient 74, patient 87 did not show strong evidence of progressive 
directional evolution with AZT therapy. Furthermore the nucleotide distance from 
the pretreatment sequences to the most divergent sequences (148 week sample) 
was markedly lower, a distance of 3.5% (figure 3.10) from the phylogeny (as 
opposed to 13% in patient 74). 
Three groups (groups M, N and 0) were apparent within the phylogeny (figure 
4.2), with phylogenetically distinct AZT resistance-conferring mutations observed 
within each group. The sequences in group M are predominantly wildtype, with 
mutations 70 and 219 appearing individually in two distinct sequences within the 
group. Group M sequences are represented from the pre-treatment to the 103 
week samples. Group N which contained the most divergent sequences, showed 
four of the AZT resistance conferring mutations, those at positions 67, 70, 215 
and 219. Both mutations 70 and 219 appeared to arise independently on more 
than one occasion. A sub-lineage of sequences containing the mutation at position 
70 also showed mutations at positions 67 and 219 in all descendants, leading to a 
67/70/219 mutant. A further mutation at position 215 was observed in two 
descendent sequences, giving rise to the combination 67/70/215/219 in the 148 
week sample. Group 0, consisting predominantly of late treatment variants 
(weeks 74, 83, 103 and 148), exhibited three of the resistance conferring 
mutations, those at positions 70, 215 and 219. Mutation 215 arose early in this 
70 
group and persisted in all descendants. Mutations 70 and 219 apparently arose 
independently in a number of the group 0 215 mutants. 
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FIGURE 4.2. 
A phylogenetic tree obtained by the neighbour joining reconstruction method oft' 
the evolutionary relationships among the RT sequences from patient 87. 
KEY. 
A 	- 	pre-treatment sample. 
B - sample after 5 weeks of AZT therapy. 
C 	- 	sample after 16 weeks of AZT therapy. 
D - sample after 17 weeks of AZT therapy. 
E 	- 	sample after 45 weeks of AZT therapy. 
F - sample after 74 weeks of AZT therapy. 
G 	- 	sample after 83 weeks of AZT therapy. 
H - sample after 103 weeks of AZT therapy. 
I 	- 	post-treatment sample obtained 8 weeks after cessation of therapy (148 weeks). 
* 	- 	viral RNA sequences obtained from plasma, unmarked sequences of proviral DNA 
67 	- 	presence of mutation (D67N). 
70 - presence of mutation (K70R). 
215 	- 	presence of mutation (T215Y). 
219 - presence of mutation (K219Q). 
e.g. H, , 70, 215. indicates a sequence obtained from plasma after 103 weeks of AZT therapy 
containing mutations at amino acid positions K70R and T215Y. 
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4.4 PHYLOGENETIC ANALYSIS OF THE V3 REGION OF THE ENV 
GENE. 
Phylogenetic trees for the env V3 region are shown in figure 4.3 for patient 74 
and 4.4 for patient 87. The patient 74 phylogeny is rooted using the 
seroconversion sequence from the patient (year 0). A seroconversion sequence was 
not obtained for patient 87 and so the phylogeny for this patient was rooted using 
an external seroconversion sequence from a another haemophiliac, patient 84 
infected with closely related sequences. Patient 87 has previously been shown to 
group closely with p84 and other members of the main Edinburgh haemophiliac 
cohort (Balfe et al., 1990; Simmonds et al., 1991; Zhang et al., 1993; Holmes et 
al., 1995). 
4.5 PATIENT 74 V3 REGION PHYLOGENY 
Interpretation of the V3 sequence phylogeny for patient 74 (figure 4.3) showed 
that three main lineages (A, B, and C) arose from the single lineage present at 
seroconversion (year 0). The clear evidence of a progressive directional pattern of 
evolution observed in the poi gene of this patient (Figure 4.1) was not apparent 
within the env gene. Sequences of lineage A were observed in samples from year 
3 through to those from year 6, although the lineage was not represented in year 
5. This lineage contained exclusively non syncytium inducing variants (NSI) 
(Fouchier et at, 1992). Lineage B contained sequences from the later samples 
only, years 5 and 6, and consisted exclusively of syncytium inducing (SI) variants. 
The group C lineage split further into two sublineages (Cl and C2) around year 3. 
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The Cl lineage contained sequences from all years (years 3, 4, 5 and 6), with the 
C2 lineage containing predominantly sequences from years 5 and 6. The bulk of 
sequence variants found in the C lineage were non syncytium inducing (NSI) 
variants with the exception of two highly divergent sequences from years 3 and 4 
(Cl) which were syncytium inducing. Cl showed greater diversity than lineages 
A, B and C2, with Cl extending to a greatest distance of 11.8% from the sero-
conversion sample. This can be compared to distances measured from the 
phylogeny of 6% for lineage A, 6.1% for lineage B and 6.6% for lineage C2. 
Thus lineage Cl is almost twice as divergent as the other three lineages. All three 
lineages were therefore present before AZT treatment commenced and persisted 
throughout the period of study. 
4.6 PATIENT 87 V3 REGION PHYLOGENY 
Three main sequence groups (A, B and C) were apparent from the V3 sequence 
phylogeny for patient 87 by the third year of infection. Group A contained only a 
small number of sequences closely related to the seroconversion sequences that 
were found in years 3 (2 sequences) and 4(2 sequences), but was not detected at 
termination of the study in year 6. Group B was the predominant form present 
within the patient and persisted in high numbers throughout the study, containing 
sequences from years 3, 4, 5 and 6. The main group of sequences (B) divided into 
two distinct groups (B 1 and B2). B 1 consisted of sequences related to A and the 
seroconversion sequence and was found in years 4, 5, and 6. B2 consisted 
exclusively of syncytium inducing (SI) variants and contained all the SI variants 
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found within the patient. These were detected from years 4, 5 and 6. A small 
number of sequences were equally distinct and related to neither group. Group C 
arose independently from seroconversion like sequences and was found in years 4 
The evolution of the V3 region in this patient was dominated by the appearance of 
SI variants from group B2 in year 4 which became a much more important 
component of the population than in patient 74. Nevertheless 2/3  of the sequences 




A phylogenetic tree obtained by the maximum likelihood reconstruction method 
of the evolutionary relationships among the V3 envelope sequences from patient 
74. 
KEY. 
3,4,5,6 - 	indicate number of years from seroconversion (1984), hence year 3 = 1987, year 4 
= 1988, etc. 







A phylogenetic tree obtained by the neighbour joining reconstruction method of 
the evolutionary relationships among the V3 envelope sequences from patient 87. 
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3,4,5,6 - 	indicate number of years from seroconversion (1984), hence year 3 = 1987, year 4 
= 1988, etc. 
SI 	- 	indicates syncytium inducing variants. 
'Min 
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4.7 COMPARISON OF PHYLOGENETIC TREES. 
Comparison of the reconstructed poi gene phylogenies from patients 74 and 87 
(figures 4.1 and 4.2), show two distinct patterns of evolution. The patient 74 p01 
phylogeny shows clear evidence of progressive evolution, with the AZT resistance 
conferring mutations appearing sequentially with time. Mutation 70 (LYS->ARG) 
appeared first in the proviral DNA population as early as 17 weeks after 
commencement of therapy, followed by the appearance of 215(THR->TYR) at 22 
weeks in the viral RNA population and 41 (MET->LEU) at 56 weeks within the 
proviral DNA population. A single evolutionary origin was identified for both the 
appearance of the 215 and 41 mutants (figure 4.1, Nodes Y and Z) with all 
subsequent sequences containing these mutations. All variants subsequent to the 
appearance of the 41 mutation were 41/215 double mutants. The K70R mutation 
observed early in therapy was retained in combination with T215Y but reverted to 
wildtype simultaneously with the appearance of M41L. The homogeneity of the 
41/215 combination in later samples suggests a definite growth advantage over 
other combinations under the selection pressure of AZT. 
In contrast to the progressive evolutionary pattern observed in patient 74, the 
patient 87 p01 phylogeny (Figure 4.2) shows a more random pattern of evolution 
in relation to the acquisition of the AZT resistance-conferring mutations. Three 
distinct groups are seen within this phylogeny each containing resistance 
conferring mutant variants. No single line of descent could be identified for the 
acquisition of poi resistance conferring mutations within this patient. However in 
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common with the patient 74 phylogeny the first mutation to appear was that at 
position 70. This appeared in the proviral DNA population after only 16 weeks. 
The mutations at positions 67, 215 and 219 appeared later, being identified first in 
the DNA sample from week 74. Only one of the mutations, that at position 67, 
could be seen to show a single evolutionary origin within the phylogeny, 
identified as node X in group N. 
The most divergent sequences within the patient 87 poi gene phylogeny were 
those containing mutations at positions 67, 70, 215 and 219.'These still showed 
only 3.5 % divergence from the pre-treatment variants in contrast to the far higher 
levels of sequence diversity seen in patient 74 (13% between the pretreatment and 
the most divergent variants). Nevertheless patient 74 only contained mutations at 
positions 41 and 215 in the most divergent sequences. 
Analysis of the env V3 region from the same proviral DNA samples as those used 
to construct the poi phylogenies showed a different pattern of evolution 
particularly in patient 74. The V3 phylogenies from both patient 74 and 87 
(figures 4.3 and 4.4) were characterised by an increasing level of within sample 
diversity and no evidence of progressive evolution was observed in either patient. 
A number of distinct V3 lineages were observed in the reconstructed phylogenies 
for both patients. This evolutionary pattern is similar to the pattern observed in an 
earlier study of V3 evolution in an asymptomatic haemophiliac from the same 
cohort but not under therapy (Holmes et al., 1992). This suggests that AZT 
001 






Antiretroviral therapy with AZT has been associated with the emergence of drug 
resistance in HIV-1 infection. Five amino acid changes within the RT domain, 
met -> leu at position 41, asp ->asn at position 67, lys -> arg at position 70, thr -> 
phe or tyr at position 215 and lys -> gin at position 219 have been shown to be 
responsible for the development of isolates with reduced sensitivity to the drug 
(Larder and Kemp, 1989a; Kellam et al., 1992). The research presented in this 
thesis investigated the response to therapy in two Edinburgh haemophiliacs in 
terms of CD4 count, viral load, acquisition of resistance associated mutations, 
timing of appearance and the evolutionary pattern associated with these mutations. 
5.2 VIRAL LOAD AND CD4 CELL COUNT 
The quantitation of HIV, viral RNA and proviral DNA and its correlation with the 
clinical, virological and immunological status of infected individuals has been 
investigated in a large number of studies (Ho et al., 1989; Coombs et al., 1989; 
Phillips et al., 1991; Venet et al., 1991; Jurriaans et al., 1992; Ved Brat et al., 
1992; Baumberg et al., 1993; Piatak et al., 1993). Infectious virus titre may relate 
directly to disease progression and its measurement could provide a method for 
assessing the efficacy of antiretroviral drugs which rely on expression of surrogate 
markers. 
Ho et al (1989) and Coombs et al (1989) first reported assays for the 
quantification of HIV in plasma and PBMC. The study of Coombs et al 
investigated which markers of HIV replication showed the closest correlation to 
disease stage. The frequency of isolation of HIV from PBMCs and plasma, the 
presence of p24 Ag in plasma and Ab to p24 Ag were compared. HIV was 
isolated from 97% of PBMC samples regardless of clinical stage whereas isolation 
from plasma increased with disease stage from 23% in asymptomatics to 82% in 
those with AIDS. Plasma virus titres increased from asymptomatics (10') to 
AIDS (102.5)  and again correlated with disease stage. No correlation was seen 
between the titre of HIV in plasma and p24 Ag levels in either serum or plasma. 
Of the four virological markers examined, plasma viraemia was the best indicator 
of disease stage. The presence of plasma viraemia was also associated with a 
marked reduction in CD4 cell count and the development of symptomatic disease. 
In contrast to these, Ho et al recovered HIV from the plasma of all infected 
individuals. However both studies showed that viral titres correlated with clinical 
status with a reduction in titre from AIDS to ARC to asymptomatic patients. Thus 
increased viral load replication is an important marker of disease progression. 
The link between CD4 cell count and viral load in both PBMCs and plasma was 
the subject of another study (Venet et al., 1991). This study looked for any 
correlation between CD4 cell number and p24 Ag, p24 Ab and both PBMC and 
plasma viral loads. Ninety-nine HIV-1 positive individuals, none of whom had 
received AZT therapy, and 10 negative controls were evaluated. All the negative 
controls tested negative in all tests. Within the infected group HIV was isolated 
from the plasma of 36/99 subjects and from 91/99 PBMC samples. The frequency 
of isolation from plasma increased with a reduction in the number of CD4 cells, 
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from 0% when the CD4 count was >800cells/mm 3 to 88% when the CD4 count 
was <100cells/mm3 . As in the study of Coombs et al, isolation from plasma 
increased with disease progression from 20% in asymptomatic patients to 40% in 
ARC patients to 94% in AIDS patients. In contrast to the isolation rates observed 
in plasma, isolation from PBMCs was 99% when the CD4 count was 
<900cells/mm3 with only 46% isolation where the CD4 count was >900cells/mm 3 . 
Comparison of p24 antigenaemia with plasma viral cultures showed poor 
correlation and was similar to the findings of Coombs et a! (1989). The findings 
of this study showed a strong correlation between CD4 cell count, viral load and 
disease progression, with clinical deterioration being associated with an increased 
viral load and a reduction in CD4 cell number. 
Non culture based assays using PCR technology have become the method of 
choice for the quantification of viral and proviral load within infected patients. 
These PCR assays have the advantage over the other methods in that they are 
sensitive, rapid and cheap. The p24 Ag assays are relatively insensitive and HIV 
culture takes weeks to complete. Also during the asymptomatic period of the 
disease, assays for culturable virus or HIV-1 p24  Ag may remain negative. 
A number of PCR methods are now being used, the most recent being quantitative 
competitive PCR methods. In the quantitative competitive PCR (QC-PCR) method 
for the quantitation of plasma viral RNA, a competitive RNA template matching 
the target RNA sequence but bearing a deletion is used as an internal control in 
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both the reverse transcription and PCR steps (Piatak et al., 1993). Quantitative 
PCR has also been developed for the quantitation of proviral HIV-1 DNA from 
PBMCs (Ferre et al., 1993). This method also involves the coamplification of an 
endogenous control within the same PCR reaction. Ferre et al also established the 
sensitivity, specificity and reproducibility of this method. They estimated the intra 
assay variability by running 4 duplicate runs of 15 samples and using a 95% 
tolerance interval that an increase of 60% or a decrease of 38% in the number of 
DNA copies was significantly greater than that expected due to error. Thus the 
variability was a true change in HIV-1 proviral copy number. 
The work presented here (Section 3.4) used an RNA PCR to detect circulating 
virus in plasma (Zhang et al., 1991). Following cDNA synthesis the 
complementary DNA was limit diluted and amplified in a double polymerase 
chain reaction (see sections 2.4,5,6). The number of positive reactions at the limit 
dilution point was then used to calculate a molecular concentration using the 
Poisson formula (see section 3.3). Two AZT treated patients were studied here 
and both show a decline in the CD4 cell count over the period of study. However 
on initiation of AZT therapy a transient rise in CD4 number was seen in patient 
87 and this lasted approximately 6 months before returning to baseline levels. 
Viral load in this patient remained relatively constant during the period of AZT 
therapy at 3,500 genomes/ml3, although a sample was not available after cessation 
of therapy. In the case of patient 74 the viral load dropped from 3,100 to 2,700 
genomes/m13 during the period of AZT therapy. After treatment was stopped, the 
viral load increased to 4,600 genomes/m13 . Whether this increase was due to the 
stopping of therapy or disease progression cannot be elucidated from this study. 
5.3 VIRAL LOAD AND ANTIRETRO VIRAL THERAPY. 
Several studies have investigated the effect of antiretroviral therapy on viral load 
and whether the development of drug resistance associated mutations in the RT 
domain have any direct effect on viraemia (Holodniy et al., 1993; Kojima et al., 
1993; Piatak et al., 1993; Loveday et al., 1995). All of these studies showed a 
reduction in HIV RNA copy number upon initiation of therapy. This observation 
of suppression of plasma RNA had previously been reported in semi-quantitative 
assays (Semple et al., 1991; Holodniy et al., 1991). CD4 cell count was also 
shown to increase by approximately 200 cells upon the initiation of AZT/DDI 
combination therapy, although this returned to baseline levels after 12 months 
(Holodniy et al., 1993). The development of drug resistance is obviously 
important in the clinical management of patients treated with antiretrovirals. 
Changes in viraemia level with the development of an AZT resistance associated 
mutation have been reported (Kojima et al., 1993). A single patient was studied 
using an RNA PCR method who, upon initiation of AZT/DDI combination 
therapy, showed a significant reduction in viral load from >iO viral particles/ml 
to <102  viral particles/mi. However after 5 months of therapy a rise to >103  viral 
particles/nil was seen. Selective PCR was used to investigate the resistance 
associated changes at positions 74 (DDI) (St Clair et al., 1991) and 215 (AZT). 
This showed the presence of the mutational change of Thr->Tyr at position 215. 
Within one year of therapy viral levels had returned to baseline. This increase in 
viraemia may have been due to resistance development. The most recent study of 
Loveday et al 1995 investigates the relationship between viral load and mutation 
development in more detail. Eleven patients with severe I-LW disease were 
studied to see if any correlation existed between the development of AZT 
resistance associated mutations at positions 41, 67, 70, 215 and 219 and the 
observed viral load. In all eleven patients a fall in serum HIV-1 RNA viral load 
was observed from a median level of 2380 copies/ml (range 320->30,000 
copies/ml) pretreatment to a median level of 220 copies/ml (40->2,000 copies/ml) 
within the first 7 days after the initiation of AZT treatment. In four patients the 
drop in viral load persisted to the end of the treatment period while in the other 
seven patients, a return to baseline levels was seen. Genotypic analysis was 
carried out using a point mutation assay to investigate the presence of changes at 
the resistance associated codons. Resistance conferring changes were identified in 
9 of the 11 patients. The two other patients showed no mutants after 27 and 43 
days of therapy. The K70R change was the first to be observed in six patients, 
with the K219Q mutation appearing first in two patients and the D67N appearing 
first in one. The initial changes at positions 67, 70 and 219 appeared after an 
average of 30, 69 and 26 days respectively. No correlation was observed between 
the development of drug resistance and the return of HIV RNA levels to baseline. 
This is in contrast to the findings of Kojima et al (1993) who reported an increase 
in viral load on the development of the 215 mutation. Genotypic resistance 
continued to develop in the serum RNA in six patients after AZT treatment was 
stopped. An increase in the frequency of the 215 mutation (from a mean of 6% to 
66%) was seen in 5 patients with an increase in the 41 mutation (from 
undetectable to a mean of 65%) observed in two patients. In five patients a 
decrease in the proportion of mutants at codon 70 (mean value of 38% reduced to 
17%) was also seen. 
The data presented here (section 3.4) show no rapid decline in the viral load of 
either patient upon initiation of AZT treatment as was observed in the study of 
Loveday et al (1995). However more detailed sampling during the early period of 
treatment may have shown a decline prior to a return to the levels seen at the next 
time point, which was not until several months after therapy had begun. An 
increase in CD4 level was seen in patient 87 which persisted during the first 3 
months of therapy before returning to baseline after 6 months; this is consistent 
with the findings of Holodniy et al (1993). In contrast, patient 74 showed a 
decline in CD4 cell count in the first four months of therapy. No correlation is 
observed between levels of viral load and development of AZT resistance 
mutations during treatment. No major change is seen in viral load during the 
study period, although resistance mutations develop (see section 3.6). This is 
consistent with the findings of Loveday et al (1995). 
5.4 ORDER OF ACQUISITION OF RESISTANCE ASSOCIATED 
MUTATIONS 
Nucleotide sequence obtained from both patients over the period of AZT treatment 
(132 weeks patient 74, 140 weeks patient 87) showed different mutational 
acquisition patterns for each of the patients (section 3.6). None of the resistance 
conferring mutational changes were observed in either patient prior to the 
commencement of AZT therapy. The first mutation to appear in both patients was 
the K70R change which was detected in the proviral DNA sequences obtained 
from patient 74 after 17 weeks and from patient 87 after 16 weeks of therapy. 
This change at codon 70 confers the highest level of resistance involving only a 
single nucleotide change (AAA->AGA), an 8 fold decrease in sensitivity to AZT 
over wildtype virus (Larder et al., 1991a). However it has been shown that the 
change at this position may in fact be a naturally occurring polymorphism which 
has been found to exist in patients never subjected to AZT therapy (Mohri et al., 
1993; Najera et al., 1995). Discontinuation of therapy when only the K70R 
change is present has been reported to result in rapid reversal to wildtype virus 
(Boucher et al., 1992). 
Following the initial change of K70R in both patients, the next mutation to appear 
was the 215 change. This involves a double nucleotide change and in all cases 
observed, the T215Y change was seen (ACC->TAC). Alone this has been reported 
to confer a 16 fold increase in resistance to the drug in vitro. It first appeared in 
patient 74 in the viral RNA sequences obtained from the 22 week plasma sample 
where it was seen in combination with the K70R change. According to the study 
of Kellam et al (1994) these two changes (K70RIT215Y) in combination in an 
HXB2 background confer only a six fold increase in resistance as opposed to the 
8 fold increase conferred by K70R alone, which may not be significant. However 
T215Y alone confers a 16 fold increase in resistance. The T215Y change is not 
seen in the viral population from patient 87 until the week 74 proviral DNA 
sample concurrent with the first observation of the D67N and K219Q mutations. 
Again the T215Y change was only seen in combination with the K70R change. 
This observation within these two patients suggests that the 70/215 combination 
may have some growth advantage over their individual existence within the viral 
population, or that it may be required for the acquisition of other resistance 
conferring mutations. 
The 56 and 81 week proviral sequences obtained from patient 74 are all 
homogeneous for the T215Y change (section 3.6) and this mutation persists in the 
population throughout the rest of the study. A shift in the viral population was 
observed within these samples with the simultaneous replacement of the K70R 
mutation by the M41L mutant, the K70R reverting to wildtype. The majority of 
samples in the 81 week sample were 41/215 double mutants. This differs from the 
suggestion of Boucher et al 1992 and Kellam et al 1994 that K70R is replaced by 
the more stable mutation at position 215. In fact it is the appearance of M41L 
that is crucial and that appears to be delayed until K70R reverts. All isolates 
obtained from both viral RNA and proviral DNA from weeks 110 and 140 were 
homogeneous for the M41L/T215Y mutant, which gives a 64 fold increase in 
resistance (Kellam et al., 1994). This outgrowth of all other mutations by the 
41/215 combination has previously been reported to be a major event in the 
development of AZT resistance (Kellam et al., 1994). 
The studies of Boucher et al 1992 and Kellam et al 1994 (previously described in 
section 1.9) show the same general pattern of acquisition as is observed here. 
The initial study of Boucher et al, investigated the appearance of the mutations at 
RT codon positions 67, 70, 215 and 219 in a group of 18 asymptomatic patients 
who had undergone 2 years of AZT therapy. A selective PCR technique was used 
to identify the presence of the wildtype or mutant codon at each of the respective 
positions. This analysis showed a similar pattern of mutation appearance in all 
patients. The K70R change was the first change observed, appearing as early as 
12 weeks after starting therapy. This seemed to be an unstable mutation and 
reverted to wildtype on the appearance of the T215Y mutation. However in two 
of three patients studied in detail the K70R mutation reappeared after which the 
change at position D67N was detected. One year after the appearance of the 67 
mutation and the reappearance of the change at position 70 highly resistant virus 
was detected with the appearance of the 219 mutation. This study also showed 
that isolates obtained from five patients around the time of AIDS diagnosis were 
only partially resistant and similar to those obtained from patients remaining 
asymptomatic. This suggests that progression to AIDS is not dependent on the 
emergence of highly resistant virus. Kellam et al (1994) extended this initial 
study of Boucher et alto include the later identified mutation M41L which was 
shown to contribute to AZT resistance (Kellam et al., 1992). The 17 
asymptomatic patients studied by Boucher and colleagues for the mutational 
changes at positions 67, 70, 215 and 219 were investigated for the change at 
position 41, again using selective PCR. The M41L mutation seemed to appear 
around the same time as the appearance of the T215Y mutant and the reversion of 
the K70R mutant to wildtype. By 76 to 132 weeks of therapy 13 of the 17 
patients were homogeneous for the 41/215 combination. Two of the patients for 
whom longitudinal samples were available and who were studied in detail by 
Boucher et al (1992) were again further investigated by Kellam et al (1994). The 
pattern of acquisition was similar in both patients, with 70 appearing first before 
being replaced by mutations at either 41 or 215 individually or in combination; 70 
then reappeared and in one patient highly resistant virus developed with the 
appearance of 67 and 219. The transition to highly resistant virus only occurred 
through the acquisition of the 41/215 double mutant (Kellam et al., 1994). To 
investigate the linkage of the mutations, DNA sequence analysis was carried out 
on isolates from these two patients which showed two double mutants, 70/215, 
and 41/2 15, with all sequences becoming homogeneous for the 41/215 double 
mutant with continuing therapy. In one of the two patients, the mutations at 
positions 67 and 70 later appeared to give 41/67/70/215 highly resistant virus. 
To investigate why one mutant population should outgrow another a series of site 
directed mutants were constructed containing different combinations of the five 
resistance conferring changes. Each virus recovered was then assayed for 
sensitivity to AZT. This showed that each new viral population gave a higher 
resistance to the drug than the previous population. 
5.5 DISCONTINUATION OF THERAPY 
Patient 87 contained a homogeneous population of 70/215 double mutants in the 
viral RNA sequences obtained at 83 weeks (section 3.6). Although the M41L 
mutation was not studied in all samples from this patient it was studied in the 83 
week sample and was not observed. This 83 week sample was the last obtained 
prior to the cessation of therapy for 30 weeks due to haematologic toxicity. 
Following this 30 week period without treatment it was surprising that on 
recommencement of therapy at 103 weeks that D67N and K219Q mutants were 
observed amongst the sequences obtained, which were not present when treatment 
was stopped. The presence of resistance conferring mutations within this time 
point at positions 67, 70, 215 and 219, after this 30 week period without therapy 
supports previous findings that reversion on discontinuation of therapy is slow 
(Albert et al., 1992; Boucher et al., 1993). Sequences obtained from both patients 
8 weeks post treatment showed little difference from the sequences obtained prior 
to treatment being stopped. In patient 87 however the 8 week post treatment 
sample contained two highly resistant isolates which were not observed during the 
period of therapy. These contained the mutational changes at positions 
67/70/215/219 which in combination confer a 121 fold increase in AZT resistance 
(Kellam et al., 1994). Continued development of resistance after cessation of 
therapy was also seen in six of the eleven patients studied by Loveday et al 
(1995). This persistence of mutants within the viral population also suggests that 
they are at little or no disadvantage in the absence of AZT, a possibility which is 
further supported by the isolation of resistant mutants after HIV transmission to 
untreated individuals (Conlon et al., 1994; Wahlberg et al., 1994; Erice et al., 
1993; Fitzgibbon et al., 1993). 
All five of the resistance conferring mutations were observed during the course of 
this study, although the change at position 41 was not observed in patient 87 and 
the change at position 219 was not seen in patient 74. The absence of these 
mutations may relate to differing patterns of resistance development or may be 
due to other host factors. The acquisition patterns reported here for these two 
patients although different show the presence of distinct viral populations at 
different time points during drug therapy. Each new population had a selective 
advantage over the previous population and in most cases conferred a higher level 
of resistance. 
Studies of env sequence variants have shown that each new sequence population 
initially appears in the plasma RNA population before eventually becoming the 
predominant sequence type amongst proviral PBMC sequences (Simmonds et al., 
1991). This suggests that the source of virus found in plasma may be either a 
subset of CD4 lymphocytes or cells from solid tissue rather than circulating 
lymphocytes. These findings have recently been supported by the study of Wei et 
al (1995), which investigated changes in the viral population with respect to 
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nevirapine resistance in plasma and PBMCs. This study showed the appearance of 
resistant genotypes, firstly in the plasma viral population followed by their later 
appearance in PBMCs (Wei et al., 1995). Little difference was observed in the 
work presented here between the timing of appearance of resistance-conferring 
changes in viral RNA as opposed to proviral DNA. The only noticeable 
difference was the appearance of the T215Y mutation in the viral RNA sequences 
obtained from the patient 74, 22 week sample, which was not observed until 74 
weeks in the proviral DNA from patient 87. This may, however, be due to host 
factors and more detailed sampling would be required to elucidate this point. 
5.6 AZT RESISTANCE MUTATION PHYLOGENIES 
Having shown different distinct patterns of resistance-conferring mutation 
acquisition within these two patients, phylogenetic reconstruction methods were 
employed to investigate the viral evolutionary patterns present during therapy 
(sections 4.2 and 4.3). The phylogenetic tree obtained from the p 74  poi sequences 
revealed highly progressive selective evolution under the strong selective force of 
the drug. Unique evolutionary origins were identified for the appearance of the 
T215Y and M41L mutations. This is supportive of the sequence work presented 
earlier in that once these mutations appear they remain fixed in the circulating 
viral population. All viral genotypes obtained later were descended from node Z 
at which the M41L mutation appeared, and they are M41LJT215Y double mutants. 
According to Kellam et al this double mutant confers a 64 fold increase in AZT 
resistance (Kellam et al., 1994a). However the p 87  poi tree in contrast to the p74 
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tree does not show as strong evidence of selective evolution. A more random 
pattern of viral evolution was observed in relation to the acquisition of the 
resistance conferring changes. A number of different sequence lineages were 
identified in which resistance conferring sequences appeared. All evolutionary 
lineages present at the outset of therapy persisted throughout the course of 
treatment. The complex evolutionary pattern with the appearance of mutants in 
several lineages, seen in this patient may have developed due to the cessation of 
therapy between weeks 83 and 103 due to haematologic toxicity. However in 
patient 74 the first bottleneck was observed before 22 weeks. 
Mean nucleotide distances calculated for the poi gene sequences obtained from 
both patients show a far greater sequence diversity amongst the sequences from 
patient 74 (section 3.7). The mean nucleotide distance between the pre-treatment 
RNA sequences and the RNA sequences obtained post treatment was 6.2% for 
patient 74 in comparison to 1.4% for patient 87. A similar observation is seen 
between the first DNA sequences and those obtained post treatment where a 4.4% 
difference is observed for patient 74 and only a 2% distance is seen for patient 87. 
This finding of greater sequence divergence in patient 74 is also seen on 
observation of the reconstructed phylogenies. The maximum branch length from 
the tree root to the most divergent sequences in patient 74 was 13% whereas in 
patient 87 the distance was markedly lower at only 3.5%. Why under the strong 
selective force of AZT, sequences should evolve faster in patient 74 than in 
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patient 87 cannot be explained by the data presented here. It is likely to be 
related to host factors. 
Having shown that drug selection plays an important role in the evolution of the 
poi gene particularly in patient 74, the V3 region of the envelope gene was 
analyzed. Proviral DNA sequence was obtained from the same samples as were 
used for the poi gene analysis to investigate whether the directional evolution 
observed in poi had any effect on the concurrent evolution within the env gene. 
5.7 SEOUENCE VARIATION IN THE ENV GENE OF HIV-1 
A large amount of sequence heterogeneity is observed within the envelope region 
of HIV-1 (Hahn et al., 1986; Simmonds et al., 1990a; Coffin, 1992), although it is 
not evenly distributed throughout the region (Willey et al., 1986; Modrow et al., 
1987). Li et al (1988) and Leigh Brown and Monaghan (1988) in a comparison of 
published HIV-1 sequences showed a particularly high substitution rate in the 
hypervariable regions of env (14 x iO nucleotide substitutions /site /year) in 
relation to the conserved regions (3.3 x iO nucleotide substitutions / site/ year) 
and the gag and poi genes (around 1.7 x iO nucleotide substitutions/ site! year). 
This high rate suggests that the env gene is evolving under different selective 
pressures from the rest of the HIV viral genome. 
This high level of HIV-1 genetic variation exists not only between viral isolates 
obtained from different individuals but also between isolates obtained from within 
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the same patient. In a group of six Edinburgh haemophiliacs the mean within 
patient nucleotide divergence was 4.2% between V3 proviral sequences and 1.65% 
in the gag gene (Balfe et al., 1990). Another study investigated sequence 
divergence between a blood donor and six recipient children. The divergence 
between sequences in this group was expressed as the mean proportion of 
differences from the consensus of the V3 region. This study gave a within sample 
mean divergence of 1.5% (Wolfs et al., 1990). The evolutionary rate of the V3 
and V41V5 regions of env were calculated by Balfe et al (1990) as 0.48% and 
0.41% per annum respectively. Two other early studies have estimated the rate of 
change in the env gene per year as 0.92% and 1.2% (Li et al., 1988; Smith et al., 
The mean between sample nucleotide distances obtained from the V3 region from 
patients 74 and 87 range from 0% at seroconversion to 6.5% and 7.5% 
respectively in year 6 (section 3.9). However in patient 87 the greatest divergence 
is seen between seroconversion and the year 4 samples (8.5%). 
An estimate of the rate of sequence change over the period of study was obtained 
by dividing the mean nucleotide distance between the seroconversion sample and 
the last sample (year 6) by 6 to give an evolutionary rate per year. This gives an 
estimate of 1.1% and 1.3% per year for patients 74 and 87 respectively. However 
on examination of the reconstructed phylogenies for both patients (figures 4.3 and 
4.4) it can be clearly seen that these are underestimates. For example in patient 
74 the most divergent V3 sequences are observed in years 3 and 4 and 
measurement of the branch length gives a distance of 11.6% on dividing this by 3 
an evolutionary rate of 3.8% per year is obtained. Thus the evolutionary rate in 
the V3 region is not constant as was shown by Holmes et al (1992). 
5.8 V3 LOOP STRUCTURE. 
The V3 loop region of the Subtype B env gene consists of 35 amino acids bound 
in a loop structure by a disulphide bridge between two cystine residues (Rusche et 
al., 1988; Palker et al., 1988; Javaherian et al., 1989). This region is highly 
variable, although it has a highly conserved amino acid tetrapeptide, Gly-Pro-Gly-
Arg at the tip of the loop (LaRosa et al., 1990). In the study of La Rosa et al 
(1990) it was conserved in 226 of the 245 sequences (92%) presented in the study. 
This study also predicted from the consensus of V3 sequences that the loop 
structure is a cystine-beta strand-type II beta turn-beta strand-alpha helix cystine. 
It is likely that the GPGR motif at the tip of the loop is maintained for structural 
reasons. 
5.9 BIOLOGICAL FUNCTION OF THE V3 LOOP AND EFFECT OF 
SEQUENCE VARIATION. 
The sequence variation which occurs in the V3 region of the env gene has been 
shown to influence viral tropism, syncytium induction and its ability to replicate in 
vitro. Viral isolates obtained from asymptomatic patients early in infection tend to 
be slow replicating, non syncytium inducing (NSI) and macrophage tropic. In 
contrast to this, isolates obtained later in infection (ARC/AIDS) tend to exhibit a 
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high replicating, syncytium inducing (SI), T-cell tropic phenotype (Tersmette et 
al., 1988; 1989a; Holodniy et al., 1991). The switch from NSI to the SI 
phenotype has been shown to precede an accelerated loss of CD4 lymphocytes and 
the development of AIDS in 50% of patients (Tersmette and Miedema, 1990; 
Koot et al., 1992; Roos et al., 1992). 
Viral tropism of HIV-1 has been shown to be altered by regions within the V3 
loop. Hwang et al.(1991) showed that by inserting a 20 amino acid segment from 
the V3 loop of a macrophage tropic isolate (BaL) into 111B a T-cell tropic isolate, 
this conferred macrophage tropism. Previously, others (OBrien et al., 1990; Shioda 
et al., 1991) had shown that a 157 amino acid region containing the 20 amino acid 
segment used by Hwang et al, had the capacity to confer macrophage tropism. 
This was further narrowed to a single amino acid change of the central proline at 
the tip of the V3 loop. Changing this to either serine or tryptophan was shown to 
alter the viral host range (Takeuchi et al., 1991), although these changes are found 
at low frequency amongst subtype B sequences (Myers et al., 1994). 
Studies have also been carried out to access the role of the V3 loop on syncytium 
formation (Freed et al., 1991; Helseth et al., 1990; Fouchier et al., 1992; de Jong 
et al., 1992a; de Jong et al., 1992b; Ivanoff et al., 1992; Shimizu et al., 1994). 
Freed et al (1991) shows that point mutations in the highly conserved GPGR motif 
at the tip of the V3 loop of HXB2 reduce or completely abolish SI capacity. 
Single point mutations at the tip of the loop of Pro->Arg and Gly->Aln reduce SI 
formation by 90%. However changes of Gly->Gln or Arg->Gln blocked SI 
formation completely. A change of Gly->Trp has also been reported to 
completely block syncytium formation (Helseth et al., 1990). None of these point 
mutations introduced into the V3 loop affected synthesis, processing, transport or 
binding to the CD4 receptor molecule. It has also been shown that isolates which 
confer an SI phenotype have a higher net charge associated with their V3 loop 
sequences than do NSI isolates (Fouchier et al., 1992; de Jong et al., 1992b). If 
either of the residues at positions 306 or 320 are positively charged the isolate 
almost always confers an SI phenotype (Fouchier et al., 1992). By mutagenesis of 
single amino acids in the V3 loop the minimum requirements to support the SI 
high replicating phenotype have been determined (de Jong et al., 1992a). A 
change at position 306 of Ser->Arg gave an intermediate SI phenotype; however 
an additional change of Asp->Gln at position 320 or a Asp->Asn change at 
position 324 along with the 306 change gave a complete SI phenotype. A single 
change at position 320 of Asp->Arg also gave a complete SI phenotype. All of 
these changes are naturally occurring mutations. In an analysis of 258 V3 
sequences from previously published data sets (LaRosa et al., 1990; Myers et al., 
1994) it has been shown that 70% of non conservative basic substitutions in the 
V3 loop occur at positions 306, 309, 320 and 327 (Milich et al., 1993). A 
positive charge at any of these positions is likely to confer the T-cell line tropic 
SI phenotype. 
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A large amount of sequence variation was observed in both patients particularly 
within the V3 loop region (amino acids 296 -> 330). Of the 30 amino acids 
which make up the loop only 15 were conserved in patient 87, and 16 in patient 
74 over the period of study (section 3.8). Amino acid changes were observed in 
both patients at positions 306, 320 and 324 which have been shown to be 
associated with the transition from a non-syncytium inducing phenotype (NSI) to a 
syncytium inducing phenotype (SI), which has been linked with more rapid 
disease progression (de Jong et al., 1992a; Fouchier et al., 1992; Tersmette et al., 
1989a,b; Schuitemaker et al., 1991; Schuitemaker et al., 1992). Furthermore 
changes are seen in the normally conserved GPGRAF motif at the tip of the loop. 
In patient 74, GWGRAF and GSGRAF are seen and in patient 87, GPGSAF and 
GPGKAF are seen. The GSGRAF and GWGRAF motifs seen in patient 74 have 
previously been reported as altering the host range of isolates (Takeuchi et al., 
1991). However both these motifs have been shown to exist as minor forms 
amongst published subtype B sequences. The GWGRAF and the GSGRAF motifs 
being seen in 22 and 2 respectively, out of the 338 subtype B sequences published 
in Aids and Human Retroviruses 1994 (Myers et al., 1994). The motifs observed 
in patient 87 are also seen at low frequency amongst this published data set 
occurring 10 and 22 times amongst the 338 sequences. 
5.10 V3 REGION PHYLOGENJIES. 
Phylogenetic reconstruction based on the V3 sequences (sections 4.5 and 4.6) 
show no sign of any directional evolution as was observed in the poi gene of 
patient 74. The phylogenies from both patients show three distinct evolutionary 
lineages which persisted over the period of AZT therapy. In both cases the SI 
variants present group together within the tree with the exception of two highly 
divergent SI variants found in patient 74. These V3 phylogenies show a similar 
pattern of evolution to that observed in a study of an asymptomatic patient not 
under AZT therapy (Holmes et al., 1992). The study of Holmes et al was based 
on analysis of 89 V3 plasma viral sequences obtained from the patient over 7 
years (1984->1991). Twelve sequences were obtained at seroconversion which 
were identical. These were shown to be the ancestors of all others, with different 
lineages being found at different frequencies in succeeding samples. Over the 
seven year period, 24 different V3 loop sequences were observed. In year 3 of the 
study two distinct lineages appeared which persisted throughout the remainder of 
the study period. This similar pattern of sequence evolution suggests that AZT 
therapy does not influence the evolution of the viral population in the env gene 
significantly. 
5.11 RATIO OF SYNONYMOUS TO NONSYNONYMOUS CHANGE IN 
POL AND ENV. 
The ratio of synonymous substitutions per synonymous site to nonsynonymous 
substitutions per nonsynonymous site (dfd,.)  obtained from p74 and p87 for the 
poi gene were 2.00 and 2.68 respectively, with the env gene ratios being 0.6 and 
0.62 (sections 3.7 and 3.9). Both poi ratios indicate a higher number of 
synonymous substitutions per synonymous site than nonsynonymous substitutions 
per nonsynonymous site. In contrast to this, the env gene shows a greater number 
of non synonymous substitutions per nonsynonymous site than synonymous 
substitutions per synonymous site. This indicates that the V3 region of the env 
gene is under much stronger selection pressure for nucleotide substitutions 
conferring amino acid change. Amino acid change conferring substitutions within 
p01 were restricted predominantly to sites implicated in development of AZT 
resistance, although others were observed. Typically for the gag and poi regions 
of I-IIV the d value is one sixth the d  value (Li et al., 1988), whereas here the 
value obtained from the poi sequences from both patients is close to half. This 
suggests that the drug is exerting a selection pressure on the pol gene which may 
extend to amino acid sites other than those known to be associated with resistance 
and confirms the findings of the phylogenetic analyses. 
5.12 AZT, SI PHENOTYPE AND DISEASE PROGRESSION. 
The link between AZT sensitivity, presence of SI phenotype and disease 
progression has been studied (St Clair et al., 1993). This study compared disease 
progressors with non progressors longitudinally for the presence or absence of the 
SI phenotype and levels of AZT resistance. It concluded that, firstly, disease 
progression may be more closely related to the presence of the SI phenotype than 
resistant virus, secondly that the presence of AZT resistance isolates alone is not 
always associated with disease progression and finally that the presence of both 
the SI phenotype and AZT resistant virus does not always lead to progression. 
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5.13 CONCLUSION. 
The work presented here set out to investigate the acquisition of AZT resistance 
associated mutations, the timing of appearance of these mutations and the 
evolutionary patterns associated with resistance development. Timing and 
appearance of the resistance-conferring changes varied between the two patients 
studied. Very little difference was observed between the appearance of these 
changes in the viral RNA as opposed to the proviral DNA. Reconstructed 
phylogenies based on the poi gene sequences, particularly in patient 74, showed 
that strong directional pressure is placed on evolution of the gene by AZT. In 
contrast to this the reconstructed phylogenies of the V3 region of the env gene 
show no sign of directional evolution. Thus the selective force placed on the poi 
gene by AZT therapy has no significant effect on the concurrent evolution within 
the env gene. The observations made in this study must take into account that 
they are based on the study of only two patients and expansion of the data set 
would provide more conclusive evidence. 
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A1.1 Nucleotide sequence obtained from the POL A region of the RT 
domain of patient 74. Sequences are aligned to HXB2, coordinates 2651-> 
2767. 
Nucleotides underlined in the HXB2 sequence indicate the positions of the 
amino acid changes which are associated with AZT resistance. 
These changes are: position 41 ATG(MET)->TTG(LEU) 
position 67 AAC(ASP)->AAC(ASN) 
position 70 AAA(LYS)->AGA(ARG) 
Samples are: 	H9E1 RNA Pre-treatment n=9 
0182 DNA Pre-treatment n=9 
0349 DNA 17 weeks n=11 
49 RNA 22 weeks n=8 
85 DNA 56 weeks n=9 
117 DNA 81 weeks n=12 
133 DNA 110 weeks n=11 
133 RNA 110 weeks n=11 
181 DNA Post-treatment n=11 
181 RNA Post-treatment n=9 
- = indicates where no sequence was obtained, 
= indicates match with the consensus sequence. 
A1.1 NUCLEOTIDE SEQUENCE OF THE POL A 
REGION FROM PATIENT 74. 
1 
I 
11 21 31 	 41 	50 
HX82 GTAGAAATTT 
I 	 I 
GTACAGAGAT GGAAAAGGAA 
I I I 
GGGAAAATTT CAAAAATTGG 
H9E1.2 .......... ....... A.............. A ....... 	.......... 
R9E1.3 .......... ....... A.. 	.......... ..A ....... 	.......... 
H9E1.4 .......... ....... A.. 	.......... ..A ....... 	.......... 
R9E1.5 .......... ....... A.. 	.......... ..A ....... 	.......... 
R9E1.7 .......... .. ..... A.. 	.......... ..A ....... 	.......... 
H9E1.8 .......... ....... A.. 	.......... ..A ....... 	.......... 
H9E1.9 .......... ....... A.. 	.......... ..A ....... 	.......... 
H9E1.10 .......... .. ..... A.. 	.......... ..A ....... 	.......... 
DNA0182.1 .......... ....... A.. 	.......... ..A ....... 	.......... 
DNA0182.2 .......... ....... A.. 	.......... ..A ....... 	.......... 
DNA0182.3 .......... ....... A.. 	.......... ..A. 	.G .............. 
DNA0182.4 .......... .. ..... A.. 	.......... ..A ....... 	.......... 
DNA0182.5 .......... .. ..... A.. 	.......... ..A ....... 	.......... 
DNA0182.6 .......... ....... A.. 	.......... ..A. 	.G .............. 
DNA0182.7 .......... ....... A.. 	.......... ..A ....... 	.......... 
DNA0182.8 .......... ....... A.. 	.......... ..A ....... 	.......... 
DNA0182.9 .......... ....... A.. 	.......... ..A ....... 	.......... 
DNA0349.1 .......... ....... A.. 	.......... ..A ....... 	.......... 
DNA0349.2 ........ A. ....... A.. 	.......... ..A ....... 	.......... 
DNA0349.3 .......... ....... A.. 	.......... ..A. 	.G.............. 
DNA0349.4 .......... ....... A.. 	.......... ..A. .G............A. 
DNA0349.5 .......... .. ..... A.. 	.......... ..A ....... 	.......... 
DNA0349.6 .......... ....... A.. 	.......... ..A ....... 	.......... 
DNA0349.7 .......... ....... A.. 	.......... ..A. 	.G .............. 
DNA0349.8 .......... ....... A.. 	.......... ..A. 	.G .............. 
DNA0349.9 .......... .. ..... A.. 	.......... ..A ....... 	.......... 
DNA0349.10 .......... ....... A.. 	A ..... A..... A ....... 	........ A. 
DNA0349.11 .......... ....... A.. 	.......... ..A ....... 	.......... 
cDNA49.3 .......... ....... A.. 	.......... ..A ....... 	.......... 
cDNA49.4 .......... ....... A.. 	.......... ..A ....... 	.......... 
CDNA49.5 .......... ....... A.. 	.......... ..A ....... 	.......... 
cDNA49.6 .......... ....... A.. 	.......... ..A. .G.............. 
cDNA49.7 .......... ....... A.. 	.......... ..A. 	. .... 	.... G ..... 
cDNA49.8 .......... ....... A.. 	.......... ..A ....... 	.......... 
cDNA49.10 .......... ....... A.. 	.......... ..A ....... 	.......... 
cDNA49.11 .......... ....... A.. 	.......... ..A. 	.G .............. 
DNA85.1 .......... ....... A.. 	.......... ..A. 	.G .............. 
DNA85.2 ........ A. ....... AC . 	.......... ..A ....... 	.......... 
DNA85.3 .......... ....... A.. 	.......... ..A. 	.G .............. 
DNA85.4 .......... ....... A.. 	.......... ..A ....... 	.......... 
DNA85.5 .......... ....... A.. 	.......... ..A ....... 	.......... 
DNA85.6 ........ A. ....... A.. 	.......... ..A ....... 	.......... 
DNA85.7 .......... ....... A.. 	.......... ..A ....... 	.......... 
DNA85.8 .......... ....... A.. 	.......... ..A. .G.............. 
DNA85.9 .......... ....... A.. 	.......... ..A. 	.G .............. 
DNA117.1 ........ A. ....... AC. 	.......... ..A ....... 	.......... 
DNA117.2 .......... ....... A.. 	.......... ..A. 	.G .............. 
DNA117.3 ........ A. ........ C . 	.......... ..A ....... 	.......... 
DNA117.4 ........ A. ....... AC . 	.......... ..A ....... 	.......... 
DNA117.5 ................. AC . 	.......... ..A ....... 	.......... 
DNA117.6 ........ A. ....... AC. 	.......... ..A ....... 	.......... 
DNA117.7 .......... ....... AC. 	.......... ..A. 	.G.............. 
DNA117.8 .......... ....... AC. 	.......... ..A. 	.G .............. 
DNA117.9 .......... ....... AC. 	.......... ..A. 	.G .............. 
DNA117.10 .......... ....... A.. 	.......... ..A ....... 	.......... 
DNA117.11 ................. AC . 	.......... ..A. 	.G .............. 
DNA117.12 ........ A. ....... AC . 	.......... ..A ....... 	.......... 
DNA133 .1 ........ A. ....... AC . 	.......... ..A ....... 	.......... 
DNA133.2 .......... ..G .... AC............. A. 	.G.............. 
DNA133.3 ........ A. ....... AC. 	.... . ..... ..A ....... 	.......... 
DNA133.4 ........A . .G. . . .AC ............. A................. 
DNA133.5 ........ A. ....... AC. 	.......... ..A ....... 	.......... 
DNA133.6 ........ A. ....... AC. 	.......... ..A ....... 	.......... 
DNA133.7 ........ A. ....... AC. 	.......... ..A ....... 	.......... 
DNA133.8 ........A . .G.. . .AC . 	.......... ..A ....... 	.......... 
DNA133.9 ........ A. ....... AC. 	.......... ..A ....... 	.......... 
DNA133.10 ................. AC . 	.......... ..A. 	.G.............. 
DNA133.11 ........A . .G. . . .AC ............. A................. 
cDNA133.1 ........ A. ....... AC. 	.......... ..A ....... 	.......... 
cDNA133.2 ........ A. ....... AC. 	....G ..... ..A ....... 	.......... 
cDNA133.3 ........ A. ....... AC. 	.......... ..A ....... 	.......... 
124 
CDNA133.4 . A. AC . A. 
cDNA133.5 ........ A. . .G. . . .AC .......... T . 	.A ................. 
cDNA133.6 ........ A. . .G. . . .AC . ........... ..A ....... 	 .......... 
cDNA133.7 ........ A. . .G. .. .AC . .......... ..A ....... 	 .......... 
cDNA133.8 ........A . .G. . . .AC ..... G ....... A ................. 
cDNA133.9 ........ A. ....... AC. .......... .. A ....... 	 .......... 
cDNA133.10 ........ A. . .G. . . .AC . .......... .. A ....... 	 .......... 
cDNA133.11 ................. AC. A 	.G ..... .. A ....... 	 .......... 
DNA181.1 ........ A. ....... AC . .......... .. A ....... 	 .......... 
DNA181.2 ........ A. . .G. . . .AC . .......... .. A ....... 	 .......... 
DNA181.3 ........ A. . .G. . . .AC . .......... ..A ....... 	 .......... 
DNA181.4 ........ A. . .G. . . .AC . .......... ..A ....... 	 .......... 
DNA181.5 ........ A. ....... AC . .......... .. A ....... 	 .......... 
DNA181.6 ........ A. . .G. . . .AC . .......... ..A ....... 	 .......... 
DMA181.7 ........ A. . .G. . . .AC . .......... .. A ....... 	.......... 
DNA181.8 ........A . .G... .AC ..... G....... A. 	.G.............. 
DNA181.9 ........A. . .G. . . .AC . .......... ..A ....... 	.......... 
DNA181.10 ........ A. ....... AC. .......... ..A ....... 	.......... 
DNA181.11 ........ A. ....... AC. .......... ..A ....... 	.......... 
cDNA181.1 ........A. . .G. . . .AC . ......... T . 	.A................. 
cDNA181.2 ........ A. ....... AC . .......... ..A ....... 	.......... 
cDNA181.3 ........ A. ....... AC. .... C ..... ..A ....... 	.......... 
cDNA181.4 ................. AC ..... G....... A. 	.G .............. 
cDNA181.5 ........A . .G. .. .AC. ....G ..... ..A ....... 	.......... 
cDNA181.6 ........A . .G. .. .AC..... G ..... ..A ....... 	.......... 
cDNA181.7 ........A . .G. . . .AC. ....G ..... ..A ....... 	.......... 
cDNA181.8 ........ A. ....... AC . .......... ..A ....... 	.......... 
cDNA181.9 ........A. . .G. . . .AC . .......... ..A ....... 	.......... 
51 61 71 81 	 91 	100 
HXB2 	GCCTGAAAAT CCATACAATA CTCCAGTATT TGCCATAAAG AAAAAAGACA 
H9E1.2A 


















DNA0349.3 	.......... 	.......... 	.......... 	...... C ............. 




DNA0349.8 	.......... 	.......... 	.......... 	...... C ............. 
DNA0349.9 	.................................................. 
0NA0349. 10 .................................................. 











DNA85.3 	.......... 	.......... 	.. ........ 	...... C.........A... 
DNA85.4 .......... 	.......... 	.. ........ 	........ G........... 
DNA85.5 	.......... 	.......... 	.. ........ 	...... C ............. 
DNA8S.6 
DNA85.7 	.......... 	.......... 	.. ........ 	.......... 	........ T. 
DNA85.8 .......... 	.......... 	.. ........ 	...... C ............. 
DNA8S.9 
DNA117.1 	.......... 	.......... 	..... A .... 	.......... 	.......... 
DNA117.2 
































cDNA133. 10 .......... 






















A .... 	 .......... 
A .... 	 .......... 
A .... 	 .......... 
A .... 	 .......... 
A .... 	 ... T ...... 
A .... 	 .......... 
A .... 	 .......... 
A.... C ......... 
A .... 	 .......... 
A.... C ......... 
A .... 	 .......... 
A .... 	 .......... 
A .... 	 .......... 
A .... 	 .......... 
A .... 	 ... T ...... 
A .... 	 ... T ...... 
A .... 	 .......... 
A .... 	 ... T ...... 
A .... 	 .......... 
A .... 	 .......... 
A .... 	 ... T ...... 
A .... 	 .......... 
A .... 	 .......... 
A .... 	 .......... 
A .... 	 .......... 
A .... 	 .......... 
A .... 	.......... 
101 	111 

















DNA0182.9 A ......... ....... 
DNA0349.1 ...... G .......... 
DNA0349.2 ...... G .......... 
DNA0349.3 ................. 
0NA0349.4 ...... G. .A ....... 
DNA0349.5 ...... G .......... 
DNA0349.6 ................. 
DNA0349.7 ...... G ... ....... 
DNA0349.8 ...... G ... ....... 
126 
DNA0349.9 . 
DNA0349.10 . A 	. 
DNA0349. 11 ................. 
cDNA49.3 ...... G ... 	 ....... 
cDNA49.4 ...... G .......... 
cDNA49.5 ...... G .......... 
cDNA49.6 ...... G ... 	 ....... 
cDNA49.7 ...... G .......... 
cDNA49.8 ...... G ... 	 ....... 
cDNA49.10 ...... G ... 	 ....... 
cDNA49.11 ...... G ... 	 ....... 
DNA85.1 ...... G .......... 
DNA85.2 
DNAB5.3 ...... G .......... 
DNA85.4 ...... G .......... 
DNA85.5 ...... G .......... 
DNA85.6 ...... G .......... 
DNA85.7 
DNA85.8 ...... G ... 	 ....... 
DNA85.9 ...... G ... 	 ....... 
DNA117.1 






















































A1.2 Nucleotide sequence obtained from the POL B region of the RT domain 
of patient 74. Sequences are aligned to HXB2, coordinates 3167-> 3222. 
Nucleotides underlined in the HXB2 sequence indicate the positions of the 
amino acid changes which are associated with AZT resistance. 
These changes are: position 215 ACC(THR)->TAC(TYR) 
position 219 AAA(LYS)->CAA(GLN) 
Samples are: 	H9E1 RNA Pre-treatment n=9 
0182 DNA Pre-treatment n=9 
0349 DNA 17 weeks n=11 
49 RNA 22 weeks n=8 
85 DNA 56 weeks n=9 
117 DNA 81 weeks n=12 
133 DNA 110 weeks n=11 
133 RNA 110 weeks n=11 
181 DNA Post-treatment n=11 
181 RNA Post-treatment n=9 
- = indicates where no sequence was obtained. 
= indicates match with the consensus sequence. 
A1.2 NUCLEOTIDE SEOUENCE OF THE POL B REGION 
FROM PATIENT 74. 
1 	 11 	 21 	 31 	 41 	50 
RXB2 AACATCTGTT GAGGTGGGGA CTTACCACAC 
H9E1.2 .......... .......... T ......... 
H9E1.3 
H9E1.4 	.......... 	.......... T ......... 
H9E1.5 .......... 	.......... 	T ......... 
H9E1.7 	.......... 	.......... 	T ......... 
H9E1.8 .......... 	.......... 	T ......... 
H9E1.9 	.......... 	.......... 	T ......... 
H9E1.10 .......... A ......... P ......... 
DNA0182.1 	.......... 	.......... T ......... 
DNA0182.2 	.......... 	.......... P ......... 
DNA0182.3 	.......... 	.......... P ......... 
DNA0182.4 	.......... 	.......... T ......... 
DNA0182.5 	.......... 	.......... 	P ......... 
DNA0182.6 .......... 	..A ....... P ......... 
DNA0182.7 	.......... 	.......... P ......... 
DNA0182.8 	.......... 	.......... T ......... 
DNA0182.9 	.......... 	.......... P ......... 
DNA0349.1 	.......... 	.......... 	P ......... 
DNA0349.2 	.......... 	.......... P ......... 
DNA0349.3 	.......... 	.......... P ......... 
DNA0349.4 	.......... 	.......... P ......... 
DNA0349.5 	.......... 	.......... P ......... 
DNA0349.6 	.......... 	.......... P ......... 
DNA0349.7 	.......... 	.......... P ......... 
DNA0349.8 	.......... 	.......... P ......... 
DNA0349.9 	.......... 	.......... P ......... 
DNA0349.10 .......... 	...... A... P ......... 
DNA0349.11 .......... 	.......... P ......... 
cDNA49.3 	.......... 	.......... P ......... 
cDNA49.4 .......... 	.......... P. .TA..... 
cDNA49.5 	.......... 	.......... P ......... 
cDNA49.6 .......... 	.......... T ......... 
cDNA49.7 	.......... 	.......... P. .TA..... 
cDNA49.8 .......... 	.......... P ......... 
cDNA49.10 	.......... 	.......... P ......... 
cDNA49.11 	.......... 	.......... P ......... 
DNA85.1 .......... 	.......... P. .TA ..... 
DNA85.2 	.......... 	.......... P. .TA..... 
DNA85.3 .......... 	.......... T..TA..... 
DNA85.4 	.......... 	.......... P. .TA..... 
DNA85.5 .......... 	.......... T. .PA..... 
DNA85.6 	.......... 	.......... P. .TA ..... 
DNA85.7 .......... 	.......... P. .TA..... 
DNA85.8 	.......... 	.......... T. .PA..... 
DNA117.1 .........G .......... T..TA..... 
DNA117.2 	.......... 	.......... P. .TA..... 
DNA117.3 .......... 	.......... P. .TA..... 
DNA117.4 	.......... 	.......... T..TA..... 
DNA117.5 .......... 	.......... T.ATA..... 
DNA117.6 	.......... 	.......... P. .TA..... 
DNA117.7 .......... 	.......... T..TA..... 
DNA117.8 	.......... 	.......... P. .TA..... 
DNA117.9 .......... 	.......... P. .TA..... 
DNA117.10 .......... 	.......... T..TA..... 
DNA117.11 .......... A ......... P. .TA..... 
DNA117.12 .......... 	.......... P. .TA..... 
DNA133.1 	.........G . .A.......P. .TA..... 
DNA133.2 .........G .......... T. .PA..... 
DNA133.3 	.........G .......... P. .PA..... 
DNA133.4 .........G .......... T..TA..... 
DNA133.5 	.......... 	.......... P. .PA..... 
DNA133.5 .........G . .A.......I. .TA..... 
DNA133.7 	.......... A ......... P. .TA..... 
DNA133.8 .........G . .A.......P. .TA..... 
DNA133.9 	.......... 	.......... T..TA..... 
DNA133.10 .......... 	.......... T. .TA..... 
DNA133.11 .........G .......... P. .TA..... 
cDNA133.1 .......... 	.......... P. .TA..... 
cDNA133.2 .......... 	.......... P. .TA..... 
cDNA133.3 .......... A ......... P. .TA ..... 



















G .. 	 ...... A... 
A... 
A... 




















































cDNA133.5 	. A.G ..A 	. T. .TA 	 . A... 
cDNA133.6 ....... A.G . .A ....... T. .TA ........ C ...... 	...... A... 
cDNA133.7 	......... G . .A ....... T. .TA ..................... A... 
cDNA133.8 	......... G .......... T. .PA ..................... A... 
cDNA133.9 .......... .......... T. .TA ..... .......... ...... A... 
cDNA133.10 ......... G . .A ....... T. .TA ..................... A... 
cDNA133.11 ......... G . .A ....... T. .TA ..................... A... 
DNA181.1 .......... .......... T..TA ..................... A... 
DNA181.2 	.......... 	 .......... 	 T..TA ..................... A... 
DNA181.3 .......... 	 .......... 	 T..TA ..................... A... 
DNA181.4 	.......... 	 .......... 	 T. .TA ..... 	 .......... 	 ...... A... 
DNA181.5 .......... 	 .......... 	 T..TA..................... A... 
DNA181.6 	.......... 	 .......... 	 T..TA..................... A... 
DNA181.7 ......... G . .A ....... T. .TA ..................... A... 
DNA181.8 	....... A.G ..AA ...... T. .TA ..................... A... 
DNA181.9 .......... 	 .......... 	 T..TA ..................... A... 
DNA181.10 	.......... 	 .......... P. .TA ..... 	 .......... 	 ...... A... 
DNA181.11 	.......... 	 .......... P. .TA ..................... A... 
cDNA18i..1 	......... G . .A ....... P. .TA ..................... A... 
cDNA181.2 	.......... 	 .......... 	 P. .TA ..................... A... 
cDNA181.3 ......... G . .A ....... P. .TA ..................... A... 
CDNA181.4 	......... G . .A ....... P. .TA ..................... A... 
cDNA181.5 	......... G . .A ....... P. .TA ..................... A... 
cDNA181.6 ......... G . .A ....... T. .PA ..................... A... 
cDNM.81.7 ......... G . .A ....... T. .PA ..................... A... 
cDNA181.8 ......... G . .A ....... P. .PA ..................... A... 





























DNA0349. 10 ..... 










































































A1.3 Nucleotide sequence obtained from the POL A region of the RT 
domain of patient 87. Sequences are aligned to HXB2, coordinates 2653-> 
2852. 
Nucleotides underlined in the HXB2 sequence indicate the positions of the 
amino acid changes which are associated with AZT resistance. 
These changes are: position 41 ATG(MET)->TTG(LEU) 
position 67 AAC(ASP)->AAC(ASN) 
position 70 AAA(LYS)->AGA(ARG) 
Samples are: 	090987 RNA Pre-treatment n=7 
159 DNA 5 weeks n=11 
160 DNA 16 weeks n=9 
160288 RNA 17 weeks n=6 
161 DNA 45 weeks n=7 
87 DNA 74 weeks n=7 
110589 RNA 83 weeks n=6 
113 DNA 103 weeks n=11 
270989 RNA 103 weeks n=7 
181 RNA Post-treatment n=9 
- = indicates where no sequence was obtained. 
= indicates match with the consensus sequence. 
A1.3 NUCLEOTIDE SEQUENCE OF THE POL A REGION 
FROM PATIENT 87. 
1 	 11 	 21 	 31 	 41 	50 






























A. 	 A ......... 
160288.2 A. A ......... 
160288.3 
	
A. 	 A ......... 
160288.4 A. A ......... 
160288.5 
	
A. 	 A ......... 

















A. 	 A ......... 
110589.2 A. A ......... 
110589.3 
	
A. 	 A ......... 
110589.4 A. A ......... 
110589.5 
	
A.... 	 A ......... 



















HS169DNA1 .......... 	A .... 	 .......... A ......... 	.......... 
HS169DNA2 .......... A .... 	 .......... A ......... .......... 
131 
HS169DNA3 -- 	 . A 	 A 	. 
HS169DNA4 -- ............A .............. A ......... 
HS169DNA5 -- ............ A.............. A ......... 
HS169DNA6 -- ............ A.............. A ......... 
HS169DNA7 -- ............ A.............. A ......... 
NS169DNA8 -- ............ A.............. A ......... 
HS169DNA9 -- ............A.............. A ......... 
51 	 61 	 71 	 81 	 91 	100 
HXB2 CTGAAAATCC ATACAATACT CCAGTATTTG CCATAAAGAA AAAAGACGT 
090987.1 
090987.2 
















































































G ... A ..... 
G ... A ..... 
G ... A ..... 
A ..... 
101 	111 	121 	131 	141 	150 




























160288.1 	. .. .G ............................................. 
160288.2 
160288.3 	. .. .G ............................................. 
160288.4 . . . .G ............................................. 
160288.5 	. . . .G ............................................. 
160288.6 
HS161DNA1 	.................................................. 
HS161DNA2 . . . . G ..... .......... .......... .......... .......... 
HS161DNA3 .................................................. 
HS161DNA4 . .. . G ..... .......... .......... .......... .......... 
HS161DNA5 .................................................. 
HS161DNA6 .................................................. 
BS161DNA7. .. . G ............................................. 
HS87DNA1 
HS87DNA2 	. . . . G ..... 	........ A. 	.......... 	.......... 	.......... 
HS87DNA3 
HS87DNA4. .. .G ............................................. 
HS87DNA5 	. .. .G ............................................. 
HS87DNA6 
HS87DNA7 	. . . .G ............................................. 
110589.1 . . . .G ............................................. 
110589.2 	. .. .G ............................................. 
110589.3 . . . .G ............................................. 
110589.4 	. . . .G ............................................. 
110589.5 . . . .G ............................................. 
110589.6 	. . . .G ............................................. 
HS113DNA1 .................................................. 
HS113DNA2 	. . . . G ............................................. 
HS113DNA3 	.................................................. 




HS113DNA8 . . . .G ............................................. 
HS113DNA9 . .. .G ............................................. 
HS113DNA1O .................................................. 
133 
H5113DNA13. 	 . 






270989.7 	. . . .G ............................................. 
HS169DNA1 	. . . . G ............................................. 
BS169DNA2 	. . . . G ............................................. 
MS169DNA3 	.................................................. 
HS169DNA4 .................................................. 
HS169DNA5 . . . . C ............................................. 
MS169DNA6 . . . . G ............................................. 
HS169DNA7 . . . . G ............................................. 
HS169DNA8. .. . G ..... 	 .......... 	 .......... 	 .......... 	 .......... 
HS169DNA9 .... G ..... 	 .......... 	 .......... 	 .......... 	 .......... 
151 	161 	171 	181 	191 	200 



















160.1 	.................................... 'P ...... 
160.2 .......... 	 .......... 	 .......... 	 ...... 'P ...... 
160.3 	.......... 	 .......... 	 .......... 	 ...... 'P ...... 
160.4 .......... 	 .......... 	 .......... 	 ... C. .T ...... 
160.5 	.......... 	 .......... 	 .......... 	 ... C. .T ...... 
160.6 .......... 	 .......... 	 .......... 	 ... C. .T ...... 
160.7 	.......... 	 .......... 	 .......... 	 ...... T ...... 
160.8 .......... 	 .......... 	 .......... 	 ... C. .T ...... 







HS161DNA1 .......... 	 .......... 	 .......... 	 ...... P ........ 
HS161DNA2 .......... 	 .......... 	 .......... 	 .......... 	 .. A.. 
HS161DNA3 .......... 	 .......... 	 .......... 	 ...... P ........ 
HS161DNA4 . . . 'P ...... 	.......... 	.......... 	...... T ........ 
HS161DNA5 	............................................. 
HS161DNA6 ............................................. 
HS161DNA7 	.......... 	 .......... 	 .......... 	 ...... T ........ 
HS87DNA1 	.......... 	 .......... 	 .......... 	 ... C. .A ............. 
HS87DNA2 	.......... 	 .......... 	 .......... 	 ... C. .A ............. 
HS87DNA3 	.......... 	 .......... 	 .......... 	 ... C. .A..... A ....... 
HS87DNA4 	.......... 	 .......... 	 .......... 	 ... C. . T ............. 
HS87DNA5 .......... 	 .......... 	 .......... 	 ... C. .T ............. 
HS87DNA6 	.......... 	 .......... 	 .......... 	 ... C. .A ............. 






110589.6 	...  
HS113DNA1 .......... 	 .......... 	 .......... 	 ... C. .T ............. 
RS113DNA2 .......... 	 .......... 	 .......... 	 ... C. .T ............. 
HS113DNA3 .......... 	 .......... 	 .......... 	 ... C. .T ..... A ....... 
HS113DNA4 .......... 	 .......... 	 .......... 	 ...... T ............. 































A1.4 Nucleotide sequence obtained from the POL B region of the RT domain 
of patient 87. Sequences are aligned to HXB2, coordinates 2998 -> 3230. 
Nucleotides underlined in the HXB2 sequence indicate the positions of the 
amino acid changes which are associated with AZT resistance. 
These changes are: position 215 ACC(THR)->TAC(TYR) 
position 219 AAA(LYS)->CAA(GLN) 
Samples are: 	090987 RNA Pre-treatment n=7 
159 DNA 5 weeks n=11 
160 DNA 16 weeks n=9 
160288 RNA 17 weeks n=6 
161 DNA 45 weeks n=7 
87 DNA 74 weeks n=7 
110589 RNA 83 weeks n=6 
113 DNA 103 weeks n=11 
270989 RNA 103 weeks n=7 
169 DNA Post-treatment n=9 
- = indicates where no sequence was obtained. 
= indicates match with the consensus sequence. 
A1.4 NUCLEOTIDE SEQUENCE OF THE POL B REGION 
FROM PATIENT 87 
1 	 11 	 21 	 31 	 41 	50 


































MS161DNA]. ---------- ---------- ---------- ---------- ---------- 
HS161DNA2 ---------- ---------- ---------- ---------- ---------- 
HS161DNA3 ---------- ---------- ---------- ---------- ---------- 
HS161DNA4 ---------- ---------- ---------- ---------- ---------- 
HS161DNA5 ---------- ---------- ---------- ---------- ---------- 
HS161DNA6 ---------- ---------- ---------- ---------- ---------- 









































HS 16 9DNA9 




I I I 










159.1 ---------- ---------- ---------- ---------- ------- CAT 
159.2 ---------- ---------- ---------- ---------- ------- CAT 
159.3 ---------- ---------- ---------- ---------- ------- CAT 
159.4 ---------- ---------- ---------- ---------- ------- CAT 
159.5 ---------- ---------- ---------- ---------- ------- CAT 
159.6 ---------- ---------- ---------- ---------- ------- CAT 
159.7 ---------- ---------- ---------- ---------- ------- CAT 
159.8 ---------- ---------- ---------- ---------- ------- CAT 
159.9 ---------- ---------- ---------- ---------- ------- CAT 
159.10 ---------- ---------- ---------- ---------- ------- CAT 
















HS161DNA1 ---------- ---------- ---------- ---------- ---------- 
HS161DNA2 ---------- ---------- ---------- ---------- ---------- 
HS161DNA3 ---------- ---------- ---------- ---------- ---------- 
HS161DNA4 ---------- ---------- ---------- ---------- ---------- 
HS161DNA5 ---------- ---------- ---------- ---------- ---------- 
HS161DNA6 ---------- ---------- ---------- ---------- ---------- 














HS113DNA1 .......... .......... 	 ....... G.. 	.......... .......... 
HS113DNA2 .................................................. 


















MS 16 9DNA2 
MS 16 9DNA3 
HS169DNA4 
HS169DNA5 




101 	111 	121 	131 	141 	150 
HXB2 TGGATGATTT GTAPGTAGGA TCTGACTTAG AAATAGGGCA GCATAGAACA 
090987.1 ---------- ---------- ---------- ------- A .. .......... 
090987.2 ---------- ---------- ---------- ------- A .. .......... 
090987.3 	---------- ---------- ---------- ------- A .. .......... 
090987.4 	---------- ---------- ---------- ------- A .. .......... 
090987.5 	---------- ---------- ---------- ------- A .. .......... 
090987.6 ---------- ---------- ---------- ------- A .. .......... 
090987.7 	---------- ---------- ---------- ------- A .. .......... 
159.1 	G.ATG ..... 	 .......... 	 .......... 	 ....... A............ 
159.2 G.ATG ..... 	 .......... 	 .......... 	 ....... A ............ 
159.3 	G.ATG ..... 	 .......... 	 .......... 	 ....... A ............ 
159.4 G.ATG ..... 	 .......... 	 .......... 	 ....... A ............ 
159.5 	G.ATG ..... 	 .......... 	 .......... 	 ....... A ............ 
159.6 G.ATG ..... 	 .......... 	 .......... 	 ....... A ............ 
159.7 	G.ATG ..... 	 .......... 	 .......... 	 ....... A ............ 
159.8 G.ATG ..... 	 .......... 	 .......... 	 ....... A ............ 
159.9 	G.ATG ..... 	 .......... 	 .......... 	 ....... A ............ 
159.10 G.ATG ..... 	 .......... 	 .......... 	 ....... A ............ 
159.11 	G.ATG ..... 	 .......... 	 .......... 	 ....... A............ 
160.1 .......... 	 .......... 	 .......... 	 ....... A ............ 
160.2 	.......... 	 .......... 	 .......... 	 ....... A ............ 
160.3 .......... 	 .......... 	 .......... 	 ....... A............ 
160.4 	.......... 	 .......... 	 .......... 	 ....... A............ 
160.5 .......... 	 .......... 	 .......... 	 ....... A ............ 
160.6 	.......... 	 .......... 	 .......... 	 ....... A............ 
160.7 .......... 	 .......... 	 .......... 	 ....... A............ 
160.8 	.......... 	 .......... 	 .......... 	 ....... A............ 
160.9 .......... 	 .......... 	 .......... 	 ....... A............ 
160288.1 ---------- ---------- ---------- ------- A .. .......... 
160288.2 ---------- ---------- ---------- ------- A .. .......... 
160288.3 	---------- ---------- ---------- ------- A .. .......... 
160288.4 	---------- ---------- ---------- ------- A .. .......... 
160288.5 	---------- ---------- ---------- ------- A .. .......... 
160288.6 ---------- ---------- ---------- ------- A .. .......... 
HS161DNA]. .......... .......... 	 .......... ....... A ............ 
HS161DNA2 .......... .......... 	 .......... .......... 	 .......... 
MS161DNA3 .......... .......... 	 .......... .......... .......... 
HS161DNA4 .......... .......... 	 .......... ....... A ............ 
HS161DNA5 .......... .......... 	 .......... .......... .......... 
HS161DNA6 ------- 	 A ............ 









HS87DNA5 A ............ 
HS87DNA6 	....... C.. 
HS87DNA7 A ............ 












HS113DNA1 .......... 	 A............ 
HS113DNA2 .......... 	 A............ 
HS113DNA3 .......... 	 A.. ...... GG.. 
HS113DNA4 ....... C.. 
HS113DNA5 .......... 
HS113DNA6 .......... 	 A............ 
HS113DNA7 .......... 	 A............ 
HS113DNA8 .......... 	 A............ 
HS113DNA9 .......... 	 A............ 
HS113DNA10 .......... 	 A............ 
HS113DNA11 .......... 	 A............ 
138 
270989.1 . A. 
270989.2 . 
270989.3 	.......... .......... .......... ....... A............ 
270989.4 	.......... .......... .......... ....... A............ 
270989.5 	.......... .......... .......... ....... A............ 
270989.6 	.......... .......... .......... ....... A............ 
270989.7 	.......... .......... .......... ....... A............ 
HS169DNA1 .......... .......... .......... ....... A ............ 
HS169DNA2 .......... .......... .......... ....... A ............ 
HS169DNA3 .......... .......... .......... ....... A ............ 
HS169DNA4 .......... .......... .......... ....... A ............ 
HS169DNA5 .......... .......... .......... ....... A ............ 
HS169DNA6 .......... .......... .......... ....... A ............ 
HS169DNA7 .......... .......... .......... ....... A ............ 
HS169DNA8 .......... .......... .......... ....... A ............ 
HS169DNA9 .......... .......... .......... ....... A ............ 
151 161 171 181 	191 	200 
HXB2 AAAATAGAGG AGCTGAGACA ACATCTGTTG AGGTGGGGAC TTACCACACC 
090987.1 	. . .G ................................... T ....... C.. 
090987.2 .......... 	 .. ........ 	 .......... 	 .. ....... T .......C. 
090987.3 	.......... 	.. ........ 	....... c.. 	......... T .......C. 
090987.4 .......... 	.. ........ 	.......... 	.. ....... T .......... 
090987.5 
090987.6 	.......... 	.. ........ 	.......... 	.. ....... T .......... 
090987.7 .......... 	.. ........ 	.......... 	.. ....... T .......C.. 
159 .1 	.......... 	.. ........ 	.......... 	.. ....... T 	.......... 
159 .2 .......... 	.. ........ 	.......... 	.. ....... T 	.......... 
159 .3 	.......... 	.. ........ 	.......... 	.. ....... T 	.......... 
159 .4 .......... 	.. ........ 	.......... 	......... P 	.......C.. 
159.5 	.......... 	.. ........ 	.......... 	.. ....... T .......C.. 
159 .6 .......... 	.. ........ 	.......... 	......... T 	.......... 
159 .7 	.......... 	.. ........ 	.......... 	.. ....... P 	.......... 
159 .8 .......... 	.. ........ 	.......... 	......... P 	.......C.. 
159.9 	.......... 	.. ........ 	.......... 	......... T 	....... 
159.10 .......... 	.. ........ 	.......... 	.. ....... P .......... 
159.11 	.......... 	.. ........ 	.......... 	.. ....... P .......... 
160 .1 .......... 	.. ........ 	.......... 	.. ....... P .......C.. 
160.2 	.......... 	.. ........ 	.......... 	.. ....... P .......C.. 
160.3 .......... 	.. ........ 	.......... 	.. ....... P .......C.. 
160.4 	.......... 	.. ........ 	.......... 	......... P 	.......... 
160 .5 .......... 	.. ........ 	.......... 	.. ....... P .......C.. 
160.6 	.......... 	.. ........ 	.......... 	......... p 	.......... 
160.7 .......... 	.. ........ 	.......... 	.. ....... P .......... 
160.8 
160 .9 	.......... 	.. ........ 	.......... 	.. ....... P 	.......... 
160288.1 	. . .G...................................T .......C. 
160288.2 . . .G ...... 	.. ........ 	.......... 	.. ....... T .......C.. 
160288.3 	. . .c...................................T .......C.. 
160288.4 . . .G ...... 	.. ........ 	.......... 	.. ....... T .......C. 
160288.5 	. . .G ...... 	.. ........ 	.......... 	......... P .......C.. 
160288.6 . . .G ...... 	.. ........ 	.......... 	.. ....... P .......C.. 
HS161DNA1 .......... 	.. ........ 	.......... 	.. ....... P .......C.. 
HS161DNA2 .................................................. 
HS161DNA3 .................................................. 
11S1610NA4 .......... 	 P.......C.. 
HS161DNA5 .......... 
HS161DNA6 .......... 	 T.......... 
















110589.1 T..TA ... C.. 
110589.2 	...... P... 	 T..TA ... C.. 
110589.3 I ..TA .. .C.. 
110589.4 I ..TA . . .C.. 
110589.5 
	
P ..TA . . .C.. 
110589.6 T ..TA . . .C.. 
HS113DNA1 .......... 	 P.......... 
HS113DNA2 .......... P.......... 
HS113DNA3 .......... 	 GT .......C.. 
HS113DNA4 .......... GT .......... 
HS113DNA5 .......... 	 GT .......... 
HS113DNA6 .......... I .......C.. 





































.A ....... P .......... 
.A ....... P ..TA 
.A ....... P ..TA 
.A ....... P ..TA . .C.. 
.A ....... T ..TA ......  
T .......... 
.A ....... P .......... 
.A ....... P ..TA ...... 
.A ....... T ....... C.. 
P ....... C.. 
	
.A ....... T 	.......... 
T ..TA . . .C.. 
.A ....... P ....... C.. 
.A ....... P .......... 
A ....... P ..TA ......  
.A ....... P .......... 
.A ....... P ..TA ......  
.A ....... T ....... C.. 
.A ....... P ....... C.. 
.A ....... P ....... C.. 
201 	211 	221 	231 











































HS87DA3 	... .0 ........................... 
HS87DNA4 
HS87DNA5 	. . . .0 ........................... 
HS87DNA6 
HS87DNA7 
110589.1 	.......... 	..... A .... 	.......... 	.. 
110589.2 .......... 	..... A .... 	.......... 	.. 
110589.3 	.......... 	..... A .... 	.......... 	.. 
110589.4 .......... 	..... A .... 	.......... 	.. 
110589.5 	.......... 	..... A .... 	.......... 	.. 
110589.6 .......... 	..... A .... .......... .. 
HS113DNA1 ................................ 
HS113DNA2 ................................ 




HS113DNA6 . 	 . 	 . 	 . C ........................... 
HS113DNA7 ................................ 
HS113DNA8 .. 	 . 	 . C ..... 	 .......... 	 .......... 	 .. 
HS113DNA9 . 	 .. 	 . C ..... 	 .......... 	 .......... 	 .. 
HS113DNA1O .... C ........................... 
HS113DNA11 .... C ........................... 
270989.1 
270989.2 . 	.. 	.0 ................. 
270989.3 
270989.4 
270989.5 . 	 . 	 . 	.0 ................. 




HS169DNA3 . 	 . 	 . 	.0 .............. 
HS169DNA4 ................... 
HS169DNA5 . 	 . 	 . 	.0 .............. 
HS169DNA6 . 	 . 	 . 	.C. 	. 	. 	.G 	......... 
HS1690NA7 . 	.. 	 . C ..... 	 ......... 
HS169DNA8 . 	.. 	.0 .............. 
HS169DNA9 ................... 
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A1.5 Nucleotide sequence obtained from the V3 region of the envelope gene of 
patient 74. Sequence begins at HXB2 nucleotide 7016. 
Samples are: 	0182 DNA n=11 year 3 
0349 DNA n=6 year 4 
117 DNA n=10 year 5 
133 DNA n=7 year 6 
181 DNA n=9 year 6 
- = indicates where no sequence was obtained. 
= indicates match with the consensus. 
A1.5 NUCLEOTIDE SEQUENCE OF THE V3 REGION 
FROM PATIENT 74. 
1 	 11 	 21 	 31 	 41 	50 
0182V3. 1 CTAGCAGAAG GAGAGGTAGT AATTAGAPCT GAAAATTTCA CGAACAATGT 
0182V3.2 	.......... A ......... 	.......... 	.......... 	.......... 
0182V3.3 
0182V3.4 	.......... AT ........ 	.......... 	... ....... 	..G ...... C 
0182V3.5 
0182V3.6 	.......... AT ........ .......... AGC ....... ... ...... c 
0182V3.7 
0182V3.8 	.......... AT ........ .......... TGC ....... ... ...... c 
0182V3.9 




0349V3.3 	.......... AT.G ...... .......... AGC ....... .. ...... c 
0349V3.4 	.......... AT.G ...... .......... A.c ....... .. ...... c 
0349V3.5 	.......... AT.G ...... .......... AGC ....... .. ...... C 
0349V3.6 	.......... AT ........ .......... AGC ....... .. ...... c 
117V3.1 .......... A ......... 	.......... 	.......... 	.......... 
117V3.2 	.......... A ......... 	.......... 	.......... 	.......... 
117V3.3 .......... A ......... 	.......... 	.......... 	.......... 
117V3.4 	.......... AT.G ...... .......... A.0 ....... .. ...... c 
117V3.5 .......... AT.G ...... .......... A.0 ....... .. ...... C 
117V3.6 
117V3.7 	.......... A ......... 	.......... 	.......... 	.... T ..... 
117V3.8 .......... A ......... 	.......... .......... .......... 
117V3.9 	.......... A ......... 	.......... 	.......... 	.......... 
117V3.10 
133V3.1 
133V3.2 	.......... AT.G ...... 	.......... AGC ....... ... ...... c 
133V3.3 .......... 	.......... 	.......... 	.......... 	.... T ..... 
133V3.4 	.......... A ......... 	.......... 	.......... 	.......... 
133V3.5 
133V3.6 	.......... A ......... 	.......... 	.......... 	.......... 
133V3.7 .......... A ......... 	.......... 	.......... 	....... c.. 
181V3.1 	.......... A ......... 	.......... 	.......... 	.......... 
181V3.2 .......... A ......... 	.......... 	.......... 	.......... 
181V3.3 	.......... A ......... 	.......... 	.......... 	.......... 
181V3.4 .......... A ......... 	.......... 	.......... 	.......... 
181V3.5 	.......... A ......... 	.......... 	.......... 	.......... 
181V3.6 
181V3.7 	.......... A .... A.................................. 
181V3.8 .......... A ......... 	.......... 	.......... 	.......... 
181V3.9 	.......... A ......... 	.......... 	.......... 	.......... 
p74. RNA 
51 	 61 	 71 	 81 	 91 	100 


















117V3.2 ... .G ..... ..... C 
117V3.3 
117V3.4 	.......... 	.......... 	.... G ..........A 











133V3 .5 	---.a ..... 	.......... 	.......... 	.......... 	.......... 
133V3.6 










p74.RNA 	- ................................................. 
101 	 111 	 121 	 131 	 141 	150 
I I I I I I 
0182V3.1 GACCCAACAA CAATACAAGA AAAGGCATAC ATATAGGACC AGGGAGAGCA 
0182V3.2 	.......... 	.......... 	.. ... I .... 	.......... G......... 
0182173.3 	.......... 	.......... 	.. ... T .... 	.......... G......... 
0182V3.4 	.......... 	.......... 	..... G ........................ 
0182V3.5 	.....GG ... 	.......... 	.. ... I .... 	.... G ... T. G......... 
0182V3.6 	.......... 	.......... 	... A.G ........................ 
0182V3.7 	......G ... 	.......... 	..... T .... 	.... G ... 1. G......... 
0182V3.8 	.......... 	.......... 	.. ... T .... 	.......... C......... 
0182173.9 	..... GG ... 	.......... 	.. ... T .... 	.... G ... 1. g......... 
0182V3.1 	.......... 	.......... 	..... T .... 	.......... 	...... I... 
0182173.1 	.......... 	........ T . 	..... I ........................ 
0349V3.1 	.......... 	.......... 	..... I ........................ 
0349V3.2 	..... GG ... .......... . G.A.T .... .... C. .ITG G ......... 
0349V3.3 	.......... 	.......... 	..... I .... 	.......... 	...... I... 
0349V3.4 	.......... 	.......... 	... A.T ........................ 
0349V3.5 	.......... 	.......... 	..... I .... 	.......... 	...... I... 
0349173.6 	.......................A.G ........................ 
117V3.1 .......... 	.. ........ 	.. ... I.... C .........G ......... 
117V3.2 	.......... 	.......... 	..... I .... 	.......... 	...... I... 
117V3.3 .......... 	.. ........ 	.. ... T.... G .........G ......... 
117V3.4 	.......... 	.......... 	... A.I ........................ 
117V3.5 .......... 	.......... 	... A.'P ........................ 
117V3.6 	.......... 	.......... 	.. ... T.... G.........G ......A.. 
117V3.7 .......... 	.......... 	..... I .... 	.......... 	...... I...  
117173.8 	.......... 	.......... 	..... I ........................ 
117V3.9 .......... 	.......... 	..... I .... 	.......... 	...... T...  
117V3.10 	.......... 	.......... 	..... I .... 	.......... 	...... T... 
133V3.1 .......... 	.......... 	..... T .... 	.......... 	...... T...  
133V3.2 	.......... 	.......... 	..... T .... 	.......... 	...... T... 
133173.3 .....GG ... .......... . G.A.I .... .... G. .IIG G ......... 
133V3.4 	.......... 	.......... 	..... I .... 	.......... 	...... I... 
133173.5 .......... 	.......... 	.. ... T.... G.........G ......A.. 
133V3.6 	.......... 	.. ........ 	.. ... I.... G .........G ......... 
133V3.7 ..... GG ... .......... . G.A.I .... .... G. .TTG G......... 
181V3.1 	.......... 	.. ........ 	.. ... a.... G ......... C......... 
181V3.2 .......... 	.. ........ 	.. ... I.... C ......... G ......... 
181173.3 	.......... 	.. ........ 	.. ... I.... G ......... C. .A...... 
181V3.4 ..... GG ... .......... .G.A.T .... .... C. .TIG G ......... 
181V3.5 	..... GG ... .......... .G.A.T .... .... G. .TTG C......... 
181V3.6 .......... 	.......... 	..... I .... 	.......... 	...... T... 
181V3.7 	. .. .1CC ... .......... .C.A.T .... .... G. .ITG G ......... 
181V3.8 ..... .. ... .......... .....T .... .... G. .IIG G ......... 
181V3.9 	.......... 	.. ........ 	.....P.... G .........C ......... 
p74.RNA ......C ... 	.......... 	... A.T .... 	.... G ..... G ......... 





0182V3.4 	C ......... 
0182V3.5 







0349173.2 	...... I... 
CACCAAATAI AAIAGCAGAP ATAAGACAAG CACATTGTAA 
A .. 	.......... 	.......... 	.......... 
GCA .. 	.......... 	.......... 	.......... 
c.c ................................ 
G .0.. 	.......... 	.......... 	.......... 
... A.C.A.. 	....... A.. 	.......... 	.......... 
CCC................................ 
C .A ................................ 
G .0 ................................ 
G .0 .. 	.......... 	..... G .... 	.......... 
A .. 	.......... 	.......... 	.......... 
C.. 	.......... 	.......... 	.......... 
G .A................................ 
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0349V3.3 	 . G.0 	 . G 	 . 
0349V3.4 	...... A ... 	 ..... G.A.. 	.......... 	 .......... 	 .......... 
0349V3.5 	.......... 	 ..... G.0 .. 	.......... 	 ..... G .... 	 .......... 
0349V3.6 	G ..... A ... ... A.C.A.. 	....... A.. 	.......... 	 .......... 
117V3.1 G ........ G . .A. .. .A ................................ 
117V3.2 	.......... 	 ..... G.0.. 	.......... 	 .......... 	 .......... 
117V3.3 . . .AT. . . .G . .A. .. .A ................................ 
117V3.4 	...... A ... 	 ..... G.A.. 	.......... 	 .......... 	 .......... 
117V3.5 ...... A ... 	 ..... G.A.. 	.......... 	 .......... 	 .......... 
117V3.6 	......... G . .A. .. .A ................................ 
117V3.7 .......... 	 ..... G.0.. 	.......... 	 .......... 	 .......... 
117V3.8 	.......... 	 ..... G.0 ................................ 
117V3.9 .......... 	 ..... G.0 ................................ 
117V3.10 	.......... 	 ..... G.0 ................................ 
133V3.1 ..... C .... 	 ..... G.0 ................................ 
133V3.2 	.......... 	 ..... G.0 .. 	.......... 	 ..... G .............. 
133V3.3 ...... T ........ G.A ................................ 
133V3.4 	.......... 	 ..... G.0 ................................ 
133V3.5 ......... G . .A.. . .A ................................ 
133V3.6 	G ........ G . .A. . . .A ................................ 
133V3.7 ...... T ........ G.A................................ 
181V3.1 	G. .AT. .. .G . .A. . . .A ................................ 
181V3.2 G ........ G . .A.. . .A................................ 
181V3.3 	G ........ G . .A.. . .A ................................ 
181V3.4 ...... T ........ G.A................................ 
181V3.5 	...... T ........ G.A................................ 
181V3.6 .......... 	 ..... G.0 ................................ 
181V3.7 	...... T ........ G.A ................................ 
181V3.8 ...... T ... 	..... G.0.. 	.......... 	.......... 	.......... 
181V3.9 	G ........G . .A.. . .A................................ 
p 74 .RNA ...............G.A................................ 
201 	 211 	 221 	 231 	 241 	250 
I I I I I 
0182V3.1 CCTTAGTAGA ACAAAATGGA ATGACACTTT AAAACAGATA GTTACAAAAT 
0182V3.2 	.......... 	.......... 	.......... 	...... T ............. 
0182V3.3 	.......... 	.......... 	.... G ..... 	.......... 	.......... 
0182V3.4 	.......... G ......... 	.......... 	.......... 	.......... 
0182V3.5 
0182V3.6 	.A ........ C ......... 	.... A ..... 	.......... 	.... T ..... 
0182V3.7 	.A ........ 	.......... 	.......... 	.......... 	.......... 
0182V3.8 	.......... G ......... 	.......... 	.......... 	.... T ..... 
0182V3.9 
0182V3.1 	.A ........ G ......... 	.... A ..... 	.......... 	.......... 
0182V3.1 	.......... 	.......... 	.......... 	...... T ............. 
0349V3.1 
0349V3.2 	.A ........ 	.......... 	..A ....... 	.......... 	.......... 
0349V3.3 	.A ........ C ......... 	.... A ..... 	.......... 	.......... 
0349V3.4 	.......... G ......... 	.... A ..... 	..G ....... 	.... T ..... 
0349V3.5 	.A ........ C ......... 	.... A ..... 	.......... 	.......... 
0349V3.6 	.A ........ G ......... 	.... A ..... 	.......... 	.... P ..... 
117V3.1 ..........G ......... 	..... G .... 	...... P ............. 
117V3.2 	.A ........ 	.......... 	.......... 	.......... 	.......... 
117V3.3 ..........C ......... 	.......... 	...... P ... 	........ G. 
117V3.4 	.......... G ......... 	.... A ..... 	..C ....... 	.... P ..... 
117V3.5 ..........G ......... 	.... A ..... 	..G ....... 	.... P ..... 
117V3.6 	..........G ....................................... 
117V3.7 .A ........ 	.......... 	..A ....... 	.......... 	.......... 
117V3.8 	.......... 	.......... 	.......... 	...... P ............. 
117V3.9 .A ........ G ......... 	..A ....... 	.......... 	.......... 
117V3.10 	.A ........ C ......... 	..A ....... 	.......... 	.......... 
133V3.1 .A ........ 	.......... 	..A ....... 	..G ................ 
133V3.2 	.A ........ C ......... 	.... A ..... 	.......... 	........ 
133V3.3 .A ........ C ......... 	..A ....... 	.......... 	......... 
133V3.4 	.A ........ G ......... 	..A ....... 	.......... 	......... 
133V3.5 
133V3.6 	..........G ......... 	.......... 	...... P ... 	.... P.... 
133V3.7 .A ........ 	.......... 	.......... 	.......... 	......... 
181V3 .1 	.......... 	......... C 	.............................. 
181V3.2 .......... 	.......... 	.......... 	...... T ... 	.... P ..... 
181V3.3 	..........G ......... 	..... G .... 	...... T ............. 
181V3.4 .A ........ G ......... 	.......... 	.......... 	.......... 
181V3.5 	.A ........ C ....................................... 
181V3.6 .A ........ 	G ....................................... 
181V3.7 	.A ........ G ......... 	..A ....... 	.......... 	.......... 
181V3.8 .A ........ G ....................................... 
181V3.9 	.......... 	.......... 	.......... 	...... T ... 	.... P ..... 
p74.RNA 
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A1.,6 Nucleotide sequence obtained from the V3 region of the envelope gene of 
patient 87. Sequence begins at HXB2 nucleotide 7006. 
Samples are: 	159 DNA n=4 year 3 
160 DNA n=9 year 4 
161 DNA n=9 year 4 
87 DNA n=6 year 5 
113 DNA n=9 year 5 
169 DNA n=6 year 6 
- = indicates where no sequence was obtained. 
= indicates match with the consensus. 
A1.6 NUCLEOTIDE SEQUENCE OF THE V3 REGION 
FROM PATIENT 87. 
1 	 11 	 21 	 31 	 41 	50 




159V3.4 	.......... 	.......... 	.......... 	.......... 	...... A... 
160V3.1 .. .GGCAGTC TAGC .................................... 
160V3.3 	. . . GGCAGPC TAGC ...... .......... .......... ........ A. 
160V3.4 . . . GGCAGTC TAGC .................................... 
160V3.5 	.. .GGCAGTC TAGC ...... .... A ..... .......... .......... 
160V3.6 .. .GGCAGTC TAGC ...... ......... C .................... 
160V3.7 	. . . GGCAGTC TAGC ...... .......... .......... .......... 
160V3.8 . . . GGCAGTC TAGC ...... .......... .......... ...... A... 
160V3.11 	. . . GGCAGTC TAGC ...... .......... .......... .......... 
160V3.12 	.. .GGCAGTC TAGC ...... .... A ..... .......... .......... 
161v3.1 .......... 	. AGC ...... A ... A......................AA. 
161v3.2 	.......... 	. AGC ...... A ......... 	.......... 	....... A.. 
161v3.3 .......... . AGA ... T.G .......... ...... AGC. ....... A.. 
161v3.4 
161v3 .5 	.......... 	. AGC ...... A ......... 	.......... 	....... A.. 
161v3.6 .......... 	. AGC ...... A ......... 	.......... 	....... A.. 
161v3 .7 	....................... . A......................AA. 
161v3.8 .......... 	. AGC ...... A ......... 	.......... 	.......... 
161v3.9 	.......... 	. AGC ...... A ......... 	.......... 	........ A. 
87.V3.1 ......... C TAGC ...... 	.... A ..... 	.......... 	....... A.. 
87.V3.2 	......... C TAGC ...... 	.... A ..... 	.......... 	....... A.. 
87.V3.3 ......... C TAGC ...... 	.... A ..... 	.......... 	....... A.. 
87.V3.4 	......... C TAGC ...... 	.... A ..... 	.......... 	....... A.. 
87.V3.5 ......... C TAGC ...... 	.... A ..... 	.......... 	....... A.. 
87.V3.6 	......... C TAGC ...... 	.... A ..... 	.......... 	....... A.. 
113v3 .1 .......... .... ------ ---------- ---------- ------- A.. 
113v3.2 
113v3 .3 	............................ 	. . G ....... ........ A. 
113v3.4 .................................... . .-- -. .. . . A.. 
113v3.5 	.......... .... ...... .......... .......... ....... A.. 
113v3.6 .......... .... ...... .......... .......... ....... A.G 
113v3 .7 	.......... .... ...... .......... .......... ....... A.. 
113v3.8 .......... .... ...... .......... .......... ....... A.. 
113v3 .9 	.......... .... ...... .......... .......... ....... A.. 
169v3.1 GGCAGTCTAG CAGA ... T.G .......... ...... AGC . ....... A.. 
169v3.2 	GGCAGTCTAG CAGA. . .--- . . . .A......................A.. 
169v3 .3 .......... .... ------ ---------- ---------- ------- A.. 
169v3.4 	GGCAGTCTAG CAGA ... T.G .......... ...... AGC . ....... A.. 
169v3.5 GGCAGTCTAG CAGA ... T .. .......... ...... AGC. ....... A.. 
169v3.6 	GGCAGTCTAG CAGA. . .--- . . . .A......................A.. 
p84.RNA 





























113v3.1 	. . . A 
113v3.2 







A.0 .... C.. 
A ......... 










A.0 .... C.. 
A ......... 
A .... 	.......... 
A ......... 
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113v3.3 	T 	 . A.. .A. .0 	A 	 . 




113v3.8 	.......... 	 .......... 	 .......... 	 .... C ..... A ......... 
113v3.9 
169v3.1 	.......... 	 .......... 	 .......... T..A ................ 
169v3.2 .......... 	 .......... 	 .......... 	 .... C ..... A ......... 
169v3.3 	.......... 	 .......... 	 .......... 	 ..... A .... 	 .......... 
169v3.4 .......... 	 .......... 	 .......... T..A................ 
169v3.5 	.......... 	 .......... 	 .......... T..A................ 
169v3.6 
p84.RNA 
101 	 111 	 121 	 131 	 141 	150 
I I I I I 
15 9V3. 1 GTACAAGACC CAGCAACAAT ACAAGAAAAA GTATATCAAT AGGACCAGGG 
159V3.2 	.......... 	 .......... 	 .......... 	 .......... 	 ...... G... 
159V3.3 .......... 	 .......... 	 .......... 	 .......... 	 ...... G... 
159V3.4 	.......... 	 .G.'P ...... 	 .......... 	 .. ........ 	 ...... G... 
160V3.1 .......... 	 .G.T ...... 	 ...... G ................... G... 
160V3.3 
160V3.4 	.......... 	 .G.T ...... 	 ...... G ...................G... 
160V3.5 . . .T ...... 	 ...... T ... 	 .......... 	 .......... 	 ...... G... 
160V3.6 	.......... 	 .G.T ...... 	 ...... G ................... G... 
160V3.7 . . .T .............................................. 
160V3.8 	.......... 	 .G.T ...... 	 .......... 	 .. ........ 	 ...... G... 
160V3.11 
160V3.12 	.......... 	 .G.T ...... 	 ...... G ..... ........ 	 ...... G... 
161v3.1 .......... 	 . a.'r ...... 	 ...... ...... ........ 	...... G... 
161v3.2 	.......... 	.G.T ... T .. 	...... G ..... ........ 	...... G... 
161v3.3 .......... 	..A ....... 	.......... 	.. .... AT ............ 
161v3.4 	.......... 	.......... 	.......... 	.......... 	...... G...  
161v3.5 .......... 	.G.T ...... 	...... ...... ........ 	...... G... 
161v3.6 	.......... 	.G.T ... T .. 	...... G ..... ........ 	...... G... 
161v3.7 .......... 	.G.T ... T .. 	...... G ...................s... 
161v3.8 	.......... 	.G.T ... T .. 	...... G ...................G... 
161v3.9 .......... 	.G.T ...... 	...... G ...................G... 
87.V3.1 	. . .T .............................................. 
87.V3.2 .......... 	.......... 	.......... 	.......... 	...... G... 
87.V3.3 	.......... 	.......... 	.......... 	.......... 	...... G... 
87.V3.4 .......... 	.......... 	.......... 	.......... 	...... G... 
87.V3.5 	.0 ........ 	.G.T ... T .. 	...... G ..... ........ 	...... G... 
87.V3.6 .......... 	.......... 	.......... 	.......... 	...... G... 
113v3.1 
113v3.2 	.......... 	.G.T ... 1 .. 	...... G ..... ........ 	...... G... 
113v3.3 .......... 	.G.T ...... 	..... c .... 	.. ....... 	...... G... 
113v3.4 	.......... 	.G.T ... T .. 	...... G ..... ........ 	...... G... 
113v3.5 .......... 	.......... 	.......... 	.......... 	...... G... 
113v3.6 	.......... 	.......... 	.......... 	.......... 	...... G...  
113v3.7 .......... 	.......... 	.......... A ......... 	...... G... 
113v3.8 	.......... 	.G.T ... T .. 	...... G ..... ........ 	...... G... 
113v3.9 .......... 	.......... 	...... G ... 	.......... 	...... G... 
169v3.1 	.......... 	..A ....... 	......... G .....CAT ............ 
169v3.2 .......... 	.G.T ... T .. 	...... G ..... ........ 	...... G... 
169v3.3 	.......... 	.......... 	.......... 	.......... 	...... G... 
169v3.4 .......... 	..A ....... 	......... G .....CAT ............ 
169v3.5 	.......... 	..A ....... 	.......... 	.. ... CAT ............ 
169v3.6 .......... 	.......... 	.......... 	.......... 	...... G. ..  
p84.RNA 	.......... 	.......... 	....... G.. 	.......... 	...... G... 
151 	 161 	 171 	 181 	 191 	200 
15 9V3. 1 AGAGCATTTT ATGCAACAGG AGAAATAATA GGAGATATAA GACAAGCACA 
159V3.2 
159V3.3 	.........A T ......... 	.... G ..... 	.......... 	.......... 
159V3.4 .........A T .......AA .0 ........ 	.......... 	... G...... 
160V3.1 	.........A T .....G.A............................... 
160V3.3 
160V3.4 	.........A T .....G.A............................... 
160V3.5 
160173.6 	..........T .....A.A............................... 
160V3.7 .........A T ....................................... 
160V3.8 	.........A T .......AA .0 ........ 	.......... 	... G ...... 
160V3.11 	.........A T ....................................... 
160173.12 	.........A T .....G.A............................... 
161v3.1 .........A T .....G.A............................... 
161v3.2 	.........A T .....G.A............................... 
161v3.3 ...... G .....A......A .0 ........ 	... A ...... 	.......... 
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161v3.4 	 . 
161v3.5 . A T 	. G.A . 
161v3.6 	......... A T ..... G.A............................... 
161v3.7 ......... A P ..... G.A............................... 
161v3.8 	......... A P ..... G.A............................... 
161v3.9 .........AT ..... G.A............................... 




87.V3.5 	......... A T ..... G.A............................... 
87.V3.6 
113v3.1 
113v3.2 	.........A P ..... G.A............................... 
13.v3.3 ......... G T ..... AGA ... ........ 	 .......... 	 .......... 




113v3.8 	......... A T ..... G.A............................... 
113v3.9 
169v3.1 	..T ....... 	 .......... 	 ... C ...... 	 .......... 	 .......... 
169v3.2 ......... A T ..... G.A ............................... 
169v3.3 
169v3.4 	..T ....... 	 .......... 	 ... C .......................... 
169v3.5 ...... G ..... A ...... A .0 ........ 	 ... A ...... 	 .......... 
169v3.6 
p84.RNA 
201 	211 	221 	231 	241 	250 
159V3. 1 TTGTAACCTT AGTAGAGCAG AATGGAATAA CACTTTAAAA CAGATATTT 
159V3.2 	.......... 	 .......... 	 ..... G .... 	 ........ P . 	...... G.. 
159V3.3 .......... 	 .......... C ......... 	 ....... G.. 	...... G.. 
159V3.4 	....... A.. 	.... A ..... 	 .......... 	 ........ G . 	...... G.. 
160V3.1 ....... A.. 	.... A ..... 	 .......... 	 ........ G . 	...... G. .A 
160V3.3 	.......... 	 .......... C ......... 	 ....... G .. 	...... G. .G 
160V3.4 ....... A.. 	.... A ..... 	 .......... 	 ........ G . 	...... G. .A 
160V3.5 	.......... 	 .......... C ......... 	 ....... G.. 	...... G. .G 
160V3.6 .......... 	 .......... 	 .......... 	 ........ G . 	...... G. .A 
160V3.7 	.......... 	 .......... 	 ..... G. .G . 	........ G . 	...... G. .A 
160V3.8 ....... A.. 	.... A ..... 	.......... 	........ G . 	...... G. .A 
160V3.11 	.......... 	.......... C ......... 	....... G.. 	...... G. .A 
160V3.12 	....... A.. 	.... A ..... 	.......... 	........ G . 	...... G. .A 
161v3.1 ....... A.. 	.... A ..... 	.......... 	........ G. 	...... G. .A 
161v3.2 	....... A.. 	.... A ..... 	.......... 	........ G. 	...... G. .A 
161v3.3 ....... A.. 	......... A ........G. A ......... 	...... G. .A 
161v3.4 	.......... 	.......... 	.......... 	........ g. 	...... G. .A 
161v3.5 ....... A.. 	.... A ..... 	.......... 	........ G. 	...... G. .A 
161v3.6 	....... A.. 	.... A ..... 	.......... 	........ G. 	...... G. .A 
161v3.7 ....... A.. 	.... A ..... 	.......... 	........ G . 	...... GC.A 
161v3.8 	....... A.. 	.... A ..... 	.......... 	........ G . 	...... G. .A 
161v3.9 ....... A.. 	.... A ..... 	.......... 	........ G. 	...... G. .A 
87.V3.1 	.......... 	.......... 	.......... 	........ G. 	...... GC.A 
87.V3.2 .......... 	......... .C ......... 	........ G . 	...... GC.A 
87.V3.3 	.......... 	.......... C ......... 	........ G . 	...... GC.A 
87.V3.4 .......... 	.......... C ......... 	........ G . 	...... GC.A 
87.V3.5 	....... A.. 	.... A ..... 	.......... 	........ G . 	...... G. .A 
87.V3.6 .......... 	.......... C ......... 	........ G . 	...... GC.A 
113v3.1 	.......... 	.......... C ......... 	........ G . 	...... GC.A 
113v3.2 ....... A.. 	.... A ..... 	.......... 	........ G. 	...... G. .A 
13.v3.3 	....... A.. 	.... A ..... 	.......... 	........ G. 	...... G. .A 
113v3.4 ....... A.. 	.... A ..... 	..... G .... 	...... P.G . 	...... GC.A 
113v3.5 	. . .0 ...... 	.......... C ......... 	........ G. 	...... GC.A 
113v3.6 .......... 	.......... C ......... 	........ G. 	...... GC.A 
113v3.7 	.......... 	.......... C ......... 	........ G. 	...... GC.A 
113v3.8 ....... A.. 	.... A ..... 	.......... 	........ G. 	...... G. .A 
113v3.9 	.......... 	.......... C ......... 	........ G. 	...... GC.A 
169v3.1 ....... A.. 	......... A ........G. A ......... 	...... G. .A 
169v3.2 	....... A.. 	.... A ..... 	.......... 	........ G . 	...... G. .A 
169v3.3 .......... 	.......... C 	.G .... 	........ G . 	...... GC.A 
169v3.4 	....... A.. 	......... A ........G. A ......... 	...... G. .A 
169v3.5 ....... A.. 	......... A ........G. A ......... 	...... G. .A 




MEAN PAIRWISE SYNONYMOUS AND 
NONSYNONYMOUS SUBSTITUTION RATES IN POL 
AND ENV. 
A2 MEAN PAIR WISE SYNONYMOUS AND NONSYNONYMOUS 
SUBSTITUTION RATES IN POL AND ENV. 
Figures A2.1 and A2.2. 	Mean pairwise synonymous and nonsynonymous 
substitution rates in the poi region from patient 74. 
Figures A2.3 and A2.4. 	Mean pairwise synonymous and nonsynonymous 
substitution rates in the poi region from patient 87. 
Figures A2.5 and A2.6. 	Mean pairwise synonymous and nonsynonymous 
substitution rates in the V3 env region from patient 74. 
Figures A2.7 and A2.8. 	Mean pairwise synonymous and nonsynonymous 
substitution rates in the V3 env region from patient 87. 
In all cases the numbers on the diagonal are the intra-sample rates with all numbers 
below the diagonal being inter-sample substitution rates. 























PRE-TREAT 0.0295  
PRE-TREAT 0.0336 0.0390  
17 WEEKS 0.0442 0.0444 0.0547  
22 WEEKS 0.0438 0.0419 0.0496 0.0460  
56 WEEKS 0.0853 0.0843 0.0851 0.0859 0.0530 
81 WEEKS 0.0555 0.0567 0.0612 0.0593 0.0940 0.0645 
110 WEEKS 0.0554 0.0591 0.0626 0.0637 0.0933 0.0548 0.0374 
110 WEEKS 0.0603 0.0666 0.0708 0.0730 0.1028 0.0627 0.0384 0.0378 
8 WKS POST 0.0685 0.0726 0.0754 0.0779 0.1057 0.0643 0.0368 0.0391 0.0333 
8 WKS POST 0.0476 0.0515 0.0550 0.0568 0.0855 0.0464 0.0243 0.0265 0.0265 0.0141 
SAMPLES IN ITALICS SIGNIFY VIRAL RNA SEQUENCES 
FIGURE A2.1 






















PRE-TREAT 0.0019  
PRE-TREAT 0.0156 0.0033  
17 WEEKS 0.0182 0.0058 0.0041  
22 WEEKS 0.0254 0.0129 0.0070 0.0064  
56 WEEKS 0.0386 0.0256 0.0215 0.0158 0.0081  
81 WEEKS 0.0404 0.0275 0.0287 0.0272 0.0160 0.0103  
110 WEEKS 0.0514 0.0379 0.0410 0.0406 0.0287 0.0170 0.0164  
110 WEEKS 0.0590 0.0451 0.0486 0.0482 0.0363 0.0231 0.0184 0.0214 
8 WKS POST 0.0507 0.0374 0.0404 0.0400 0.0280 0.0163 0.0163 0.0189 0.0140 
8 WKS POST 0.0661 0.0513 0.0556 0.0552 0.0433 0.0301 0.0209 0.0203 0.0235 0.0180 
SAMPLES IN ITALICS SIGNIFY VIRAL RNA SEQUENCES 
FIGURE A2.2 






















PRE-TREAT 0.0279  
5 WEEKS 0.0216 0.0138  
16 WEEKS 0.0221 0.0151 0.0253  
17 WEEKS 0.0184 0.0212 0.0173 0.0000  
45 WEEKS 0.0442 0.0350 0.0496 0.0376 0.0490  
74 WEEKS 0.0337 0.0287 0.0480 0.0301 0.075 1 0.0550  
83 WEEKS 0.0450 0.0437 0.0399 0.0256 0.0590 0.0557 0.0000  
103 WEEKS 0.0421 0.0324 0.0468 0.0411 0.0802 0.0624 0.0625 0.0603 
103 WEEKS 0.0230 0.0145 0.0172 0.0228 0.0382 0.0315 0.0477 0.0354 0.0179 
8 WKS POST 0.0309 0.0244 0.0254 0.0262 0.0437 0.0404 0.0517 0.0455 	1 0.0263 0.0310 
SAMPLES IN ITALICS SIGNIFY VIRAL RNA SEQUENCES 
FIGURE A2.3 






















PRE-TREAT 0.0062  
5 WEEKS 0.0043 0.0029  
16 WEEKS 0.0053 0.0038 0.0047  
17 WEEKS 0.0136 0.0138 0.0142 0.0069  
45 WEEKS 0.0092 0.0078 0.0070 0.0162 0.0084  
74 WEEKS 0.0138 0.0116 0.0106 0.0193 0.0120 0.0150  
83 WEEKS 0.0233 0.0208 0.0206 0.0240 0.0222 0.0204 0.0000  
103 WEEKS 0.0116 0.0099 0.0094 0.0186 0.0125 0.0131 0.0197 0.0116  
103 WEEKS 0.0115 0.0099 0.0105 0.0195 0.0141 0.0148 0.0175 0.0121 0.0132 
8 WKS POST 0.0203 0.0187 0.0188 0.0238 0.0213 0.0190 0.0150 0.0172 0.0166 0.0161 
SAMPLES IN ITALICS SIGNIFY VIRAL RNA SEQUENCES 
FIGURE A2.4 
SYNONYMOUS MEAN PAIRWISE DISTANCES IN THE V3 REGION OF PATIENT 74 




YEAR 0 0.0000  
YEAR 3 0.0128 0.0393  
YEAR 4 0.0336 0.0437 0.0398  
YEAR 5 0.0226 0.0339 0.0382 0.0300  
YEAR 6 0.0338 0.0484 
(EARLY)  





0.0568 0.0423 0.0480 0.0351 
YEAR 0=1984 YEAR 3=1987 YEAR 4=1988 YEAR 5=1989 YEAR 6=1990 
FIGURE A2.5 
NON SYNONYMOUS MEAN PAIR WISE DISTANCES IN THE V3 REGION OF PATIENT 74 




YEAR 0 0.0000  
YEAR 3 0.0454 0.0571  
YEAR 4 0.0561 0.0678 0.0750  
YEAR 5 0.0629 0.0639 0.0749 0.0651  
YEAR 6 0.0612 0.0666 
(EARLY)  
0.0769 0.0671 0.0740 
YEAR 6 0.0703 0.0717 
(LATE)  
0.0915 0.0709 0.0685 0.0639 
YEAR 0=1984 YEAR 3=1987 YEAR 4=1988 YEAR 5=1989 YEAR 6=1990 
FIGURE A2.6 
SYNONYMOUS MEAN PAIRWISE DISTANCES IN THE V3 REGION OF PATIENT 87. 









YEAR 0 0.0000  
YEAR 3 0.0183 0.0296  
YEAR 4 0.0272 0.0320 
(EARLY)  
0.0360 
YEAR 4 0.0244 0.0541 0.0549 
(MID)  
0.0329 
YEAR 5 0.0123 0.0413 0.0476 
(EARLY)  
0.0427 0.0182 
YEAR 5 0.0247 0.0535 0.0571 
(LATE)  
0.0483 0.0368 0.0602 
YEAR 6 0.0346 0.0601 0.0651 0.0545 0.0344 0.0695 0.0463 
YEAR 0=1984 YEAR 3=1987 YEAR 4=1988 YEAR 5=1989 YEAR 6=1990 
FIGURE A2.7 
NON SYNONYMOUS MEAN PAIRWISE DISTANCES IN THE V3 REGION OF PATIENT 87. 









YEAR 0 0.0000  
YEAR 3 0.0437 0.0586  
YEAR 4 0.0800 0.0634 0.0619 
(EARLY)  
YEAR 4 0.1002 0.0803 0.0684 
(MID)  
0.0611 
YEAR 5 0.0423 0.0571 0.0708 
(EARLY)  
0.0828 0.0398 
YEAR 5 0.0666 0.0678 0.0756 
(LATE)  
0.0720 0.0541 0.0648 
YEAR 6 0.0849 0.0988 0.1130 0.1164 0.0937 0.1073 0.1055 
YEAR 0=1984 YEAR 3=1987 YEAR 4=1988 YEAR 5=1989 YEAR 6=1990 
FIGURE A2.8 
